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Summary 
National reports on the drugs situation in Austria are drawn up annually for the European 
Monitoring Centre for Drugs and Drug Addiction and the federal ministry responsible for 
health affairs, and deal with the subject of illicit drugs. This report gives an overview of cur-
rent developments regarding the political and legal framework, the epidemiological situation 
and demand reduction interventions in the reporting period 2003/4. Every year specific is-
sues are highlighted; this year the themes of buprenorphine, alternatives to prison and public 
nuisance associated with drug use have been selected for detailed presentation. 
Summary and discussion of the most important trends 
The available data confirm the trend described last year, towards a widening range of sub-
stances used in the context of both experimenting use and problem use. 
In particular adolescents and young adults tend to experiment with many different sub-
stances - in addition to cannabis also amphetamines, cocaine, biogenic drugs, poppers, and 
to a limited extent, opiates and LDS or other hallucinogens. This has meanwhile resulted in 
slightly elevated prevalence rates that show in representative surveys. More than one third of 
young adults have experience of cannabis, and up to 5% of the young people and up to 10% 
of the young adults have already used cocaine, amphetamines and ecstasy. A noticeable dif-
ference compared to previous studies is stable or slightly declining figures for ecstasy, paral-
leled by increases with regard to cocaine and amphetamines. Prevalence rates for shorter 
periods (last year, past 30 days) are significantly lower, which indicates that drug use among 
young people is experimental use over a limited period of time in most cases. 
A few provinces also report increases with regard to high-risk behaviour by a number of 
young drug users. It is difficult at present to assess to which degree drug use by young peo-
ple can no longer be regarded as experimental but already constitutes problem drug use. 
Still, at least in some regions a trend also towards increased problem drug use by adoles-
cents and young people is emerging. At all events, close attention should be paid to this de-
velopment. 
With regard to problem patterns of drug consumption, as a rule poly-drug is still predominant. 
Here, in addition to opiates in particular stimulating substances, primarily cocaine, play a 
central role. A number of provinces report that different to previous years heroin, apart from 
morphines, has again become more relevant. Many substances, especially opiates and co-
caine, are injected in most cases. In the street scene, high risk consumption patterns with 
phases of cocaine binges (massive use for a limited time) are frequently found. Thus the 
concept of primary drug has become obsolete for Austria in many respects, as the preferred, 
and therefore primarily used, substance may change several times within a few months. No 
recent estimates of the prevalence of problem drug consumption are available, but a few re-
gions still report rises in problem patterns of use. 
In 2003 163 persons died as a direct consequence of drug use in Austria, thus the number of 
directly drug-related deaths is higher than in the year before (2002: 139 deaths). Increases 
are mainly found in the age group between 20 and 24 (2003: 37 cases, 2002: 20 cases). At 
first sight, this development seems to be in accordance with reports of rising problem drug 
 X 
use among adolescents and young people (see above), however, one should bear in mind 
that a similar rise was also registered already in 2000, but in the following two years the 
number of directly drug-related deaths again fell to the level of 1999. Data from Vienna on 
ambulance services called because of suspected overdoses also show an upwards trend. 
As far as drug-related infectious diseases are concerned, the picture is inconsistent. HIV pre-
valence among directly drug-related deaths has slightly risen for the first time in many years 
(to 8%), however, no trend can yet be deduced as the number of cases are small. With re-
gard to hepatitis a decline was found (hepatitis B: 34% maximum; hepatitis C: 51% maxi-
mum). What is especially interesting is that the prevalence rate of hepatitis C (approximately 
40%) has turned out to be considerably lower than the formerly estimated rate of 70 to 80% 
among direct drug deaths. This could indicate that the data available so far, which are based 
on voluntary tests in most cases and thus do not constitute an independent sample, include 
disproportionately large shares of drug users with elevated infection rates and that the hepa-
titis C prevalence rate has been overestimated as a consequence. Another relevant factor in 
the context of infectious diseases is fears that HIV and hepatitis cases could go up as a re-
sult of increased cocaine use among the street scene, because this is often paralleled by 
non-observance of safer use rules. 
It is difficult to give a conclusive interpretation of these trends as hardly any in-depth re-
search or analyses are available. Increases in drug use in particular among adolescents and 
young adults seem to reflect the sprit of the time on the one hand and general social devel-
opments on the other. For many decades, drug use by young people has followed a kind of 
cycle, and seems to come to a new peak at present. Moreover, the differences between ur-
ban and rural areas tend to disappear in many respects (an aspect of globalisation), and as a 
result, illicit drugs now seem to be available in all regions of Austria. A (small) share of young 
people who experiment with drugs develop patterns of problem drug use, associated with 
psychological and social problems. According to Austrian drug experts, increasing stress and 
achievement orientation as well as rising “new poverty” are important factors that may aggra-
vate drug problems. 
The trends found in Austria correspond to the developments in other member states of the 
European Union and in particular Austria’s neighbouring countries. In the EU high prevalence 
of cannabis use and rises in cocaine use are generally registered. In almost all countries the 
range of substances used has widened and thus a trend towards poly-drug use is showing. A 
few countries - among them Germany - report rising problem drug use. All over the EU, after 
a series of upwards and downwards developments of drug-related deaths in the past dec-
ade, recently new increases have been found (EMCDDA 2003). 
A number of drug policy measures have been taken as a response to this epidemiological 
development. In recent years interventions in the field of primary prevention have increas-
ingly often been accompanied by secondary prevention approaches. New strategies and 
methods for working with young people in danger of becoming addicted have been drawn up, 
with promising results. In future, the corresponding projects and activities will be intensified in 
order to prevent young people from slipping into problem drug use and addiction. 
In the reporting period, measures targeting persons who already show patterns of problem 
drug use primarily focused on substitution treatment. At present an optimisation of medically 
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assisted therapy is discussed with the aim both to improve quality and to reduce misuse of 
substitution substances (e.g. intravenous use, sale in the black market). Harm reduction in-
terventions concentrate on the prevention of infectious diseases and overdoses. In view of 
the present epidemiological situation, experts are discussing the question whether it would 
be sensible to expand the existing services by establishing consumption rooms and heroin 
programmes. Such measures have already been taken in many EU member states. In Aus-
tria these approaches have been discussed for several years but not implemented so far. 
Social reintegration of (former) drug addicts continues to play an important role. On the one 
hand, such measures may motivate drug users to go into drug-free treatment and on the 
other, drug experts regard them as a most effective way to prevent relapse. However, due to 
the tight situation of the labour market at present, it is especially difficult for (former) drug ad-
dicts to find jobs. Therefore current services concentrate on occupational reintegration; for 
instance, several projects are implemented in the context of the EQUAL programme of the 
European Union. In addition, new services in the field of housing (e.g. temporary sleeping fa-
cilities for young people) and recreational programmes have been started. 
Selected issue “Buprenorphine” 
In Austria buprenorphine was admitted as a substitution substance in 1999. It had already 
been used since the mid-1990s at the drug outpatient department of the General Hospital of 
Vienna within the framework of clinical trials. Experience with buprenorphine in substitution 
treatment has been positive. Its use is recommended on the one hand for short- to medium-
term substitution in young drug-dependent persons and patients who aim at medium-term 
abstinence. On the other hand, buprenorphine has successfully been used in the substitution 
treatment of pregnant drug patients, as different from other substances, neonatal abstinence 
syndrome has hardly been found in newborn babies. Furthermore buprenorphine generally 
has less side-effects than methadone, and the reduction of doses is less problematic. How-
ever, buprenorphine should not be used in cases of high psychiatric comorbidity. Over the 
past few years the use of buprenorphine has continually risen; at present, it is chosen as a 
substitution substance in approximately one fifth of all first treatments. 
There are hardly any data or information on misuse of buprenorphine. In general, most ex-
perts hold the view that because of its agonist-antagonist properties buprenorphine is rather 
unattractive for misuse. There is very little evidence of intravenous consumption of buprenor-
phine or of its existence in the black market. The parallel use of other drugs appears to occur 
less frequently than with other substitution substances. 
Selected issue “Alternatives to prison” 
In Austria, specific alternatives to punishment for drug using offenders have a long tradition. 
Already in 1971 the legislation on narcotic substances provided corresponding options. The 
Narcotic Substances Act (SMG) of 1998 represented the provisional completion of the ongo-
ing development of alternatives to punishment in cases where narcotic substances are in-
volved. There are two relevant types of alternatives: deferment of charges (Section 35 SMG) 
and suspension of sentence (Section 37 SMG) can be applied in cases of petty crimes and 
serve as an alternative to conviction. Application of these measures is not contingent on de-
pendence on a narcotic substance. A stay of execution of sentence (Section 39 SMG) is ap-
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plicable for serious offences and serves as an alternative in cases of a conviction on account 
of an offence committed to finance drugs. Application of these measures is limited to persons 
who are dependent on narcotic substances and agree to undergo a health-related measure. 
In addition there are a number of general regulations on the alternatives to punishment which 
are not specifically oriented to drug-related offences but may also be applied in drug cases.  
The principle of therapy instead of punishment is shared unanimously as a drug-policy con-
sensus of all political parties and is widely supported by the general population. Application 
of alternatives to punishment rose from approximately 1 200 cases in the early 1980s to 
more than 9 000 cases in 2003. It is frequently combined with the prescription of a health-
related measure. For implementing these alternatives, the entire drug-help system is avail-
able. In former years, the services provided in this respect used to be considered sufficient. 
Recently, however, some provinces have reported capacity problems, as the demand for 
such measures has sharply risen, but budgets have not been raised correspondingly. 
Selected issue “Public nuisance in connection with illicit drugs” 
In Austria, the issue of public nuisance in connection with illicit drugs primarily involves de-
bates about public safety, social acceptability of the drug scene and the feeling of security or 
social disturbance among the population. It is not so much a question of actual (fear of) 
crimes but rather an irritation of the personal feeling of security. In general drug users have 
turned out to be perceived as a public nuisance only to a small degree. On the one hand this 
could be due to the Austrian drug policy with its focus on prevention, which reduces many 
possible fields of conflict in the public sphere. On the other hand, the view of drug addicts as 
patients rather than criminals has been politically communicated and widely accepted by the 
general public, which contributes to the understanding of this population group. The situation 
is different in the case of drug dealing, which is viewed as a disturbance to a much higher 
degree.  
Measures explicitly focusing on the field of public nuisance in connection with drugs have lit-
tle tradition in Austria. In Vienna, in spring 2003 a drug policy focus on the promotion of so-
cial acceptability of the drug scene was defined as a reaction to complaints about the street 
drug scene and drug dealing in the public sphere. In addition to new approaches to social 
work in the public sphere, the close cooperation and the involvement of relevant actors (po-
lice, streetworkers, public transport providers, local residents and businesses, etc.) play an 
important role. 
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Introduction 
This is the 9th time the REITOX Focal Point at the Austrian Health Institute (ÖBIG) presents 
its annual National Report drawn up for the European Monitoring Agency for Drugs and Drug 
Addiction (EMCDDA) and the Austrian Federal Ministry for Health and Women (BMGF). 
This report deals with illicit drugs and serves both as a national report on the situation in Aus-
tria and as Austria’s contribution to describing the drug situation in the European Union (EU). 
Similar reports are submitted by the REITOX Focal Points in all EU member states and by 
the EU candidates, according to a structure defined by the EMCDDA. They form the central 
basis of the EMCDDA’s Annual Report on the State of the Drugs Problem in the European 
Union (latest publication: EMCDDA 2003). 
This year’s report follows a new structure, in which information on epidemiology and demand 
reduction are integrated to a greater extent. The first part deals with current developments 
and trends concerning the drug policy framework, the epidemiological situation and health 
policy interventions aiming at demand reduction. This part refers to the reporting period from 
summer 2003 to summer 2004, while routine statistics refer to the year 2003. As this part is 
based on the previous reports (latest report: ÖBIG 2003b), it has been kept concise deliber-
ately. The second part gives a detailed presentation of selected issues, which in the present 
report deal with buprenorphine, alternatives to prison and public nuisance associated with 
drug use. In addition the Annex includes a number of tables with detailed information and 
data. 
Every year the REITOX Focal Points also submit to the EMCDDA annual standard tables 
and structured questionnaires. These data and information have also been included in this 
report. For an overview of all standard tables and structured questionnaires please consult 
Annex C. Upon request, the individual tables and questionnaires are made available to all in-
terested parties. 
This report is based on many different data and information communicated to ÖBIG by vari-
ous experts in the field of drugs. In this respect, the reports on the drug situation in the indi-
vidual Austrian provinces drawn up by the Drug Coordinators and Addiction Coordinators 
have been especially significant. In addition a number of experts have provided background 
information and specific data for individual chapters of this report (see Selected Issues). We 
would like to express our gratitude for their cooperation. 
We are especially indebted to the members of the advisory working group of the REITOX 
Focal Point Austria, Michael Dressel (Drug Coordinator of the City of Vienna and Provincial 
Representative). Thomas Neubacher (Addiction Coordinator of Vorarlberg and Provincial 
Representative), Franz Pietsch (Federal Drug Coordinator and head of the Federal Drug Co-
ordination), Robert Scharinger (BMGF), Johanna Schopper (head of the Drugs Department 
at the BMGF) and Wolfgang Werdenich (BMJ), whose comments and input have been most 
helpful. 
  
 
  
 
 
 
PART A 
New Developments 
and Trends 
  
  5
1 National Policies and Context 
The Narcotic Substances Act (SMG) of 1998 constitutes the central framework of Austria’s 
drug policy. The SMG focuses on quantities and not on kind of substance, with the exception 
of a special provision concerning cannabis, and provides a wide range of alternatives to pun-
ishment (see Chapter 12). At the federal level the central actors in the field of drug policy in-
clude the Federal Drug Coordination and the Federal Drug Forum, which serves as a coordi-
nating body with the provinces (see Fig. 1.1). Due to the federalist structure of Austria’s 
health and social care system, the provinces play an important role with regard to adoption 
and implementation of drug policy measures. All nine provinces have drawn up drug strate-
gies or addiction plans and nominated Drug or Addiction Coordinators. In addition to the pro-
vincial strategies and plans, a federal drug strategy paper is under preparation (see Chapter 
1.2). Drug policy measures are financed primarily by the Federal and Provincial Govern-
ments as well as the social insurance funds. Public discussion of the issue of drugs primarily 
concentrates on questions related to public security and delinquency (see also Chapter 13). 
Although Austria’s political parties take greatly differing positions with regard to drug policy, 
they unanimously endorse the principle of therapy instead of punishment (see Chapter 12), 
which is also widely accepted by the general public. 
1.1 Legal framework  
In the reporting period the synthetic substances GHB, 2C-B und PMMA were included in the 
SMG as the relevant decisions adopted at EU level were implemented. In summer 2004 an 
amendment to the Decree on Narcotic Drugs was sent out for examination: it includes addi-
tional substances and also lays down rules for substitution substances dispensed to patients 
to take with them (see Chapter 5.3). Other than these, no relevant changes in the legal 
framework that directly concern drugs have been made. However, further amendments to ex-
isting legislation are to be expected in the course of the year 2005, when the EU Framework 
Decision laying down minimum penalties for drug trafficking will be implemented (Rat der Eu-
ropäischen Union 2003). 
Changes in the legal framework that indirectly relate to drugs have not occurred either. What 
deserves mention, however, is the plan to create a statutory basis for defining protection ar-
eas around schools, kindergartens and homes for the aged, giving the police the right to 
send away for a maximum period of 30 days any person who is suspected of committing of-
fences in the protection area. The pertinent amendment to the Security Police Act was drawn 
up by the Council of Ministers in June 2004 but has not yet been discussed in Parliament. 
The envisaged measures have met with criticism by prevention and drug experts (see Chap-
ter 1.4) on the one hand and human rights organisations on the other, who point to the fact 
that the existing laws provide sufficient means to prevent drug trafficking around the above 
institutions. 
 
  
Figure 1.1: Overview of the organisational structure of the drug sector in Austria 
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1.2 Institutional framework, strategies and policies 
At the federal level, endeavours to draw up a nation-wide drug strategy paper were contin-
ued in the reporting period. It is planned to harmonise this paper with the EU drugs strategy 
for the period from 2005 to 2012, which is being prepared and will be implemented in the 
context of two action plans on drugs. The Federal Drug Forum (see Figure 1.1) met twice in 
the reporting period (December 2003 and May 2004) to discuss themes such as drug-related 
legal issues (communication of data, confidentiality, refusal to give evidence etc.), problems 
of execution in the provinces due to rising numbers of reports to the police as well as capac-
ity and budget problems in the drug help sphere (see Chapters 1.3 and 12.2), further devel-
opment of drug monitoring (in particular, introduction of a uniform documentation and report-
ing system of drug help centres), optimisation of substitution treatment (see Chapter 5.3) as 
well as reports on recent developments and interventions. 
At the provincial level, the reporting period saw an adoption by the Upper Austrian Provincial 
Parliament of the provincial drug strategy. In Carinthia, the framework plan on addiction pre-
vention and drug help for the period from 2001 to 2005 was included in the government pro-
gramme of the new legislative period. In all provinces, measures to implement drug strate-
gies or addiction plans were taken, in accordance with defined priorities. Apart from the es-
tablished fields of primary prevention as well as harm reduction and treatment, in recent 
years secondary prevention in particular for young people (see Chapter 3.2) and social rein-
tegration measures (see Chapter 9.1) have played prominent roles. Furthermore, drug moni-
toring, quality assurance and research continue to be of rising relevance. 
In Vienna, social acceptability of the street drug scene has become a focal theme (see Chap-
ter 13.1). Carinthia adopted a number of quality assurance measures aimed at retransferring 
to the district level examinations according to Section 12 of the SMG, which had been carried 
out centrally in past years (see Chapter 12.3 and ÖBIG 2003b). 
1.3 Budget and public expenditure 
No data on drug-specific budgets are available for the reporting period. The financing system 
in the field of drugs has not been noticeably changed either. Vienna is drawing up a model 
aimed at finding ways to obtain refunding by the Vienna Health Insurance Fund of drug-help 
services provided by physicians, psychotherapists and clinical psychologists (FSW 2004c). 
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1.4 Social and cultural context 
There are a number of studies that provide data on public attitudes to drug policy measures. 
Since 1995 Vienna has conducted drug surveys in comparable settings every two years. In 
autumn 2003, 670 persons over 15 were interviewed (IFES 2004; see also Chapter 2.1). 
Long-term comparison shows continued strong acceptance of the principle of therapy instead 
of punishment (see also Chapter 12.1), paralleled by disapproval of any legalisation of illicit 
drugs (see Figure 1.2). 
Figure 1.2: Attitude to drug policy measures among the population of Vienna, comparison 
from 1995 to 2003 (percentages of approval to measures) 
Source: IFES 2004 
While it is regarded as sensible to distribute sterile syringes and to provide substitution 
treatment (66% approval), measures such as establishing consumption rooms or prescribing 
heroin tend to be rejected (10% approval). Both the survey in Vienna and a population sur-
vey carried out in Upper Austria (see Chapter 2.1) indicate slight tendencies towards more 
repressive positions. In Vienna, the share of people who would like to see “more police activ-
ity” as a focus of drug policy has doubled from 1999 (8%) to 2003 (16%). In Upper Austria, 
approval of “intensified prosecution of drug users and dealers” has significantly risen from 
19% in 2000 to 32%5 in 2003 (ISP 2003).  
In Styria, similar questions were asked in autumn 2002 in the context of a telephone survey 
covering 1 000 persons between 14 and 60 years (IFES 2002), and a picture resembling the 
situation in Vienna showed: strong approval of increased prevention (95%), sustaining drug 
prohibition while decriminalising addicts (82%), establishing additional treatment centres 
(80%), but little approval of imprisonment because of drug use (26%) and legalisation of soft 
drugs (16%). 
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In the context of the study Beyond Borders that was carried out in summer 2003 parallel to 
the conference Beyond Borders (see Chapter 5.1), 1 218 persons all over Austria were inter-
viewed face to face (Gehmacher et al. 2004): 72% said they were in favour of the prohibition 
of “dangerous drugs” and severe punishment for drug dealers, while 57% also welcomed 
treatment measures for drug addicts. 40% thought that it would be important to distribute 
drugs in a controlled way to reduce drug-related crime. 
All studies generally show that drug-related attitudes correlate with educational level and 
age: younger groups and persons with high levels of education tend to have more liberal atti-
tudes. 
Political discussion and the media primarily concentrated on issues such as drugs in schools. 
Both at federal level and in a number of provinces (Burgenland, Salzburg) the Freedom Party 
demanded drug tests to be carried out in schools, which was generally rejected, however. In 
spring 2004 the weekly magazine News launched a campaign with the slogan “no drugs at 
our schools”. Plans to introduce protection areas (see Chapter 1.1) were defended on 
grounds that they were necessary to prevent drug dealing around schools. This form of as-
sociating schools with drugs or drug trafficking met with critical comment in particular on the 
part of prevention experts, as this may give rise to fears among parents and teachers that 
are unjustified in face of the actual situation (see Chapter 10.1; Fachstellen für Suchtpräven-
tion 2004) and moreover, the activities mentioned above do not correspond to the principles 
of addiction prevention in Austria. 
In recent years, both media coverage and political discussion of drug issues have tended to 
relate (organised) drug trafficking to Africans living in Austria. This is due to the fact that a 
few groups of Africans have intensively, and visibly, been involved in street drug dealing, 
which has also been reflected in the statistics on reports to the police. In these statistics Ni-
gerian is the nationality most frequently found among non-Austrians concerned (i.e. the 
group “aliens” in the statistics), with more than 1 000 persons reported to the police in 2003 
(BMI 2004), however, only 371 of these reports refer to felonies. 
In a recent publication on drug policy as a policy focusing on aliens, Eisenbach-Stangl 
(2003a) thoroughly investigated this theme and concluded that social differences - in particu-
lar in terms of class and generation - as well as conflicts and problems arising in this context, 
have been transformed to ethnic differences and conflicts especially since the early 1990s. 
Such a development is typical of multi-cultural societies and not restricted to the field of 
drugs. However, in Austria this has coincided with the arrival of larger groups of immigrants 
from Africa, who are perceived as “actually different and foreign”, and some of whom are in-
volved in street trafficking (see above). This situation has facilitated the construction of the 
image of “dangerous African drug dealers”, which does not correspond to the actual situa-
tion.
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2 Drug Use in the Population 
In Austria experience of illicit drug use primarily concerns cannabis, with prevalence rates of 
at least 30% among young adults. According to representative studies, approximately 2% to 
4% have experience of ecstasy, cocaine and amphetamines, and between 1% and a maxi-
mum of 2% also of opiates. In the last few years, the range of substances taken in the con-
text of experimental use has obviously widened. In certain scenes and groups of young peo-
ple, high prevalence rates for a variety of substances are found, including biogenic drugs and 
poppers. New results of representative studies indicate that this has led to a general increase 
in prevalence rates in particular among adolescents and young adults. 
2.1 Drug use in the general population 
In spring 2004 a representative study on prevalence and consumption patterns of legal and 
illicit narcotics was drawn up on behalf of the Federal Ministry for Health and Women 
(BMGF), which is the first study that will provide nation-wide data in conformity with Euro-
pean Union standards. Its results will be available in 2005. For the present reporting period, 
data from a number of regional surveys can be given. 
In autumn 2003, 670 persons over 15 were interviewed in the context of a drug survey con-
ducted in Vienna (IFES 2004; see also Chapter 1.4). Comparison to previous surveys shows 
that the trend towards a rise in lifetime experience with cannabis has continued (1993: 5%; 
2003: 16%; see Figure 2.1 and Table A1 of Annex A). However, it is assumed that up to a 
certain extent, higher “confession rates” are due the fact that social taboos have become 
smaller in this field, thus the actual increase in cannabis use may be overestimated. A rise 
has also been found with regard to cocaine, while no changes have shown for the rest of 
substances covered. 
Use of biogenic drugs (mushrooms, cacti etc.) was included in the survey for the first time, 
and a total of 3% of the respondents said they had used natural drugs at least once in the 
past. In the case of almost all substances, lifetime prevalence is higher among persons with 
higher education levels and among younger age groups. This is most obvious with regard to 
cannabis, where prevalence rates go down with rising age (under 30 years: 40%; over 50 
years: less than 5%). Cocaine consumption is highest among (self-)employed men of the 
middle age group who have high education levels (5% to 7%), while prevalence rates are 
generally lower for women, with the exception of amphetamines and ecstasy, where hardly 
any differences between the genders are found. 
Use in the past three years and in the past 30 days was also studied. Here, significant data 
were obtained only for cannabis (7% and 2%, respectively), as prevalence rates were 1% or 
lower with regard to any other substance included. 
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Figure 2.1: Lifetime experience of illicit drugs among the population of Vienna from 1995 to 2003; 
percentages 
Source: IFES 2004 
The drug survey of Styria (IFES 2002, see Chapter 1.4) does not give results in such detail. 
14% of the total number of 1 000 respondents aged between 14 and 60 said that they had 
used illicit drugs at least once in the past (see Table A1 of Annex A). 13% indicated canna-
bis, 2% named a different or additional substance. Again, prevalence rates are markedly 
higher among the younger age groups (see Chapter 2.2), men, persons with higher educa-
tion levels and among the urban population. For instance, 29% of the respondents who have 
used illicit drugs at least once live in the provincial capital of Graz, and 25% have completed 
upper secondary school. 
In 2003 Upper Austria saw a repetition of the representative general population survey that 
was conducted for the first time in 2000. Here the general picture with regard to lifetime ex-
perience of illicit drugs has hardly changed (ISP 2003). 23% of the sample of 1 018 persons 
over 15 said they had already used cannabis at least once (2000: 21%). The results for all 
other substances are 3% or less (see Table A1 of Annex A). 
2.2 Drug use in the school and youth population 
In 2003 a school survey was conducted among 5 619 pupils between 13 and 18, in the con-
text of the ESPAD study financed by the BMGF. Detailed analyses are not yet available, but 
first results regarding experience of drug use can already be given (Uhl et al. 2004). Thus, 
approximately one out of four respondents have used an illegal substance at least once in 
their life. Broken down by substance, as expected, the highest prevalence rates are found for 
cannabis (22.5%), followed by amphetamines/stimulating substances (4.7%), ecstasy 
(3.1%), cocaine (2.2%) and eventually LSD and other hallucinogens (2.2%). What cannot 
easily be explained is the prevalence rate given for crack (1.5%), a substance hardly found in 
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Austria. Estimates of the plausibility of this figure and an interpretation cannot be provided 
before detailed analyses have been made. Among other factors, it has to be considered to 
which extent young people actually know the difference between individual substances. 
With the exception of amphetamines, ecstasy and LSD, prevalence rates tend to be higher 
for male adolescents than for girls. In addition, drug experience is clearly rising with age. 
Generally speaking, prevalence rates have been slightly higher than those found in previous 
school surveys (see Table A2 of Annex A). However, as consumption figures for the past 12 
months and the past 30 days are considerably lower for all substances included, this seems 
to reflect a rise in experimental use with a variety of substances, a trend already showing 
over several years. 
In the city of Salzburg a representative survey was conducted in 2003 among 609 trainees at 
vocational schools aged between 15 and 25. An online questionnaire based on the ESPAD 
study was used for this purpose. 31% of the respondents said they had already used canna-
bis at least once, and 15% indicated experience of poppers. Lifetime prevalence for all other 
substances was under 10% (hallucinogenic mushrooms: 9%; ecstasy 7%, LSD and cocaine: 
5% each; Schabus-Eder, personal information). 9% of the trainees also showed problem use 
patterns of alcohol. Compared to other representative school studies the prevalence rates 
found here are fairly high (see Table A2 of Annex A). However, if the age range is taken into 
account as well as the fact that previous studies have also shown high rates of drug use 
among trainees attending vocational schools, such prevalence rates are hardly surprising. 
Information on drug use among adolescents and young adults also comes from the drug sur-
veys conducted in Vienna and Styria as well as the general population survey of Upper Aus-
tria (see Chapter 2.1). In Styria, 15% of the young people between 14 and 19 and 21% of the 
age group between 20 and 29 said they had already used illicit drugs in the past (IFES 
2002). Data from Vienna only cover the group between 15 and 29 years: 40% indicated ex-
perience of cannabis and approximately 5%, of ecstasy (IFES 2004).  
In Upper Austria the sample for adolescents and young adults was overrepresented 
(n = 567) so as to permit a more detailed analysis. The prevalence rates found among the 
age group between 15 and 24 are considerably higher than the rates for the overall popula-
tion (see Table A2 of Annex A), with differences also within the younger age group: lifetime 
experience of cannabis continually rises from 18% for 15-year olds to 38% for the group be-
tween 20 and 24. However, in the case of all other substances included, the highest rates 
are found in the group between 18 and 19 years (ISP 2003). The elevated prevalence rates 
in this group must be qualified, however, as around 3% of the persons interviewed also indi-
cated use of a non-existent drug that was included in the survey in order to test the plausibil-
ity of responses. Thus one may conclude that actual experience of illicit drugs is slightly 
lower than the results indicate. 
A few provinces (Burgenland, Carinthia, Lower Austria) have also provided reports on the 
practical experience of regional drug experts, which confirm trend that was registered last 
year, towards a widening range of patterns of use in the context of experimental drug con-
sumption by adolescents and young adults. Apart from cannabis, it is cocaine, ampheta-
mines and biogenic drugs that play relevant roles in this context. 
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2.3 Drug use among specific groups 
Data on drug use among specific groups in Austria (e.g. conscripts, ethnic minorities, immi-
grants etc.) are regularly gathered by ChEck iT!, a secondary prevention project that pro-
vides on-site testing of substances (see also Chapters 3.2 and 10.3). In the reporting period, 
a secondary analysis was made of the data gathered by means of questionnaires on con-
sumption patterns in the years 1998, 2001 and 2003. All data were collected during large, 
commercial rave events with 1 000 to 8 000 visitors (n = 838). Preliminary results show that 
frequencies of use of the individual recreational drugs have hardly changed over the years, 
with the exception of cannabis and ecstasy. Cannabis consumption has clearly risen in the 
course of time with regard to both frequency of use and percentage of regular users (con-
sumption on 20 to 30 days/month). On the other hand, frequencies of ecstasy use have gone 
down from two days in 1998 to one day at present, with the number of pills taken per evening 
rising from 1 to 2.5. Furthermore, it has shown that the group of recreational or party drug 
users is not homogeneous but that different types of use can be distinguished. More detailed 
results of the secondary analysis will be available in autumn 2004, and a publication is being 
prepared (Eggerth and Lachout, personal information).  
2.4 Attitudes to drugs and drug users  
The drug surveys of Vienna and Styria as well as the general population survey conducted in 
Upper Austria (see Chapter 2.1) also investigated which substances were regarded as dan-
gerous with regard to health consequences. In each of the three studies, the majority of the 
respondents (90% and more) thought that almost all illicit drugs were dangerous, with the 
exception of cannabis, which was estimated to be considerably less risky. In Vienna, a time 
series since 1993 also permits an assessment of trends. In the course of time, cannabis has 
been regarded as less and less dangerous (1993: 84%; 2003: 65%), while the results for all 
other substances have basically remained unchanged (IFES 2004). Furthermore, a number 
of legal substances were also included in the surveys: in Vienna, 80% of the respondents 
said natural drugs (mushrooms, cacti etc.) were dangerous. In Styria, alcohol was regarded 
as a very dangerous substance by 39%, and nicotine, by 34% (IFES 2002). 
The study Beyond Borders (see Chapters 1.4 and 5.1), which goes into greater detail with 
regard to risk awareness, shows a more diversified picture. In the case of “use of small 
amounts” assessment of danger differs according to substance involved: opiates/heroine are 
considered dangerous by 73%, cocaine by 60%, ecstasy by 43%, amphetamines by 42%, 
cannabis by 28%, nicotine by 14%, and alcohol by 12% (see Gehmacher et al. 2004). In 
terms of sociodemographic parameters, hardly any differences were found. The study also 
investigated which causes were regarded to be relevant for (rising) drug use. In the repre-
sentative survey, 64% of the respondents thought that drug use in society could go down if 
there were less stress and loneliness. 54% said that more discipline would lower drug con-
sumption. In addition, in the course of the conference a Delphi study was carried out among 
attending drug experts from Austria, Slovakia, the Czech Republic and Hungary. In their 
opinion, increased stress and achievement orientation as well as rising “new poverty” and the 
collapse of family and neighbourhood ties are the most relevant factors aggravating drug  
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problems. The former two factors were regarded as particularly relevant by Austrian and Slo-
vakian experts, and the latter factor was assessed as decisive by Czech and Slovakian ex-
perts. 
In Vienna and Styria, attitudes to drug users were also investigated. 10% of the persons in-
terviewed in Styria said they did not want to have close contact with persons who had ex-
perience of drugs (IFES 2002). The survey of Vienna focused on reactions to drug use 
among close friends. In the case of cannabis, approximately one third indicated that they 
would generally tolerate this, whereas 20% would stop seeing these persons immediately. 
Regarding the other substances included (in particular opiates, cocaine, amphetamines and 
LSD) only 10% would basically tolerate use, while around half of the respondents would 
break off contact at once (IFES 2004). For further data on social acceptance of drug users 
please consult Chapter 13. 
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3 Prevention 
In Austria prevention measures are primarily taken at local and regional levels, in accordance 
with expert consensus. The Addiction Prevention Units at provincial level play a central role 
in this field. Generally, the distinction between primary and secondary prevention is regarded 
as fundamental. Primary prevention (universal prevention) aims at avoiding the development 
of addiction among persons who do not belong to a specific at-risk group and who have not 
had addiction problems so far. The corresponding measures are often based on the principle 
of health promotion or life skills approaches and use a variety of methods (e.g. educational 
theatre play and peer education). Secondary prevention (selective prevention) addresses de-
fined at-risk groups and persons with problems, which have not yet become manifest to their 
full extent. The measures taken are oriented towards the specific needs of the respective 
groups. The main target group of secondary prevention is young people. Since the early 
1990s, when the Addiction Prevention Units were established, primary prevention has been 
pursued at a professional level. In recent years the focus has been placed on intensified pri-
mary prevention and an expansion of secondary prevention. 
Most of the activities mentioned in this report, as well as other interventions, are described 
on the websites, or in the annual reports, of the Addiction Prevention Units (Fachstellen für 
Suchtprävention; see Bibliography). 
3.1 Universal prevention 
Primary prevention plays a central role in Austria, which is reflected in a wide range of perti-
nent measures, thus only a number of relevant examples can be given in this report. Schools 
are important settings for prevention measures, with the focus placed on primary prevention. 
Preventing addiction is regarded as an integral part of health promotion and has thus been 
laid down as a statutory educational principle in the context of health promotion. Prevention 
measures in schools are to be implemented in cooperation with teachers, parents and pupils 
as well as regional drug and prevention experts. Thus, in the context of the iSch campaign, a 
health promotion measure of the Ministry of Health, a workshop on addiction prevention was 
held at a congress of school medical officers in Linz. Since April 2004 health cards for young 
people in their 8th school years have been tested; and nation-wide use and publication of a 
booklet on the health card are planned for 2005 (www.bmgf.gv.at). 
All provinces aim to expand addiction prevention measures in schools so as to achieve over-
all coverage and quality assurance activities are also carried out. In spring 2004 the Ministry 
of Education, in cooperation with the Working Group for Addiction Prevention ARGE Sucht-
vorbeugung, organised a conference on the quality of prevention activities in schools, in the 
context of the Joint Dialogue initiative (www.schule.at/gesundheit). In addition general princi-
ples for addiction prevention in schools will be published (Haller, personal information). Vi-
enna has started to investigate the demand for prevention projects for different types of 
schools, age groups of pupils as well as school-related professions (FSW 2004a). This will 
form the basis for specific prevention activities in schools in Vienna. Furthermore, guidelines 
including a check list for procedures in the case of drug incidents in schools have been
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drawn up. In the Tyrol a pilot stage is under way in order to professionalise the envisaged 
model of expert-assisted addiction information in schools before its realisation on a large 
scale. In Styria, Step by Step - Next Step is implemented in the whole province and in addi-
tion a modified version for legal substances has been developed for use at lower secondary 
schools. Apart from quality standards for addiction prevention in schools, a checklist for as-
sessing the quality of such activities has been drawn up by a special working group (SAG 
2003a, b). In summer 2004, these quality standards were unanimously adopted by the Pro-
vincial Parliament and the Provincial Government of Styria and have since served as a basis 
for deciding on subsidies for corresponding projects. In Vorarlberg the school programme Ei-
genständig werden (Becoming Independent) was evaluated, and those interviewed said it 
had been very helpful (see EDDRA). 
Prevention in kindergartens continues to focus on further training methods, distribution of in-
formation material as well as work with parents. Typical examples include KIGAFO further 
training courses and the new manual Die Reise zum ICH (Travelling to Your Self) in Styria. 
Prevention initiatives for parents also include further training schemes for multipliers as well 
as Styria’s approach to draw up a curriculum for provincial parent training schemes in addic-
tion prevention. Services directly addressing parents include the parent manual Wie schütze 
ich mein Kind vor Sucht (How to Protect My Child from Addiction) in Upper Austria and the 
booklet Schultüte (School Cone) in Vienna as well as the corresponding website 
(www.schultuete.at) on the one hand, and higher-threshold “active parents” seminars on pre-
vention in Upper Austria or the six-part course Elternsein ist manchmal scho(e)n schwer (Be-
ing a Parent May be Pretty (Difficult)). In addition to being given information on addiction, 
parents are assisted in integrating addiction prevention in everyday life. 
Prevention in the workplace is another focal theme in Austria. Typical examples include a 
prevention project in Lower Austria’s Provincial Government offices, for which guidelines on 
addiction in the workplace were drawn up, including accompanying interventions and a 
stage-by-stage plan for early detection. The Addiction Prevention Unit of Lower Austria con-
ducted a questionnaire survey on prevention in the workplace, which will form the basis for a 
future focus of activities. In Upper Austria, based on the results of a working group on alcohol 
and illicit drugs in the workplace, a booklet on this subject was issued (for a download go to 
www.praevention.at). Most of the activities specifically designed for trainees are further train-
ing schemes for trainers. For instance, in Vienna a trainee workshop was held in cooperation 
with the bank BAWAG, and a conversation training course for trainers was drawn up (FSW 
2004a). Projects were also organised for trainees of Erste Bank, Jugend am Werk and WUK 
Monopoli. 
Prevention measures in recreational settings addressing young people often combine pri-
mary and secondary approaches (see Chapter 3.2), as do activities for trainees, because 
young people are likely to experiment with drugs (ÖBIG 2001b). Here the Addiction Preven-
tion Units increasingly often cooperate with relevant associations such as Styria’s Football 
Association, whose training scheme for coaches includes two addiction prevention modules. 
In autumn 2003 the Youth Department presented its fourth report on the situation of young 
people in Austria. Part B of the report deals with prevention in the context of youth work out-
side schools (BMSG 2003b). Here it is stated that youth work as such has preventive effects 
but that the structures of youth social work should more often be used for preventive inter-
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ventions by experts. The report also points to a number of structural measures and methods 
(e.g. qualification in recreational youth work in line with actual demand, easily understand-
able communication of prevention themes, developing prevention measures in a participatory 
way, low-threshold communication) that may improve prevention in recreational settings. In 
order to improve the cooperation between interventions addressing young people in recrea-
tional settings on the one hand and prevention on the other it has been suggested to estab-
lish regional coordination offices in charge of building networks in this field. 
In the field of prevention at community level the Vienna-based project Miteinander leben 
(Living Together) has been modified on the basis of experience made so far and has been 
expanded to a further district (see EDDRA). Another project aimed at the development of 
community structures is the Interreg project Guat beinand (Feeling Good) of Salzburg’s Ad-
diction Prevention Unit. In Salzburg, regional coordination bodies are now well established 
and have started to draw up and implement measures of universal addiction prevention in 
their regions (Schabus-Eder, personal information). The project b.rauschend (n.toxicating) in 
Salzburg aims at helping children and adolescents to use intoxicating substances and prod-
ucts such as tobacco and in particular alcohol, in a deliberate, low-risk manner, with the aid 
of mentors of various associations, from the fields of peer group education and adult educa-
tion, and by integrating the whole district (Akzente 2004a). Lower Austria’s touring exhibition 
Alles im Griff (Everything Under Control) was evaluated in 2003 and assessed very favoura-
bly by the persons interviewed (see EDDRA). The experience made in the context of this ex-
hibition was incorporated in a special paper on work in communities (Brunner, personal in-
formation). 
The community project implemented at Trofaiach/Styria (see ÖBIG 2002b and EDDRA) was 
evaluated in 2004. A representative survey of the population was conducted to investigate 
the sustainability of interventions as well as the perception and acceptance of prevention 
measures around the contact point (Fazekas/Stigler 2004). The results have shown that the 
approach adopted and the way of intervention chosen have been perceived as sustainable 
and valuable and that there is great general interest in the issue of young people and addic-
tion. The authors also point out that it is essential for the success of a project that volunteers 
are given opportunities to reflect critically on their own attitude to drugs and addiction on the 
basis of current expert knowledge. 
3.2 Selective/indicated prevention 
In Austria, prevention addressing specific target groups primarily exists in recreational set-
tings, and aims at communicating a critical attitude to psychoactive substances (risk compe-
tence). In the reporting period activities focused on further training in prevention approaches 
for recreational settings, a field where primary and secondary prevention overlap (see 
Chapter 3.1). In order to be able to organise specific further training schemes for the profes-
sions concerned, the pertinent demand was investigated in all professional youth social work 
organisations in Vienna (open and outreach child and youth social work as well as animating 
recreational education; FSW/ISP 2003). The results obtained were used to draw up a frame-
work curriculum for a concise course in addiction prevention in youth social work settings, 
where methods and approaches of addiction prevention are taught in a practice-oriented way 
Chapter 3: Prevention 
 18 
(FSW/ISP and IFP 2004). A training scheme based on a questionnaire survey was also 
drawn up for centres run by Municipal Department No. 11 (Youth and Family Offices) of the 
City of Vienna (FSW 2004a). In order to improve the cooperation of outreach youth work, 
prevention, social education and social work structures, work conferences between the 
Youth and Family Offices, mobile youth work organisations and organisations in the field of 
addiction and drugs were started. What also deserves mention is the research series immer 
gut drauf?! (Always Having a Good Time!?) and the high genug? (High Enough?) courses 
organised in Styria as well as Salzburg’s courses Ich will hier RAUSch (High Time to Get 
Out) and Rauchen, Saufen, Kiffen, Kaufen, ... denn sie wissen was sie tun (Smoking, Drink-
ing, Toking, Buying ... Rebels with a Cause?), all of which address youth social workers in 
recreational settings. In autumn 2004 Connected! Beziehungen:Genießen:Lernen (Connec-
ted! Learning to Enjoy Relationships), an international conference on preventive youth social 
work focusing on relationships, took place in Salzburg (Akzente 2004b). 
The project Supromobil in Vorarlberg, which is based on the mobile youth social work ap-
proach (ÖBIG 2003b), started to organise district conferences in 2003, whose agendas in-
cluded drug use among young people, problems in the district as well as ideas for new pro-
jects. The results are further dealt with in working groups and concrete project ideas are de-
veloped. In Lower Austria, streetwork projects were expanded to include mobile youth social 
work facilities in the districts of Krems, Horn and Traisen (Brunner, personal information). In 
cooperation with the Addiction Prevention Unit, a manual on quality assurance in mobile 
youth social work and streetwork in Lower Austria was prepared. Way out, Carinthia’s six-
month early intervention service for young drug using first offenders, was extended due to 
positive evaluation results (EDDRA). 89% of the young drug users, most of whom took drugs 
regularly, showed positive changes with regard to use of problem substances. Improvements 
were also registered in other fields, for instance the young people concerned improved their 
general problem-solving strategies and became more secure with regard to behaviour and 
decision-taking. 
The rave scene continues to be a specific at-risk group. However, a development of this 
scene towards a subculture (small clubs) on the one hand and mainstream culture (large dis-
cos) on the other showed already last year. As a result, mobile secondary projects such as 
ChEckiT! (see Chapters 2.3 and 10.3) or MDA basecamp have to be adapted to the new 
situation so that the target group of young recreational drug users may still be addressed 
(VWS 2004d, MDA basecamp 2004). 
ChEckiT! therefore plans to create a contact point for this target group, where testing of sub-
stances is also possible, and has started to observe the scene and to analyse demand, par-
alleled by information initiatives for the new rave organising generation. Investigations of the 
goa, free techno and drum’n bass scenes in the period 2003/4 showed that ChEckiT! was 
well known in all scenes interviewed (68%) although it had not been present on the spot so 
far. The following figures underline the acceptance of outreach prevention services in these 
scenes: 80% of the respondents would have their substances tested by ChEckiT!, and 55% 
said they would welcome information and counselling (Eggerth and Lachout, personal infor-
mation). ChEckiT! also took part in a cooperation initiative involving several provinces, for 
preparing a model for online counselling. This guideline will be published in 2004. 
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MDA basecamp, in cooperation with the Addiction Prevention Unit of the Tyrol and with the 
participation of young people, produced the drug information film Nightflight and Daydream, 
which has been tailored to meet the information levels and interests of young people be-
tween 15 and 18. Meanwhile, the film has also been available as a teaching aid and is used 
for this purpose. In Linz, Upper Austria, a mobile service similar to MDA basecamp was es-
tablished: Chill-Out-X-Press (MDA basecamp 2004). 
Another important task of secondary prevention centres is counselling for drug users and 
their relatives. In the reporting period, relevant activities in this field also include the start of a 
new addiction hotline in Lower Austria (Brunner, personal information) and the preparation of 
quality standards for e-mail counselling in the new call centre of the Vienna Drug Assistance, 
(FSW 2004a). 
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4 Problem Drug Use 
Problem drug use here means frequent use of hard drugs (in particular opiates and cocaine), 
which is often accompanied by dependence and consequences for the health, social and le-
gal situation of the consumers (see Chapters 6 and 8). One has to bear in mind however that 
it is primarily patterns of use and not substances as such that are risky or safe. Problem use 
may therefore be found in the case of other drugs as well. 
In Austria, poly-drug use including opiates, with intravenous use predominating, has tradi-
tionally played a central role. In the last few years trends towards a wider range of sub-
stances taken in the context of poly-drug use has emerged. This goes hand in hand with the 
rising importance of stimulants on the one hand and the tendency to replace heroin by mor-
phines in the context of opiate use on the other. Intravenous use of cocaine has also become 
more relevant in the street scene. 
A prevalence rate of 20 000 to 30 000 persons at the most who show patterns of problem 
opiate use - probably in the context of multiple drug use in most cases - seems realistic for 
Austria (see Chapter 4.1). However, prevalence estimates are difficult to give as methodo-
logical problems arise due to the complexity of the subject. Therefore the figures obtained 
are conclusive to a limited extent only (for more details see ÖBIG 2003b). Thus any results 
are rough approximations and have to be interpreted with caution. 
4.1 Prevalence and incidence estimates 
In Austria scientific estimates regarding the prevalence of problem drug use are only avail-
able for opiates or poly-drug use including opiates. The most recent data (see above) relate 
to the year 2002 and have already been discussed in detail in last year’s report (ÖBIG 
2003b). For the capture-recapture method, on which the prevalence estimate is based, data 
on substitution treatment and reports to the police relating to opiates were used. A number of 
methodological problems with regard to data quality of the sources used will be investigated 
in autumn 2004, when an additional study will be carried out. 2005 will see an update of the 
prevalence estimate of the number of problem opiate users in 2003 and 2004 ÖBIG drew up 
in its function as REITOX Focal Point. 
Recent information has confirmed the interpretation given in the report of 2003, i.e. that the 
estimate for 2002 in part reflects increased experimental use and on the other hand shows 
general problem drug use in the form of poly-drug consumption. With regard to experimental 
use, a number of provinces report risky patterns of use by young people, which to some ex-
tent includes simultaneous use of various substances. As no scientific analyses are available 
in this field it has become increasingly difficult to distinguish between problem use and ex-
perimental use (see Chapter 2.2). Regarding intravenous use of cocaine it has been reported 
that almost all members of the cocaine-taking drug street scene of Vienna also show pat-
terns of problem opiate use (VWS 2003b). Thus a large part of the group of intravenous co-
caine users has apparently been included in the prevalence estimate mentioned above. 
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4.2 Profiles of clients in treatment (characteristics, 
patterns of use) 
As Austria has no uniform data collection system, only few data of limited interpretative value 
are yet available for the field of treatment. At present the political and technical implementa-
tion of a nation-wide treatment documentation system is being prepared. Data on clients of 
drug help centres cannot be collected on the basis of this system before 2005. 
For the first time, data for Vienna are now available from the basic documentation compiled 
by the Viennese working group on documentation (IFES 2003b). The evaluable data relate to 
a total of 2 006 clients who turned to one of 20 drug help centres in Vienna for counselling for 
the first time in 2002. In this context, counselling was defined as a minimum of three contacts 
at intervals of no more than three months. Regarding data quality, it should be mentioned 
that 3 633 sets of data had to be excluded as they were incomplete to an extent that made 
analysis impossible. Furthermore, the data sets used for analysis were also incomplete to 
varying degrees, therefore the total number to which the individual percentages relate are 
given in brackets in each case. The data were gathered among clients of drug counselling 
centres, therefore they only refer to those persons with drug problems who have actually 
turned to the drug help system. 
28% of the clients receiving counselling were women and 72% were men (n = 1 933). 46% 
were between 21 and 30 years old, 20% were under 21, 26% were between 31 and 40, and 
8% were over 40 (n = 1 926). While 31% of the female clients were under 21, the share of 
men in this age group was only 15%. 22% of the clients had one or more children 
(n = 1 208). Approximately half of the respondents had completed lower secondary school or 
the polytechnic year after lower secondary school, and only 14% had completed upper sec-
ondary schools of general or vocational education (n = 1 176). The majority of clients was un-
employed when they turned to the counselling centres (70% of n = 1 263; see Chapter 8.1). 
32% of the clients turned to a drug counselling centre for the first time, and 68% of them had 
already received drug counselling at such a centre at least once (n = 838). 35% were under-
going substitution treatment (n = 1 392). 
Their average age of first use was 14.2 years in the case of alcohol (n = 669), 15.5 years for 
cannabis (n = 792), 18.4 years for ecstasy (n = 417), 20 years for benzodiazepines (n = 434), 
19.3 years for heroin (n = 943), and 20.2 years for cocaine (n = 727). With the exception of 
alcohol, women were between 1 and 2 years younger when they used any of these sub-
stances for the first time. Regarding drug use in the past four weeks, 48% indicated canna-
bis, 48% had used heroin, 39% had taken other opiates and substitution substances, 41% 
indicated cocaine and 30%, benzodiazepines (n = 849). What was less frequently found was 
use of tranquillisers and hypnotics (10%), ecstasy (7%), stimulants, amphetamines or speed 
(4%), LSD (1%) and poppers (0.5%). Both heroin and cocaine were used intravenously in 
most cases. 
National monitoring of substitution treatment is performed by the BMGF and based on the 
reports of attending doctors. Although their reports are not complete and frequently not pro-
vided in due time (for more details on data quality see ÖBIG 2003b), they still give a general 
impression of both quantitative developments and characteristics of clients. Currently efforts 
are being made to improve the monitoring system.  
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The increasing acceptance of, and resort to, medically assisted treatment is reflected in the 
annually rising number of persons reported as currently undergoing substitution treatment. 
The number of first treatments (number of clients reported as undergoing substitution treat-
ment for the first time in life), after a slight decline in recent years, has risen again in 2003 
(see Figure 4.1). 
Figure 4.1: Development of annual registrations of persons currently undergoing substitution treatment 
in Austria by first treatment and continued treatment, from 1994 to 2003 
 
 
Note: Continued treatments are treatments started before the respective year or repeated treatments of persons having un-
dergone substitution treatment before. First treatments are treatments of persons who have never been in substitution treat-
ment before.  
Sources: BMGF, calculations by ÖBIG 
 
Figure 4.2 shows that the rise in first treatments is primarily accounted for by the age group 
up to 19 and the group between 20 and 24. From 1995 to 2000 the share of these two 
groups was between 25% and 40%, continuously rising since then to 54% in 2003. On the 
one hand this may indicate easier access to substitution treatment for young opiate users. 
On the other, this rise may also point to an increasing prevalence of (poly-)drug use including 
opiates. What is interesting in this connection is that the rise in first treatments greatly differs 
according to region. For instance, the highest increases have been registered in Lower Aus-
tria (2000: 86 first treatments; 2003: 152 first treatments) and Styria (2000: 68 first treat-
ments; 2003: 211 first treatments), while Vienna (2000: 392 first treatments; 2003: 287 first 
treatments) and Vorarlberg (2000: 67 first treatments; 2003: 40 first treatments) report slight 
declines. 
 
 
 
 
1,493 1,768
2,024
2,375
2,765
3,049
3,534
4,121
4,712
5,168
5,522
458
502
546
602
633
822
725
891
689
782
566
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
5,500
6,000
6,500
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Year
Pe
rs
on
s 
tre
at
ed
First treatments
Continued
treatments
Chapter 4: Problem Drug Use 
 23
Figure 4.2: First substitution treatment in life by age, from 1994 to 2003 
 
Sources: BMGF, calculations by ÖBIG 
Gender-related analyses show that the share of women in persons undergoing substitution 
treatment for the first time has been between 25% and 35% over the years. In 2003, as in 
previous years, the share of women in the group under 20 undergoing treatment for the first 
time (37%) was markedly higher than in any other age group. In the older age groups men 
predominate: in the group between 20 and 24 years the share of women is 25%, in the group 
between 25 and 34, 16% and among patients over 34, 28%. 
4.3 Main characteristics and patterns of use 
from non-treatment sources 
Helpful information on current patterns of use in the drug scene of Vienna, and on a number 
of other sociodemographic data, also comes from studies on intravenous use of hard drugs 
based on syringe tests, which were carried out in the context of the syringe exchange pro-
gramme (Haltmayer and Schmid 2004; for more details see Chapter 10.3).  
A total of 491 persons returned standardised questionnaires; 79% of them were men and 
21%, women. 9% were between 15 and 19 years old, 30% between 20 and 24, 23% be-
tween 25 and 29, 17% between 30 and 25 and 21% over 35. 24% lived on the street, 5% 
lived in shelters and 71% in a flat (see Chapter 8.1). 
362 persons provided information on the kind of substance(s) they had thought to have in-
jected with the syringe handed in for exchange (in many cases the substance actually con-
sumed is not identical with the substance users believe to have bought or consumed; see 
Chapter 10.3). Only 4.7 of the persons said the syringes exchanged ought to contain nothing 
but heroin. 27% indicated cocaine, 24% a blend of heroin and cocaine, 21% pharmaceutical 
products containing morphine, which are substances frequently used for substitution treat-
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ment, and 16% indicated poly-drug use without specifying any kind of substance. Single indi-
cations concerned Rohypnol, methadone and speed. 
A comparison of the shares of syringes containing pure morphine from pharmaceutical pro-
duction has shown a decline in use of this substance from 1998 to 2002 (from 37% to 26%). 
The authors relate this to the fact that morphines prescribed for substitution treatment in Vi-
enna increased by more than 200 percent in the same period. They conclude that the market 
for morphine that is injected under misuse conditions seems to be saturated and that better 
availability of oral morphine in the context of medically assisted treatment has not led to a 
rise in intravenous morphine use (see Chapter 5.3). 
The EU study “The Support Needs for Cocaine and Crack Users”, in which Vienna is partici-
pating, includes qualitative interviews with cocaine users, toxicological urinalyses of clients of 
the Vienna drug outpatient department as well as interviews with experts (Fischer 2004). The 
cocaine users were divided into a treatment group (additional use of cocaine during substitu-
tion treatment), a scene group (intravenous cocaine use - no treatment) and a party group 
(only snorting - no treatment). The most pronounced differences were found between the 
party group and the scene group. The average party group member had a higher level of 
education, was younger (25.6 years v. 29.4 years), had used the substance for a shorter time 
(3.7 years v. 5.8 years) and less often (8 days v. 22 days in the past month). The party group 
was (still) fully integrated in working life (8 days per month without a job v. 25 days). The uri-
nalyses carried out for the study to detect additional use of drugs by persons undergoing 
substitution treatment showed a rise in additional cocaine use (1996: 33%; 2000: 39%; 2001: 
47%; 2002: 53%). 
Giacomuzzi et al. (2004) conducted an anonymous survey among 158 patients of the Uni-
versity Hospital of Innsbruck who were undergoing outpatient substitution treatment. 31% of 
the respondents were women and 69% were men. The average age of the women was 28.5 
years and of the men, 31.5 years. 18% indicated daily additional use of slow release mor-
phines, and 14% daily additional use of benzodiazepines. 4% said they used additional daily 
doses of cocaine. 64% of the men and 91% of the women had used cocaine at least once 
within a year. Regarding additional use of morphines, easy availability in the black market 
was pointed out as a relevant factor. Furthermore the study stresses the rising importance of 
cocaine both in the form of excessive cocaine use (cocaine binge) and as a substance used 
intermittently or in addition to opiates. 
The study on cocaine use in Vienna’s street drug scene (VWS 2003b) also reports increasing 
cocaine consumption in the street scene. The authors assume that approximately 40% of the 
street scene members regularly inject cocaine, and that around 25% of them pursue the 
high-risk pattern of cocaine binges (massive cocaine use up to 20 times a day for a few 
days) followed by crash phases. The binge stage is often accompanied by delinquency, non-
observance of safer use rules and general personal neglect (see Chapter 6.2). 
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5 Drug-Related Treatment  
Austria attributes great importance to a diversification of treatment options. As a result, in the 
past decade the inpatient sector saw a development from long-term to short-term treatment 
and generally, to more flexibility with regard to possible kinds of therapy, for instance in the 
form of modular systems. This more flexible approach aims at taking individual needs into 
account more strongly. Trends towards diversification also show in the field of medically as-
sisted treatment, where a widening range of substances have been prescribed. In quantita-
tive terms, substitution treatment has become the most important form of therapy in Austria, 
and efforts to improve this form of treatment are continuously made. 
Drug-specific counselling, care and treatment services are provided both by specialised cen-
tres and in the context of the general health care system (e.g. psychiatric hospitals, psycho-
social services, established physicians). They include - primarily in the outpatient sector but 
increasingly often also for inpatients - both measures oriented towards drug-free treatment 
and substitution treatment. Therefore they can be classified to a limited extent only. As the 
general aim is to build a comprehensive care network, most centres also provide a variety of 
preparatory and aftercare measures as well as sparetime and reintegration services (see 
Chapter 9.1) and also interventions for specific target groups (e.g. young people or persons 
with psychiatric comorbidity). 
5.1 Treatment systems 
By now Austria has an almost nation-wide network of drug-related counselling, care and 
treatment centres (see Maps 5.1 and 5.2). So far, the existing scope of treatment and care 
services have been regarded as sufficient, however, a number of problems have emerged. 
By the end of 2003, all inpatient and outpatient drug help facilities of Vienna had reached 
their limits, so outpatient capacities have to be expanded and the inpatient sector should be-
come more flexible in order to enhance utilisation (FSW 2004a). In Upper Austria, the addic-
tion counselling centres no longer have any free capacities, and waiting lists had to be intro-
duced (see Chapter 12.2). Unless subsidies are increased, the pertinent services will have to 
be restricted and full coverage will be impossible (Suchtkoordination OÖ 2003). In Styria, a 
few district counselling centres also report long waiting times due to capacity problems 
(Ederer, personal information). On the other hand, based on the new expansion plan for 
general coverage of Styria, the counselling services at Liezen were improved, and new 
counselling centres were established at Schladming and Weiz. In Styria’s provincial capital 
Graz, a new drug outpatient department of the University Hospital of Psychiatry was opened 
in January 2004, which focuses on substitution treatment for adolescents and young adults 
and is currently in the process of becoming established. In Salzburg, the issue of decentralis-
ing substitution is under discussion (Schabus-Eder, personal information). SUST, Salzburg’s 
centre for drug patients without social insurance, which in addition to providing comprehen-
sive treatment and care, also dispenses substitution substances, has proven its worth. It 
could thus serve as a model with regard to the plan to widen the range of possible treat-
ments.
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Drug help centres whose names have officially been announced after an examination proce-
dure according to Section 15 of the SMG have to meet federal quality standards defined by 
the Ministry of Health. Also at the provincial level relevant criteria and standards exist for the 
field of drug counselling and drug treatment. In order to review its quality standards, the as-
sociation Dialog conducted a survey among its clients, which led to a very positive feedback 
in particular with regard to quality of relationships and fast, non-bureaucratic help (Dialog 
2003). In autumn 2003 the Medical Association of Vienna issued a drug manual to assist es-
tablished doctors in their work with addicted patients (FSW 2004a). In Carinthia a working 
group will draw up guidelines for decisions on substitution treatment and drug-free treatment, 
from which requirements for treatment and care structures are derived (Prehslauer, personal 
information). 
Other important measures to improve drug-related treatment include further training schemes 
and improvement of regional cooperation structures. In Vienna the CONTACT hospital con-
nection service organised a series of further training courses on the subject of addicted pa-
tients in hospital treatment (FSW 2004a). In March 2004 ARGE Suchtkompetenz, a working 
group for addiction competence, held a further training event on addiction families as com-
munities of fate and the meaning of addiction for families (b.a.s. 2004). Eventually, perspec-
tives for transboundary regional cooperation were discussed in the meeting Beyond Borders 
- Perspectives for Regional Cooperation in Treating Addiction, organised by Dialog in autumn 
2003 (see Chapter 1.4). 
In the Tyrol, a cooperation model to treat under-age addicted patients exists between the 
Outpatient Department of Dependence-Related Diseases and the Department of Child Neu-
ropsychiatry at the University Hospital of Psychiatry (Kern, personal information). In Styria, a 
networking meeting was held for the first time with the aim to improve the cooperation of the 
individual inpatient departments and clinics. In Vienna regular networking meetings take 
place for all drug centres, and a weekly e-mail newsletter provides information on services 
and waiting times (FSW 2004a). The drug social work services at Vienna General Hospital 
(see Chapter 7.4) also contribute to better networking between different therapy departments 
in the General Hospital, counselling services by established doctors and the Municipal Youth 
and Family Offices, in particular for the group of pregnant opiate addicts. Furthermore treat-
ment and care for withdrawal patients at intensive care units and referral to long-term therapy 
institutions are organised. 
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Map 5.1: Specialised providing treatment, counselling and care services for drug users and drug patientsfacilities
2 Number of facilities (to the right of the symbol) if more than
one facility of the category in question is available in one district
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Inpatient facilities for short-term treatment
Inpatient facilities for physical withdrawal
Outpatient drug facilities and departments
Low threshold facilities
Counselling centres
Outpatient counselling centres (open less than 15 hours/week)
Inpatient facilities for long-term treatment
Therapeutic facilities in prison
Note:
Themap provides an overview of selected drug-related facilities, broken down by district. Themap does not specify quantitative and qualitative aspects (i.e. opening hours or number and qualification
of personnel, respectively). However, a distinction was made in the field of counselling, which is frequently offered by general facilities covering a broader range of services (psychosocial counselling
centres, addiction counselling centres, etc.) though limited to a few hours a week. Specialised drug counselling organisations with limited opening hours have been listed seperately (see legend).
Please note also that in addition general health services (e.g. general practitioners, hospitals) are available for drug users and addicts - they are not included in this map.
Source: ÖBIG - based on information by the Drug Coordinators and Drug Representatives as of August 2004
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Map 5.2: Specialised treatment, counselling and care for drug users and drug patientsservices
2 Number of services (to the right of the symbol) if more than
one service of the category in question is available in one district
Prevention of infectious diseases - testing and vaccination
Outreach work (Streetwork, bus, connection services, mobile youth work, etc.)
Housing for former drug addicts - aftercare (HalfWayHouse, housing communities, etc.)
Housing for drug addicts (temporary sleeping facilities, etc.)
Occupation projects for drug addicts (low threshold)
Occupation projects for former drug addicts (aftercare, reintegration, etc.)
Prevention of infectious diseases - syringe exchange and distribution
Outpatient psychotherapy for drug addicts
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Note:
The map provides an overview of selected drug-related services, broken down by district. The map does not specify quantitative and qualitative aspects (i.e. opening hours or number and qualificati-
on of personnel, respectively). It distinguishes between kinds of service and not facilities (see Map. 5.1), therefore a single facility can appear in several categories. Please note that general services
(e.g. public employment service, emergency shelters) are also available for drug users and addicts - they are not included in this map.
Source: ÖBIG - based on information by the Drug Coordinators and Drug Representatives as of August 2004
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5.2 Drug-free treatment 
No relevant changes took place in the field of drug-free treatment. In Austria withdrawal 
treatment is mostly carried out in inpatient departments, but more and more often also in 
outpatient settings. A publication by Eisenbach-Stangl (2003b) analyses this trend towards 
outpatient forms of treatments and attributes it to factors such as market pressure, i.e. the 
fact that the least expensive therapy, and not the best one, is sought. As a result, help ser-
vices for addicted patients (primarily inpatient treatment), self-help organisations and estab-
lished psychotherapists are becoming competitors at the expense of patients, instead of pro-
viding complementary services in the help network for addicted patients and jointly taking ac-
tion against the great number of existing restrictions. 
Quality assurance has continued to be an issue. For instance Grüner Kreis had its services 
in the field of preparatory care, vocational orientation and aftercare evaluated (Grüner Kreis 
2003). Analyses by Grüner Kreis (2004) show that long-term therapy is more successful for 
male patients than for women. This effect is more pronounced among young people than 
among adults, however. A comparison of persons undergoing short-term therapy v. long-
term treatment patients has revealed significant differences with regard to age, drug use and 
age at first use. Persons undergoing short-term therapy are usually older at the beginning of 
treatment and rather tend to use alcohol than illicit substances (cannabis, heroin, opiates, 
amphetamines) and benzodiazepines or other tranquillisers, and their average age is higher 
at the time of first use of the individual substances. Patients taking part in the special pro-
gramme on psychogenic multimorbidity display differences to conventional long-term therapy 
patients with regard to drug use and the treatment process (see Chapter 7.3). The former 
consume significantly more alcohol and considerably less heroin and cocaine and less often 
other opiates or opiate substitutes, and eventually a larger share of them successfully com-
plete therapy (26% v. 14%). 
A thesis (Felder 2004) comparing inpatient drug-free therapy and outpatient methadone 
treatment has shown that in the course of either form of treatment considerable improvement 
is achieved, but also that distinctive differences appear. For instance, the inpatient group was 
better able to alleviate their psychological problems and stress with regard to housing situa-
tion or further legal proceedings to be expected, while the outpatient group was better able to 
solve family problems. What is also interesting in this respect is that satisfaction with their 
sparetime activities had not significantly risen in the outpatient group. According to the au-
thor, a greater number of sparetime and everyday-routine projects for substitution patients 
should be created, preferably for a heterogeneous target group so as to facilitate social con-
tacts also to persons outside the drug scene. However it was not possible in the context of 
this study to find out which form of treatment was more efficient. What could be demon-
strated however is that different groups are addressed: outpatient methadone treatment 
rather attracts older patients with more severe addiction problems who also have more 
pressing financial problems, while inpatient drug-free therapy is rather an option for younger 
persons who have more frequently been charged and sentenced and who may rely on help 
in particular by relatives. 
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5.3 Medically assisted treatment 
The general conditions for substitution treatment have not fundamentally changed. In the re-
porting period the tendency to prescribe slow release morphines more frequently was a point 
of discussion. In Austria the share of methadone prescriptions for first treatment patients fell 
to 28% in 2003, while treatment with slow release morphines and buprenorphine rose to 45% 
and 26% respectively (see Figure 5.1 and Chapter 11). A number of experts say that misuse 
(black market problem, intravenous use) of slow release morphines has strongly risen (see 
Chapter 4.2). A bibliographical study on intravenous use of talcum powder focused on the 
health consequences when pills or capsules originally produced for oral use are injected 
(ÖBIG 2004b). It was found that intravenous use of talcum powder could cause serious, and 
in most cases irreversible, damage of the lungs and also other organs. Such damage may be 
induced by intravenous use of pharmaceuticals containing talcum powder, for instance sub-
stitution substances, but also heroin or cocaine cut with talcum powder. Consequently, the 
Ministry of Health called an expert hearing, and as a result, it was decided at the Drug Forum 
held in April 2004 to establish a working group dealing with an optimisation of medically as-
sisted drug treatment. It studies ways to improve the general conditions of substitution treat-
ment (e.g. safe dispensing, further training; see also below), and in addition a subgroup fo-
cusing on slow release morphines will specifically study the benefits and risks of the use of 
slow release morphines for medically assisted treatment. 
Figure 5.1: Development of kinds of substitution substance used for first treatment, from 1998 to 2003 
Sources: BMGF, calculations by ÖBIG 
Quality assurance was also a subject treated by a working group in Vienna that met in spring 
2004 to prepare recommendations in this regard (FSW 2004a). These include diagnosing for 
addicted patients under 18 by recognised drug centres or drug outpatient departments as 
well as expert opinions by specialists in child psychiatry, among other measures. If slow re-
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lease morphines are prescribed, particularly accurate diagnosis is imperative, and the coop-
eration of attending physicians, drug units and public health officers should be improved. The 
working group also prepared a draft for a legally binding regulation concerning substances 
dispensed to patients to take with them. This proposal was taken up by the Ministry of Health 
and a corresponding amendment was presented for examination. In Carinthia a working 
group deals with the advancement of safety standards aimed at preventing the misuse of 
substitution substances. Here the focus is placed on the need for further training for and as-
sistance of pharmacy staff who have difficult addicted clients (Prehslauer, personal informa-
tion). In Lower Austria further training courses in substitution treatment were held for physi-
cians and pharmacists (Brunner, personal information). Additional further training schemes 
dealing with addiction have been planned in the context of a curriculum in cooperation with 
the Medical Association. In Styria, talks among Addiction Coordinators, diagnosing and at-
tending physicians and other treatment centres have been held (Ederer, personal informa-
tion). It has also been planned to establish a substitution data base to optimise the coopera-
tion of all parties involved in treatment. Early in 2004 informal meetings of physicians in Bur-
genland were started (Siegl, personal information). At the first meeting an adaptation of Vi-
enna’s model for the province of Burgenland was discussed. 
As patients suffering from multimorbidity or having multiple problems often find it difficult to 
sustain regular substitution treatment, the Ganslwirt centre drew up a plan for low-threshold 
medically assisted treatment (VWS 2004c). 
In the reporting period the Ludwig-Boltzmann Institute for Addiction Research, commissioned 
by the Vienna Social Fund, drew up an expert opinion on heroin-assisted treatment of 
chronic opiate addicts, in which the results of existing international programmes were ana-
lysed (Springer 2003a). This subject gives rise to controversial debate both in Austria and the 
European Union. Springer recommends to expand and optimise medically assisted treatment 
in terms of a multidimensional, diversified range of treatment options (with regard to sub-
stances, doses and modes of use) paralleled by corresponding research. This research 
should preferably include comparative studies on intravenous heroin and intravenous Di-
laudid as well as peroral administration of slow release heroin or slow release morphines so 
that any differences in effects may be identified and indications for heroin-assisted treatment 
may be defined. 
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6 Health Correlates and Consequences 
The Ministry of Health has collected data on drug-related deaths in Austria since 1989. After 
a peak in the mid-1990s (see Figure 6.1) the overall number of (directly and indirectly) drug-
related deaths went down. In the last few years again a slight rise has shown (see ÖBIG 
2002a). 
Infectious diseases are relevant in particular with regard to the risk of transmission due to in-
travenous drug use. The available data in this context are mostly based on a few small sam-
ples from treatment institutions or low-threshold counselling centres (see ÖBIG 2000). At the 
end of the 1980s the HIV prevalence rate still was around 20% and has since then stabilised 
at a low level (maximum: 5%). However, the prevalence rates of hepatitis have been high in 
recent years: between 50% and 80% in the case of hepatitis C and between 30% and 50% 
for hepatitis B. 
Psychiatric comorbidity has increasingly been discussed in the context of drug dependence 
in Austria. Although no routine data have been collected in this field, many data and reports 
from treatment centres are available. These data indicate a high prevalence of psychiatric 
co-morbidity (dual diagnoses) among problem drug users (see ÖBIG 2003b).  
6.1 Drug-related deaths and mortality of drug users 
In 2003 the number of directly drug-related deaths (163 persons) was higher than in the two 
previous years (2001 and 2002: 139 cases each year) and about at the same level as in 
2000 (167 cases, see Table A4 of Annex A). As in previous years the data show a strong 
predominance of poly-drug intoxications including opiates (71% of all intoxications). Adding 
intoxications exclusively due to opiates (25% of all cases) one may conclude that 96% of all 
persons who die as a direct consequence of drug use have taken opiates. The number of in-
toxications solely involving opiates was 25%, which is a rise compared to previous years 
(1999: 18%, 2000: 11%, 2001 and 2002: 12%). 
A more detailed analysis according to substance used of the total number of 163 intoxica-
tions reveals that 39% of the persons in question had exclusively taken illicit drugs (single 
substances or combinations). In addition to illicit drugs in 18% of the cases alcohol was 
found as well, 30% had also taken psychoactive medicines and in 12% of the cases both al-
cohol and psychoactive medicines were detected (see Tables A8 and A9 of Annex A). Co-
caine was found in 30% of the cases (2000: 29%, 2001: 25%, 2002: 35%), but only three 
persons had exclusively taken cocaine. In one case death was caused by cocaine use com-
bined with inhaling of a propane and butane gas blend. One person had exclusively used 
amphetamine derivatives (MDMA and MDE). 
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Figure 6.1: Number of drug-related deaths in Austria by cause of death, from 1994 to 2003 
Note: Intoxications solely involving psychoactive medicines have not been included as of 2000 (see annex A). 
Source: BMGF 
Figure 6.2: Age distribution of directly drug-related deaths in Austria, from 1994 to 2003 
Source: BMGF 
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Closer examination of the kinds of opiates involved shows that morphine was used in 79% of 
the cases of fatal intoxications, heroin was found in 7%, and other opiates, in 24% of the 
cases. Methadone was detected in 10% of the fatal intoxications. However, when interpreting 
shares of morphine and heroin, one has to take into consideration that heroin is quickly me-
tabolised into morphine and thus any detection of morphine may also indicate a heroin in-
toxication. Therefore, according to experts one cannot safely assume misuse of slow release 
morphines when morphine is detected. Furthermore, the shares of directly drug-related 
deaths in which morphine is detected have varied considerably in the course of time (1999: 
46%, 2000: 85%, 2001: 68%, 2002: 73%).  
Table A5 in Annex A gives data broken down by cause of death as a direct or indirect conse-
quence of drug use. 
The share of women among persons who died as a direct consequence of drug use was 
18%, which is in line with the long-term average. Regarding indirect drug mortality women 
accounted for 31% of the cases, which is slightly above the average of the past 10 years 
(see Tables A6 and A7 of Annex A). 
Until 2002 the average age of persons dying as a direct consequence of drug use was rising. 
It was 27.7 years in 1991 for directly drug-related deaths, while in 2002 the average age of 
this group was 31.9 years. In 2003 a decline of average age was found for the first time, to 
29.5 years. The share of persons under 20 among the total number of direct drug fatalities 
was 12%, which is roughly the same as in previous years (1999: 12%, 2000: 11%, 2001: 
15%, 2002:13%); however, the share of persons dying from drug use at the age between 20 
and 24 rose to 23% (1999: 17%, 2000: 20%, 2001: 14%, 2002: 14%).  
With regard to indirectly drug-related deaths, average age further increased also in 2003, to 
36 years. 
The number of directly drug-related deaths has developed differently in the individual prov-
inces. In Upper Austria and Vienna rises have been found compared to the year before, 
while no relevant changes have occurred in the other provinces (see Table A4 of Annex A). 
However, these regional differences should not be over-interpreted as the number of cases 
is small in statistical terms and in a number of provinces considerable variations are found 
over time. 
It cannot yet be said whether the rise of directly drug-related deaths in 2003 may indicate a 
trend towards a quantitative increase of the drug problem in general. Many aspects of the re-
cent development are similar to the situation in 2000, a year in which an increase was also 
registered. However, in the two following years, directly drug-related deaths again declined to 
the level of 1999. Nevertheless in 2003, different to the year 2000, other areas of monitoring 
also point to an increase in problem drug use (see Chapter 4). 
The growing number of intoxications solely involving opiates could indicate a new rise in the 
relevance of opiates in the drug scene, which corresponds to a few individual reports from 
other areas of drug monitoring (see Chapter 4). Again, further interpretation will only be pos-
sible in comparison with data collected in the next few years. Poly-drug intoxications includ-
ing opiates, in spite of their declining share, are still the most frequent cause of death among 
persons dying as a direct consequence of drug use. Combinations with alcohol and psy-
choactive medicines are also found very frequently. High-risk patterns of poly-drug use, 
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where the effects of different substances may be potentiating and thus can hardly be con-
trolled, continue to be wide-spread (see Chapter 4) and constitute serious health hazards. 
With regard to cohort studies no new results are available for the reporting period.  
6.2 Drug-related infectious diseases 
Reliable statements regarding changes and trends in the context of drug-related infectious 
diseases can hardly be made because of the limited number of available data. Based on ex-
isting data, the HIV prevalence rate obviously continues to be low (2% to 8% at the most). 
The prevalence of hepatitis B (0% to a maximum of 34%) has significantly gone down in two 
facilities and remained at the same level as before in Vienna’s Ganslwirt drug centre. Lower 
prevalence rates than in the past have also been reported with regard to hepatitis C (39% to 
a maximum of 51%; see Table 6.1). However, on the basis of the samples available hardly 
any interpretation can be given for the slight decline in hepatitis prevalence rates, as the cor-
responding data come from voluntary tests and are thus not independent. For instance, per-
sons who already know that they have HCV infections do not tend to have tests repeated 
and therefore they are not included in the annual statistics. As a result, incidence and preva-
lence rates cannot be separated from each other. 
Table 6.1: Data on hepatitis B, hepatitis C and HIV infection rates in 2003 
Source of data HBV rate HCV rate HIV rate 
Lukasfeld therapy department 7% (2/27)1 44% (12/27) 4% (1/27) 
API long-term therapy department 1% (1/81)2 51% (41/81) 2% (2/81) 
Low-threshold centre Ganslwirt 34% (30/89)3 50% (51/103) 4% (6/151) 
Caritas Marienambulanz outpatient department 0% (17/0) 39% (11/28) not available 
Directly drug-related deaths not available 33% (54/163) 
42% (54/130)4 
7% (11/163) 
8% (11/130) 4 
1 This percentage relates to persons in whom antibodies to hepatitis B were found and whose medical history did not indicate a 
hepatitis B vaccination. 
2 This percentage relates to persons in whom antibodies to hepatitis B were found and for whom it was proved that they had not 
received vaccinations.  
3 This percentage relates to persons in whom hepatitis B antibodies or antigens were found and who had not yet received hepa-
titis B vaccinations (data obtained from Ganslwirt’s vaccination project). 
4 Only 130 out of a total number of 163 expert opinions on directly drug-related deaths explicitly indicate the presence or ab-
sence of HCV and HIV infections. In the case of the remaining 33 opinions it is not clear whether no tests for the relevant in-
fections were carried out or whether the results were negative and thus not mentioned. The two percentages given thus indi-
cate maximum and minimum levels of HCV and HIV prevalence rates. 
Sources: Duspara, personal information; API 2004; Haltmayer, personal information; BMGF; Anderwald, personal 
information 
In this context, the data concerning directly drug-related deaths are interesting as they are 
based on independent samples. For 2003, a HIV prevalence rate of 8% is reported, which is 
slightly higher than in previous years (5%). Furthermore, the prevalence rate of hepatitis C 
was included for the first time. At approximately 40%, it is markedly lower than estimated for 
the last few years (see above). Further analyses and statements will be possible on the basis 
of the sero-prevalence study on hepatitis C financed by the BMGF, which ÖBIG plans to 
carry out in 2005. While the above trend of declining hepatitis prevalence rates is undoubt-
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edly encouraging, according to recent reports by low-threshold facilities intravenous cocaine 
users of the street scene often do not tend to obey safer use rules. This is explained in par-
ticular by the substance-related consequences of cocaine use such as strong craving and 
cocaine-induced restlessness. As a result, HCV and HIV infections are rising in phases of 
excessive use (VWS 2003b, see Chapters 6.3 and 4.2). 
According to experts, TB infections still hardly constitute a problem in the context of drug-
related comorbidity in Austria. Only a few isolated cases have been reported. The data of the 
Vienna Basic Documentation (BADO) show prevalence rates of only 1% for sexually trans-
mitted diseases (IFES 2003b). 
6.3 Psychiatric comorbidity 
For an overview of psychiatric comorbidity in connection with drug use in Austria please con-
sult the corresponding key issue chapter of last year’s report (ÖBIG 2003b). 
Generally speaking, no routine data on psychiatric comorbidity are yet available, and recent 
data primarily come from treatment facilities. As different codes for diagnosing are used 
(DSM IV, ICD-9, ICD-10) and no uniform methods of documentation are applied, the data 
cannot easily be compared. However, what can be deduced nevertheless is high prevalence 
rates of psychiatric comorbidity (dual diagnoses) among problem drug users. This particularly 
applies to persons undergoing inpatient long-term treatment. For instance, in API’s long-term 
therapy department at Mödling, Lower Austria, 82% out of a total of 51 newly admitted pa-
tients suffered from at least one personality disorder, with narcissistic and avoidant personal-
ity disorders as well as borderline cases (according to DSM IV) predominating. Six out of 
nine young patients suffered from antisocial personality disorders starting before the age of 
15 (API 2004). Vienna’s BADO, which includes a larger number of data, reports that one out 
of five clients covered had undergone psychiatric treatment in the past 12 months. With re-
gard to age groups, a noticeable rise up to the age of 25 shows, and after this age the rele-
vant figures remain constant (IFES 2003b). 
In connection with phases of excessive cocaine use (binges), specific personality changes 
such as delusional disorders (e.g. persecutory delusion) as well as auditory, visual or tactile 
hallucinations, distrust, anxiety and panic attacks may occur. These psychiatric symptoms 
are acute effects of cocaine binges and disappear after the crash. However, such personality 
changes may be a problem on the one hand in contacts with the police and on the other they 
may affect adherence to safer use rules in the case of injection of drugs (VWS 2003b, see 
Chapter 6.2). 
The typical consumption patterns of the party scene are also becoming more and more rele-
vant in a psychiatric sense. The rapid spread of metamphetamine derivatives sold in many 
different structures and doses, paralleled by a tendency to combine them with other psy-
choactive substances, may induce panic or anxiety disorders, affective disorders, psychotic 
reactions and other symptoms (Kocsis et al. 2003). 
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6.4 Other drug-related health correlates and consequences 
In addition to psychiatric comorbidity and the physical consequences of the aforementioned 
infections such as AIDS or hepatitis, there are also other somatic diseases and problems that 
particularly affect injecting drug users as a result of the problematic living conditions which 
they are often facing. 
In Vienna the number of ambulance services called because of drug emergencies with sus-
pected overdoses further rose in 2003, thus continuing the upwards trend of previous years 
(1998: 360 calls, 2001: 448, 2002: 525, 2003: 618; FSW 2004d). According to low-threshold 
facilities in Vienna, in 2003 a total of 67 life-saving measures had to be taken (VWS 2004b, 
VWS 2004c), and the Vienna-based streetwork facility reports that 614 wounds had to be 
dressed (VWS 2004b).  
The statistics of the Vienna Basic Documentation show that only 30% of the persons in-
cluded did not have any current health problems. This percentage definitely correlates with 
the age of the drug users concerned. Among the group aged 15 or younger it is still 88% and 
goes down to 30% for the group between 21 and 24, and to 13% in the case of drug users 
between 36 and 40. The health conditions primarily named include dental problems, gastro-
intestinal problems, spasms, epileptic seizures and skin or vein problems (IFES 2003b). 
Typical health consequences of excessive cocaine use include high degrees of lesions and 
pronounced physical and mental fatigue (crash) paralleled by psychomotor restlessness 
(VWS 2003b; see Chapter 6.2). 
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7 Responses to Health Correlates and 
Consequences 
In Austria responses to health correlates and consequences include a wide range of inter-
ventions. The relevant measures focus on drug-related infectious diseases, thus low-
threshold assistance aimed at harm reduction prevails. For instance, syringe exchange, 
hepatitis vaccinations and information on safer sex/safer use are typical services performed 
by low-threshold centres and outreach facilities (streetwork). Treatment of health conse-
quences is primarily provided by the general health-care system (e.g. emergency physicians, 
psychiatrists, general practitioners). In the last few years prevention of overdoses and co-
morbidity have played increasingly important roles in this context. 
7.1 Prevention of drug-related deaths 
Measures to prevent overdoses mainly focus on opiates and poly-drug use. However, re-
cently other substances such as cocaine, amphetamines or ecstasy have also been taken 
into account to a greater extent: for instance, the websites of Do it Yourself (www.doit.at) and 
ChEck iT! (www.checkyourdrugs.at) give very detailed first-aid instructions for dealing with 
overdoses of various substances, and in an analysis of the risk potential of recreational drugs 
it is pointed out that emergency rooms should not forget to consider possible use of am-
phetamines and methamphetamines when differential diagnoses are made (Kocsis et al. 
2003). 
The responsible federal and provincial authorities have demanded that autopsy reports on 
drug-related deaths should more quickly be communicated to the competent provincial health 
departments and the Federal Ministry of Health so that any necessary measures to be de-
rived from these reports may be planned and relevant actions may be taken. 
In Vienna the CONTACT hospital connection service has further increased first contacts to 
persons having overdosed drugs (2002: n= 429; 2003: n= 478). The number of persons re-
ceiving counselling in hospital or after release from hospital has remained at a constant level 
of 1 110 contacts (FSW 2004b). 
The secondary prevention activities of ChEck iT!, Vienna’s mobile pill-testing service, con-
tinue to play a central role in the field of synthetic drugs. In the reporting year, 221 samples 
of illicit psychoactive substances were analysed. Furthermore, overdosing is an important 
theme in the talks that take place during events (VWS 2004d; see Chapter 3.2). In the Tyrol 
the drug-testing programme [fact] was prepared. At the implementation state, analyses of 
substance samples will be carried out at five large dance floor events in Innsbruck, in coop-
eration with the laboratory of the psychiatric department (MDA basecamp 2004). 
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Safer use measures such as safer use trainings serve the purpose of preventing both over-
doses and infection. In the Tyrol the low-threshold centre KOMFÜDRO organised such a 
training for staff of various social institutions and also for drug users (Komfüdro 2004). In Vi-
enna, safer use training is more and more often replaced by specific information initiatives 
such as publication of booklets and special training for the staff of low-threshold centres, with 
the focus placed on information talks on this subject (VWS 2004b). 
MDA basecamp has repeatedly organised training courses dealing with drug use and drug 
emergencies for the target groups of ambulance and security staff on the one hand and 
young drug users on the other. As it has turned out that young people often do not call emer-
gency services for fear of subsequent prosecution, the latter target group is regarded as par-
ticularly important (MDA basecamp 2004).  
The issue of consumption rooms continues to be debated. The Ludwig Boltzmann Institute 
for Addiction Research, on behalf of the Vienna Social Fund (FSW), has drawn up an expert 
opinion on this subject, which summarises the historical development, evaluations, (com-
parative) studies, recommendations as well as arguments put forward in this context. One 
obvious positive effect of consumption rooms is that fatal opiate overdoses are reduced in 
this way (Springer 2003b, FSW 2004a). Consumption rooms have also been demanded with 
regard to support for the cocaine street scene (VWS 2003b). At present it has not been 
planned to implement any concrete project. 
7.2 Prevention and treatment of drug-related infectious 
diseases 
A nation-wide hepatitis vaccination programme for the target group of intravenous drug users 
continues to be inexistent in Austria, but regional and local initiatives have been active in this 
field. Vorarlberg has continued its current hepatitis A and B programme started in 1999. In 
Vienna, the Ganslwirt low-threshold centre carried out a total of 108 HBV vaccinations in 
2003 and since the beginning of 2004 hepatitis A vaccinations have also been included 
(VWS 2004c). In the drug outpatient department of Innsbruck 89 persons were vaccinated 
against hepatitis B in 2003 (Universitätsklinik für Psychiatrie Innsbruck 2004). At the federal 
level the HCV sero-prevalence study under preparation (see Chapter 6.2) will include hepati-
tis B vaccination services for the participating drug users. 
Syringe exchange is possible in six of the nine provinces, as a service provided by a total of 
16 centres and one mobile facility. Table A24 of Annex A gives an overview of the number of 
syringes exchanged and sold in 2003 in the individual provinces. The return rate again was 
between 93% and 96%. In 2003 the Vienna Social Projects Association published a separate 
report on its activities in the syringe exchange programme, which states that the number of 
syringes exchanged in Vienna has further risen and that the return rate has gone up to 
94.1% (VWS 2004a; see Figure 7.1). In Lower Austria a strong increase of intravenous her-
oin use was registered and thus urgent need for syringe exchange services (vending ma-
chines) was stressed (Brunner, personal information). In Carinthia syringe exchange is pos-
sible only in a small number of centres and limited to members of the - rather closed - drug 
scene (Arbesser, personal information). 
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Figure 7.1: Number of syringes sold or exchanged in the context of the syringe distribution programme 
in the open drug scene in Vienna from 1994 to 2003 
Source: VWS 2004a 
Currently a total of 12 syringe vending machines are operated in the provinces of Salzburg, 
Styria, the Tyrol and Vorarlberg. In 2003, 70 135 safer use sets were sold through these 
channels at prices between EUR 1 and 1.70. In all provinces mentioned these sets include 
sterile needles, syringes, swabs and a safer use booklet including addresses of drug help 
centres. Ascorbic acid, distilled water or condoms are distributed only in a few provinces. 
Graz plans to establish a second vending machine, as the existing one has been well ac-
cepted and has resulted in higher contact frequencies in the centre (Ederer, personal infor-
mation). In Upper Austria a plan for placing a vending machine already exists, and in Lower 
Austria this option is under discussion. Vienna, due to its specific regional situation, has 
opted against a vending machine and prefers a mobile exchange programme, as personal 
contacts are regarded as essential for communicating prevention messages. In Styria the 
sets sold in the vending machines are prepared by clients in the context of an occupational 
project. A similar procedures is also envisaged by Upper Austria. 
Information material is available as booklets or safer use cards on practical subjects such as 
how to inject correctly or emergency disinfection; furthermore the issues of drug depend-
ence, pregnancy and cocaine are raised (FSW 2004c, VWS 2004e; Zeder, personal informa-
tion). Last year Streetwork of Vienna distributed specific information material for Russian na-
tive speakers, who have increasingly often been found in the drug scene (FSW 2004c). In 
addition a fact sheet on cocaine smoking was prepared for experts, focusing on a description 
of crack use by the techno scene of Vienna (VWS 2004d). 
In the context of the EU-wide study “Living with the Daily Dose” the situation of HIV-infected 
intravenous drug users was analysed and strategies to improve access and adherence to 
antiretroviral treatment (ARV) were sought. The study underlines the importance of social re-
lationships in treatment and care settings during ARV therapy, on the one hand between 
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HIV-infected drug users and the treatment and care staff, and on the other, in the form of 
structural networking of medical HIV/AIDS treatment facilities, professional AIDS help ser-
vices and drug help centres (see ÖBIG 2004a). Both inpatient and outpatient addiction 
treatment departments stress the relevance of professional networks (see Grüner Kreis 
2004, VWS 2004c). 
Cost-free, anonymous HIV and hepatitis tests are carried out by low-threshold centres such 
as do it yourself, Ganslwirt or H.I.O.B and also by a number of drug counselling and AIDS 
help centres of the individual provinces. In Graz, drug users may also have these tests made 
by the Marienambulanz low-threshold outpatient medical centre (www.caritas-graz.at). 
The theme of infectious diseases is increasingly often addressed in the context of services 
for women who work as prostitutes to finance drug use, for instance by low-threshold centres 
such as H.I.O.B or psychosocial care services in prisons (Dialog 2004, www.caritas-
vorarlberg.at/hiob; see Chapter 9.2). Eventually the drug counselling centre VIVA of Klagen-
furt has organised a hepatitis C support group for drug-dependent clients (www.gesundheit-
kaernten.at). 
7.3 Interventions related to psychiatric comorbidity 
In the field of interventions related to psychiatric comorbidity, the proven strategies and ap-
proaches to treatment and care have been continued (see ÖBIG 2003b). What is described 
as a particular challenge is the need to coordinate addiction-related care with general medi-
cal and psychiatric treatment. 
Grüner Kreis reports that their special programme for multimorbid addicted patients has 
shown good results with regard to completion of therapy as planned among this group of pa-
tients, who usually show strong tendencies to discontinue treatment (Grüner Kreis 2004; see 
Chapter 5.2). 
Specific problems have shown with regard to intravenous cocaine users, as they are difficult 
to access and compliance is low in this group. In most cases of depressive symptoms and 
suicidal patients, crisis intervention with admission to inpatient-treatment in psychiatric hospi-
tals is needed. For this reason Vienna has demanded acute care beds for this group, com-
bined with adequate forms of support focusing on the needs of these patients (VWS 2003b). 
7.4 Interventions related to other health correlates and 
consequences 
The drug social work centre at Vienna General Hospital provides services for the opiate-
addicted patients of three different departments of the General Hospital. The main focus is 
placed on pregnant opiate addicts and women who have recently given birth to babies. In 
2003 a total of 1 681 contacts were registered, 1 272 of them were contacts to women and 
409, contacts to men (FSW 2004c; see Chapter 5.1).  
The services for women provided by the low-threshold centre H.I.O.B include the regular 
presence of a female physician, who may carry out gynaecological examinations of female 
clients (www.caritas-vorarlberg.at/hiob). 
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8 Social Correlates and Consequences 
As in previous years, the most pressing social problems drug users are facing include in par-
ticular homelessness, unemployment and debts, which primarily applies to heavily addicted 
persons of the street scene. This development is further aggravated by the tight situation of 
the labour market. The number of reports to the police because of violations of the Narcotic 
Substances Act (SGG) has generally been at a constant, slightly declining level. Regarding 
the situation in prisons, according to experts between 25% and 50% of the prisoners use il-
licit drugs. 
8.1 Social exclusion 
The available data show that the social problems of drug addicts mentioned in past reports, 
in particular unemployment and unstable accommodation, continue to play an important role. 
For instance, in Vienna more than two thirds of drug clients had no, or no regular, jobs before 
they turned to drug counselling centres. The majority of these persons said they lived alone 
or with their parents, and approximately 10% lived on the street or in institutions. The main 
income of most clients was unemployment benefits or welfare assistance, and one out of 10 
clients said they had no source of income at all. Regarding highest level of education com-
pleted, the clients of drug help centres in Vienna fall noticeably short of the general popula-
tion average. The education of around half of the persons receiving counselling and care 
does not go further than attending or completing lower secondary school or the subsequent 
polytechnic year (IFES 2003b).  
This shows that the social situation of persons registered by the drug help system of Vienna 
is definitely worse compared to society in general (in terms of housing situation, educational 
level, employment, income and state of health). However, this does not necessarily mean 
that drug problems primarily concern socially disadvantaged groups, but only that these 
groups will more readily turn to the drug help system of Vienna than persons who (still) have 
social and financial resources (IFES 2003b). For more details of the data of the Vienna Basic 
Documentation of clients please consult Chapter 4.2. 
In 2001 and in May 2002, based on an evaluation of the emergency sleeping facility at the 
Ganslwirt centre, the corresponding situation was thoroughly investigated in order to obtain 
information on any changes in demand and supply of overnight accommodation. Sleeping 
facilities for drug users were created in centres now owned by the Vienna Social Fund 
(FSW). Although other organisations meanwhile also accept drug-using clients, demand is 
still fairly high. In particular, the problem of long-term accommodation for drug users has not 
yet been solved, as due to their patterns of use they are hardly able to meet conventional ob-
ligations demanded in this context, thus it is difficult for them to stay in the social network of 
institutions providing accommodation. If one looks at the distribution of overnight stays per 
person, it shows that many persons use overnight accommodation occasionally and few per-
sons use overnight facilities extremely often (VWS 2002). 
A demand analysis carried out in the Tyrol with regard to homeless young problem poly-drug 
users has been finished and will be presented to the public in autumn 2004. 
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8.2 Drug-related crime 
In 2003, 22 245 reports to the police for violation of the Narcotic Substances Act (SMG) were 
filed (2002: 22 422, see also Table A11 of Annex A), which is a slight decline compared to 
the previous year, but still a greater number than in the years before 2002. A total of 21 780 
reports referred to narcotic drugs, the rest to psychotropic substances. Regarding type of re-
port (see Figure 8.1), different to the year 2002, a decline in misdemeanours (possession, 
small-scale trafficking; Section 27 of the SMG) is found, while felonies (large-scale trafficking, 
commercial trafficking; Section 28 of the SMG) have gone up. 
In terms of substances involved (see Table A13 of Annex A) increases compared to the pre-
vious year are found in reports to the police concerning heroin and opiates, cocaine and am-
phetamines, which is paralleled by a decline with regard to the rest of illicit substances. What 
is particularly striking is that the number of reports in connection with cannabis has declined 
for the first time (see Figure 8.2). Great differences regarding substances involved have 
again been registered in the individual provinces (see Tables A12 and A14 of Annex A). In 
Vienna the proportion of reports because of opiate- and cocaine-related offences is compara-
tively large, while the majority of reports in the other provinces concern cannabis. As in the 
year before a disproportionately large number of reports to the police referring to ampheta-
mines were registered in Lower Austria, Upper Austria and Styria. In Salzburg the number of 
those reports was somewhat lower than in 2002 but still considerably above the figures of 
previous years. 
The total of 22 245 reports to the police in 2003 led to 2 983 arrests in connection with nar-
cotic drug investigations (2002: 2 437), but for the latter no details (type of offence, sub-
stance involved, etc.) are available.  
As explained in previous years and also pointed out by the responsible Ministry of the Interior 
(BMI 2004), the data concerning reports to the police only permit limited conclusions as to 
the development of consumption and misuse of illicit drugs, because they primarily reflect the 
intensity and focus of police activities in this field. 
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Figure 8.1: Development of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act by misdemeanours and felonies in Austria from 1994 to 2003 
 
Note: The Narcotic Drugs Act was replaced by the Narcotic Substances Act on 1 January 1998. In order to facilitate compari-
son, for the period from 1998 to 2001 only reports concerning narcotic drugs have been considered here. The difference 
to the total number of reports results from reports that are not assignable. 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
Figure 8.2: Development of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act in Austria by drug type from 1994 to 2003 
 
Note: The Narcotic Drugs Act was replaced by the Narcotic Substances Act on 1 January 1998. 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
The number of convictions for violation of the SMG has slightly risen in 2003 (4 532 convic-
tions; 2002: 4 394). While the number of convictions according to the SMG and their share in 
10,163 10,420
13,834 14,283
15,090 15,779
18,936 19,559 19,290
2,459
2,162
2,712
2,198
1,789
2,366
2,293 2,490
15,006
1,956
2,250
0
5,000
10,000
15,000
20,000
25,000
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Year
R
ep
or
ts
 to
 th
e 
po
lic
e
Felonies
Misdemeanours
0
1,500
3,000
4,500
6,000
7,500
9,000
10,500
12,000
13,500
15,000
16,500
18,000
19,500
21,000
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Year
R
ep
or
ts
 to
 th
e 
po
lic
e
Cannabis
Heroin and opiates
Cocaine
LSD
Ecstasy
Amphetamines
Chapter 8: Social Correlates and Consequences 
 45
the total number of convictions (1993: 3.6%; 2003: 10.9%) have thus reached a new peak, 
they are still only insignificantly higher than the figures of the previous year. Again, the num-
ber of misdemeanours (violation of Section 27 of the SMG - possession and small-scale traf-
ficking), i.e. 3 318 cases (2002: 3 243) is considerably higher than the number of felonies 
(Section 28 of the SMG - trafficking), namely 1 161 cases (2002: 1 108 cases, see Table A15 
of Annex A). About 67% of all persons convicted were punished with imprisonment (see Ta-
ble A17 of Annex A). The share of sentences that were suspended on probation was 47%, 
which is somewhat lower than in the year before (2002: slightly more than 50%). Thus, in 
2003 a greater number of persons were sentenced to imprisonment without probation, which 
according to media coverage has contributed to rising numbers of prisoners in Austria. 
In addition to the data on convictions, information concerning a temporary (provisional) with-
drawal of reports to the police (Section 35 of the SMG) and waiving of proceedings (Section 
37 of the SMG) is also relevant. These legal alternatives to criminal prosecution (see also 
Chapter 12) were applied in 9 023 cases in 2003, which is an insignificant decline compared 
to the previous year (2002: 8 950 cases). 
Please note that the figures given in last year’s report (ÖBIG 2003b) have turned out to be 
incorrect because changes in the data processing systems in the Ministry of Health led to an 
error in the data on application of legal alternatives to punishment in 2001. The corrected 
data are presented in Table A18 of Annex A in this report. 
Alternatives to punishment that may be applied in Austria are described in more detail in 
Chapter 12: Alternatives to Prison. 
In 2003 a total of 23 171 driving licences were withdrawn according to Section 39 of the Driv-
ing Licences Act (2002: 25 289). In 21 188 cases (91%) the driving licences were suspended 
because of alcohol influence (2002: 24 097 cases) and in 688 cases (3%) it was due to nar-
cotic drug use (2002: 407 cases; Parlamentarische Anfrage 1345/J, 2004). 
Again, no data on crimes committed to finance drugs or other drug-related crimes are avail-
able. 
8.3 Drug use in prison 
Regarding drug use in prison detailed information was given in the key issues chapter on 
drug use in prison in our report of 2001 (ÖBIG 2001a). No new data are available. 
8.4 Social costs 
Again, no recent studies or data on social and economic costs of drug use are available. Ex-
penditure for drug-related demand reduction has been described in detail in 2001 in the cor-
responding key issues chapter (see ÖBIG 2002a). 
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9 Responses to Social Correlates and  
Consequences 
Interventions aimed at social (re)reintegration of (former) drug addicts address both clients 
who have undergone drug-free treatment and persons who are currently using drugs. In Aus-
tria this kind of interventions has traditionally played a central role, particularly with regard to 
housing, occupation, education and training. Some of the pertinent measures are part of the 
chain of treatment and constitute specific care modules, while others are services provided 
by low-threshold centres in the context of accepting drug assistance. Recently, activities to 
this effect have also been promoted for sparetime settings. Austria’s prisons and police de-
tention centres have taken a wide range of drug-related measures for prisoners, from pre-
vention of addiction, medically-assisted treatment and prevention of infectious diseases to 
drug-free treatment (see Table 9.1). 
9.1 Social reintegration 
Austria has taken measures in the context of training and occupation particularly in the 
context of subprojects of the EU EQUAL programme, which aims at sustainable support for 
groups that are especially disadvantaged in the labour market. 
Rehabilitation measures that promote social integration, especially in the fields of jobs, hous-
ing and sparetime activities, are the most effective form of support that help to prevent re-
lapse. For this reason, the Drug Coordinators of Styria will particularly focus on the estab-
lishment and coordination of such measures. Their efforts include cooperation with the 
Chamber of Labour in Styria and the City of Graz to have the Law Faculty of the University of 
Graz investigate the status of drug users with regard to social insurance and unemployment 
insurance as well as the relevant consequences. Participation of the Economic Chamber of 
Styria will also been aimed at. In the context of social integration and rehabilitation measures 
for drug users, an open space event was organised in St. Martin in spring 2004, as a first 
concrete step in this direction. In addition a working group developed to an EQUAL partner-
ship with seven partner institutions, including ANKER 1525, a quaternary prevention project 
funded by the Ministry of Health, which aims at preventing relapses through social integra-
tion. Currently, application for this EU programme is under preparation (Ederer, personal in-
formation). 
The conference “New ways of lobbywork” held in Vienna in spring 2004 saw a presentation 
of the results of an interim evaluation of the drugaddicts@work development partnership es-
tablished in the context of the EQUAL programme of the European Social Fund (see also 
ÖBIG 2003b). The aim of drugaddicts@work is to (re)integrate (former) drug addicts in, and 
reduce their exclusion from, the primary labour market. This partnership is coordinated by the 
Vienna Social Fund (FSW) and implemented in cooperation with various Vienna-based or-
ganisations in the fields of drug help and social reintegration. Many different measures and 
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projects were developed (see below) that complement the existing services of the drug help 
system of Vienna. In 2003, drugaddicts@work provided support for 227 (former) drug users. 
Jobs were found for 46 persons, and 8 of them have already been employed outside the de-
velopment partnership. 180 clients received long-term counselling by the occupation assis-
tance service of the Vienna Job Exchange, and 41 persons obtained qualifications through 
the @kurse module organised by the association DIALOG and the Public Employment Ser-
vice. As a result, already in 2003 nearly 50% of the objectives set for September 2005 could 
be met (diepartner.at 2004). 
In the context of drugaddicts@work, the Vienna Social Projects Association (VWS) started 
the operative organisation of their TeleCenter for active telephone marketing in 2002. Its offi-
cial start was celebrated at the 10-year anniversary of fix und fertig, in October 2003 (VWS 
2004f). 
Also in connection with the development partnership, the Anton Proksch Institute established 
the socioeconomic enterprise Gabarage workshop. Here persons who have successfully 
completed inpatient long-term drug therapy are prepared for employment in the primary la-
bour market by means of creative and practical team work. This is paralleled by further train-
ing schemes, which may be organised in the context of the occupation assistance and 
@kurse services of EQUAL partners (see above), As Gabarage is located in a culture- and 
arts-dominated neighbourhood, and work in an open workshop is possible, the project also 
counteracts the risk of social stigmatisation which the target group is often facing (Werkstatt 
“Gabarage” 2004). 
Another occupation module connected to the EQUAL programme drugaddicts@work is 
pool7.at run by the non-profit education and training company Grüner Kreis - Gemeinnützige 
Aus- und FortbildungsgesmbH. The activities of pool7.at include interior design, catering, or-
ganisation of events, provision of seminar rooms as well as artistic and cultural programmes. 
Persons with drug experience are working in all areas in order to obtain professional qualifi-
cation through employment with pool7.at and thus to improve their opportunities in the labour 
market. pool7.at understands itself as a shop window and a sales point for all drug help cen-
tres and initiatives, therapy workshops and socioeconomic enterprises (pool7.at o. J.). 
In order to provide opportunities also to try out office work, in 2003 Needles or Pins founded 
its “virtual firm” in the context of the EQUAL programme. In this enterprise persons who have 
already obtained the relevant training may gather practical experience and persons who are 
interested in office jobs may try this kind of work to find out whether job reality is what they 
imagined. In the first completed module, support tasks and event organisation work were 
performed for the association DIALOG. This had the advantage that the participating workers 
were confronted with concrete jobs and deadlines and on the other hand, the administrative 
work load of DIALOG’s staff was reduced. Staff turnover was high among the workers in this 
project, which, however, prevented fixed roles or divisions of tasks to develop. In this way the 
workers also learned that while the personalities of their colleagues were relevant for team-
work, it was fulfilment of tasks that was decisive for the success of the company (DIALOG   
o. J.). 
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The evaluation of the Needles or Pins reintegration project carried out in 2002 (cf. EDDRA) il-
lustrates the success of the measures taken. For instance, in the long run up to 21% of the 
clients found jobs in the primary and secondary labour markets, and eventually up to 14% 
were employed in the first labour market. 26% of the clients could be referred to training 
courses or qualification schemes after they had turned to Needles or Pins. Almost 60% of 
those persons who succeeded in finding employment could sustainably be integrated in the 
labour market. In a reemployment group especially targeting women, clients may talk about 
their specific problems and concerns. As a rule, it is possible for women to turn to a female 
counsellor and for men to go to male counsellors. This project is especially helpful for job re-
orientation of clients, for strengthening self-confidence and in addition, regular daily routines 
are more easily kept and reliability is improved. A central strong point of Needles or Pins is 
that clients are prepared for referral in the long run to employment in the first labour market 
(SORA 2003). 
With regard to interventions in the field of housing, JUMP, a temporary sleeping facility for 
young people in danger of becoming addicted at St. Pölten, Lower Austria, deserves men-
tion. Currently JUMP is at the implementation stage and will be opened in autumn 2004 
(Brunner, personal information). 
The work of Komfüdro, a communication centre for drug users run by Caritas of the Diocese 
of Innsbruck, comprises psychosocial counselling and care, provision of syringes (see Chap-
ter 7.2), crisis intervention and also sparetime activities as well as visits to clients in prison 
and hospital. The sparetime events include horse riding and glass painting for women, and 
for men and women, an alpine tour with overnight stays in shelters and also climbing was or-
ganised (Komfüdro 2004).  
9.2 Prevention of drug-related crime 
 
 
The legal and organisational framework of drug-related interventions in prisons has not 
changed in the reporting period and was described in detail in Chapter 13 of our report of 
2001 (ÖBIG 2001a). Recent data and information show that imprisonment because of SMG 
offences still plays an important role and is even of rising relevance (see Chapter 8.2). 
Generally, a wide range of drug-related services are provided in prisons (see Table 9.1). 
Four out of 28 prisons have drug-free zones and six have treatment departments. The prison 
of Favoriten, Vienna, specialises in addiction treatment. Syringe exchange is still not possible 
in Austrian prisons; possession of needles or syringes is generally prohibited for prisoners. If 
such articles are detected, administrative proceedings are instituted, and in every case of 
suspicion of violation of the SMG a report to the public prosecution is filed (Kahl, personal in-
formation). 
For the purpose of preventing infections, all prisons provide condoms and disinfectants for 
safer use, which prisoners may obtain anonymously in some cases (see also Table 9.1). 
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Table 9.1: Demand reduction interventions in prisons in 2004 
Kind of intervention Activities Number of service- 
providing prisons1 
Notes 
Detoxification/withdrawal 28 In all prisons, by physicians 
Drug-free zones 4  
Drug-free treatment 
Treatment department in prison 6  
Medically assisted treat-
ment 
 
      28 Specific forms exist in four 
prisons; 
substitution substances: mostly 
methadone, in some cases also 
other substances 
Blood testing 28 On demand 
Vaccination programmes 28 On demand 
Distribution of disinfectants 28 On demand 
Syringe exchange 0 Project under preparation 
Prevention 
Distribution of condoms 28 3 condoms in the take-care set 
handed out to each prisoner on 
commitment to custody 
Preparation for release 28 
Support for relatives 28 
Continuous care and counselling 28 
Part of standard social care 
measures 
Therapeutic communities outside 
prison 10 
 
Cooperation with other  
institutions 
Cooperation with public health care 
institutions 
     28 Cooperation with local health 
authorities is part of standard 
medical care services 
1 Total number of prisons in Austria: 28 
Source: Kahl, personal information 
Another new development is that in September 2003 the scope of the agreement between 
the prison of Favoriten and the FSW was expanded so that continuous medical care is pos-
sible for clients in the prison of Favoriten in need of psychiatric treatment and support. This 
also permits a more flexible form of service provision in the prison of Favoriten and its affili-
ated institution at Münchendorf (FSW 2004c). 
The services of the outpatient addiction prevention centre of Innsbruck include psychother-
apy, psychological counselling and care for prisoners of the Provincial Court Prison who 
have been sentenced to a maximum of six months of imprisonment. In 2003 the association 
BIT provided support services for 97 clients in the Provincial Court Prison of Innsbruck (Kern, 
personal information). 
For persons arrested in the Police Detention Centre (PAZ) of Vienna Alsergrund, both addic-
tion-related medical care and psychiatric assistance is provided by DIALOG. Since 2002 
psychosocial counselling for women arrested because of administrative offences has also 
been possible. The main fields of social work include establishment of the social insurance 
and health insurance status of clients, finding emergency sleeping facilities for clients re-
leased from prison, contacts to assisted housing and assistance in obtaining financial sup-
port. Other relevant activities include strategies to promote self-empowerment and self-
confidence of women (such as safer sex practices), preparation of a first treatment plan as 
well as organising continuing support after imprisonment. More than 50% out of 78 female 
clients who received counselling and care in 2003 had been arrested because of illegal pros-
titution. Almost half of them were also intravenous drug users. Over 60% of the female cli-
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ents were dependent on illegal psychotropic substances, 6% were addicted to alcohol, and 
31% did not have an addiction. Furthermore, DIALOG endeavours to improve cooperation 
with established physicians in Vienna by presenting its work in the PAZ in the context of 
quality circles, and by organising further training events on the disease of addiction for the 
staff of various police detention centres in the east of Austria. Eventually, standards for su-
pervisory measures to ensure that psychoactive substances prescribed by DIALOG for cli-
ents in the PAZ of Vienna are actually taken were prepared and implemented, which also in-
cludes the necessity to organise regular training for the civil servants working in the PAZ (see 
also Chapter 7.2; Dialog 2004). 
Since February 2003, DIALOG’s counselling centre at Hegelgasse, Vienna, has also carried 
out specific after-care measures in the context of the women’s project dialog - Frauensache, 
for former female detainees of the PAZ. The objective of this project is to facilitate access to 
after-care and sustainable long-term support of these clients. This is achieved by combining 
substitution treatment with medical and psychosocial care for these drug-addicted women 
who face massive social disadvantages. After medical and social stabilisation the clients may 
use the standard services provided by DIALOG, for instance individual and group counselling 
regarding labour market integration, where women-specific aspects are addressed (Dialog 
2004). 
An evaluation of the drug-free zone (DFZ) of the prison of Hirtenberg, Styria, has shown that 
the DFZ has led to a relative absence of drug use and trafficking and thus to a decline of 
subculture and a normalisation of everyday prison routines. This has particularly been appre-
ciated by drug users as a helpful factor on their way out of addiction. Prisoners released from 
the drug-free zone are significantly less often sentenced again than prisoners released from 
normal prison units of Hirtenberg (62% v. 35%). In the case of repeat offenders among for-
mer DFZ inmates, the time elapsed before new offences are committed tends to be longer 
(73% v. 57% not incurring penalties for more than 2 years), and they are punished with im-
prisonment less often (28% compared to 53% in the case of non-DFZ prisoners). The share 
of first offenders is highest in the DFZ, namely 25%. This could also explain why the average 
period spent in prison so far is shortest among these persons in the DFZ. Previous convic-
tions because of drug offences are less frequently found among DZT prisoners compared to 
the rest of prison inmates (7% v. 25%). Although leave from prison and other privileges in the 
DFZ result in better stabilisation of prisoners and facilitate the transition to everyday routines 
outside prison, reintegration in society is difficult for all former prisoners (Spirig 2003).  
The principle of therapy instead of punishment continues to play an important role in all drug 
or addiction plans and programmes in Austria (ÖBIG 2002a). The pertinent measures are not 
implemented in specialised institutions, but the whole range of drug help services may be 
used. For a more detailed discussion of this subject please consult Chapter 12 of this report. 
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10 Drug Markets 
The substance most frequently seized in Austria is cannabis, followed by heroin and cocaine. 
However, quantities seized are not a good indicator for availability of a substance in Austria, 
as Austria often is not the final destination of these drugs but a transit country, and because 
these figures also reflect the extent and intensity of police measures. Regarding potency and 
concentration of the substances available in Austria, experience of recent years has shown 
that considerable variations occur. This applies to both substances used by the traditional 
street scene (opiates and cocaine) and also new synthetic drugs (ecstasy and ampheta-
mines). As actual ingredients and potency are often unknown, this is a considerable risk fac-
tor for drug use. 
10.1 Availability and supply 
For the Ministry of Health’s fourth report on the situation of young people (BMSG 2003a) a 
nation-wide representative survey among persons aged between 14 and 30 was conducted 
(n = 1 549). This study also included the question which drugs the respective adolescents 
and young adults had already been offered. Table 10.1 shows that cannabis/marihuana and 
ecstasy were indicated most often and with similar percentages for either substance, which 
range between 11% and 36% depending on gender and age group. For ampheta-
mines/speed, cocaine, LSD and magic mushrooms the relevant shares are between 3% and 
15%, and for heroin, between 3% and 5%. 
Table 10.1: Drugs offered, according to gender and age (percentages) 
Drugs offered  
Cannabis/ 
marihuana 
Ecstasy Amphetamines/ 
speed 
Cocaine LSD Magic mush-
rooms  
Heroin 
14 to 19 years 19% 11% 3% 6% 4%  4% 3% 
20 to 24 years 28% 28% 12% 10% 10% 12% 3% 
W
om
en
 
25 to 30 years 22% 13% 7% 7% 6%  5% 3% 
14 to 19 years 21% 21% 9% 6% 7%  5% 5% 
20 to 24 years 36% 30% 15% 12% 14%  9% 5% Me
n 
25 to 30 years 26% 17% 5% 8% 8%  5% 4% 
Source: BMSG 2003a 
Approximately half of those persons who had already been offered drugs said that this had 
occurred at a party or in a disco. Around one third indicated “in a pub/bar” and one fifth, “at a 
clubbing”. A significantly smaller share said this had happened “at school” (between 7% and 
20% depending on age group) or “in front of school” (between 6% and 9%). 
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10.2 Seizures 
The Federal Ministry of the Interior (BMI) reports a massive increase in cocaine and heroin 
seizures in 2003. With regard to cannabis and amphetamines a slight rise has shown, while 
the number of seizures relating to ecstasy and LSD has somewhat gone down (see Table 
A19 of Annex A and Figure 10.1). 
Figure 10.1: Number of seizures of narcotic drugs in Austria from 1994 to 2003 
Source: BMI Bundeskriminalamt  (Federal Criminal Agency) 
The amount of substances seized reflect these trends only to a limited extent, as individual 
seizures of exceptionally large quantities strongly influence the general picture (see Table 
A20 of Annex A). For instance, the amount of heroin seized (42.9 kg) has gone down by 28% 
compared to the previous year, while cocaine seizures (58.3 kg) have risen by 58% (BMI 
2004). 
In January 2004 the substances fentanyl, DOM and DMT were seized for the first time when 
an illegal drug producing laboratory was searched (Held, personal information). 
10.3 Price/purity 
In 2003 the project ChEckiT!, in which the purity and ingredients of substances bought as 
ecstasy or speed during raves are tested (see also Chapters 2.3 and 3.2) was present at five 
rave parties, where 145 pills bought as ecstasy and 57 samples purchased under the name 
of speed were handed in for testing. The percentage of pills bought as ecstasy that did not 
contain psychotropic substances other than MDMA, MDE or MDA remained the same as in 
previous years (2000: 88%, 2001 and 2002: 89%, 2003: 91%). 35% of the substances 
bought as speed and analysed by ChEckiT! had amphetamines as their only ingredient, 
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while 16% combined amphetamines and caffeine, and 30% contained amphetamines with 
additions of other psychotropic substances (see Tables A21 and A22 of Annex A). Thus one 
out of ten ecstasy pills and every second speed sample contained ingredients which their 
purchasers would not have expected (Eggerth, personal information). 
The final report on the update of the syringe check project of 1998 is now available 
(Haltmayer und Schmid 2004). 526 syringes were sampled from the syringes exchanged in 
one week in July and in one week in November 2002 in the three syringe distribution points 
in Vienna, i.e. Ganslwirt, social centre Karlsplatz and the mobile syringe bus, and their ingre-
dients were subsequently analysed by means of the REMEDi method. As one-way syringes 
may be purchased in pharmacies in Vienna but not exchanged there, the data obtained may 
be regarded as representative of the clients who use syringe exchange services. In addition, 
362 of the questionnaires distributed were completed to an extent that they could be used for 
analysis and related to the REMEDi results. This questionnaires included information on the 
kind of drug the clients thought to have used, it is therefore possible to compare substances 
apparently taken to those actually consumed (see Table 10.2). This has shown that in 58% 
of the cases when clients thought they had purchased pure morphine this was indeed cor-
rect, while this was true for cocaine in only 17% of the cases. Generally, there are great dif-
ferences between substances supposedly bought and actual ingredients. 
Table 10.2: Comparison of supposed and actual ingredients of used syringes 
Bought under the name of  
Heroin Morphine 
(pure) 
Heroin + 
cocaine
Cocaine Methadone Poly-
drug use
Speed Not indi-
cated 
Total 
Cocaine/pure 0 2 3 12 0 5 0 9 31 
Cocaine and adulterant 0 0 5 22 0 3 0 10 40 
Cocaine and other sub-
stances 0 2 12 22 
0 4 0 14 54 
Cocaine and opiates 0 0 0 0 0 3 0 2 5 
Cocaine + opiates +  
other substances 2 1 25 2 0 2 0 8 40 
Morphine/pure 0 45 2 6 1 9 0 25 88 
Methadone 0 1 0 1 0 0 0 0 2 
Heroin 0 3 0 0 0 0 0 2 5 
Opiates/pure 2 0 0 0 0 0 0 0 2 
Opiates and others 6 24 5 3 0 7 0 8 53 
Other substances 1 0 5 3 0 3 0 5 17 
No ingredient 0 5 7 6 0 1 1 5 25 
R
es
ul
t o
f a
na
ly
si
s 
Total 11 83 64 77 1 37 1 88 362 
Source: Haltmayer und Schmid 2004, calculations by ÖBIG 
This year, information by the Ministry of the Interior on potency and prices of various drugs 
sold at street level have been available for the first time. They have been summarised in Ta-
ble 10.3. These data are based on information and fictitious purchases by undercover police 
agents. 
. 
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Table 10.3: Purity and price (EUR per gram) of various drugs sold on the street 
  Herbal- cannabis 
Cannabis
resin 
Brown 
heroin 
White 
heroin Cocaine 
Ampheta-
mines Ecstasy LSD 
Minimum 0.5% 0.1% 3% - 3% 1% 3% - 
Maximum 19% 17% 50% - 90% 99% 80% - 
Pu
rit
y 
Typical 4% 8% 6% - 40% 10% 40% - 
Minimum 3 7 50 80 70 20 10 30 
Pr
ic
e 
Maximum 4 8 70 100 90 25 15 35 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 2004 
What is striking is the variations in potency, which are often considerable in drugs sold on the 
street. However, further interpretation and analysis of trends will be possible only after sev-
eral years of analysis of relevant data. 
An analysis of the potency of cannabis the BMI carried out for the EMCDDA Insight “An 
overview of cannabis potency in Europe” has not shown any changes for neither cannabis 
resin nor herbal cannabis (EMCDDA 2004). 
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11 Buprenorphine 
In Austria buprenorphine has been used for several years in substitution treatment under the 
trade mark Subutex®. Buprenorphine is a synthetic agonist-antagonist, i.e. a partial µ-agonist 
and κ-antagonist. Because of its limited opioid effects (ceiling effect) and its high opioid re-
ceptor affinity, compared to other opiates buprenorphine has a relatively wide safety margin, 
which makes it an important alternative option in medically assisted treatment. However, 
over the last few years misuse of buprenorphine has been increasingly reported, first in 
Scandinavia, then in other parts of Europe. This development raises some questions, and so 
buprenorphine has been chosen as a topic for the Selected Issues chapter of the 2004 Na-
tional Report. In this chapter the framework conditions and the significance of substitution 
treatment with buprenorphine are presented as well as evidence of misuse of this substance 
in Austria.  
11.1 Treatment with buprenorphine 
The legal basis of substitution treatment has been laid down in Austria in 1997 with the De-
cree on Oral Substitution Treatment of Addiction Patients (Orale Substitutionsbehandlung 
von Suchtkranken). This Substitution Decree defines the legal framework of medically as-
sisted treatment and is binding for all public institutions and agencies as well as the authori-
ties reporting to the Ministry of Health. In the Narcotic Substances Act (SMG, BGBl. Nr. 
112/1997), which entered into force on 1 January 1998 (see also Chapter 1), substitution 
was legally declared an equivalent treatment to withdrawal treatment.  
Under item V, 4. in principle methadone is described as the substance of first choice. Only if 
a patient is pregnant, substitution substances other than methadone may be used already at 
the first administration. Otherwise only in cases of proven and objectively perceivable intoler-
ance of methadone or after the occurrence of massive side effects other substitution sub-
stances may be prescribed. As examples slow release morphines, codeines and buprenor-
phine. The definition of methadone as the substance of first choice is not undisputed, how-
ever. For example, Bertel (2003) says that this does not correspond to the medical state of 
the art, which should be the standard for physicians to treat their clients. Therefore he rec-
ommends to consider methadone for treatment in the first place, but consequently to choose 
the substitution substance that is deemed appropriate.  
Furthermore the Substitution Decree includes e.g. guidelines for diagnosing, administration 
of the substitution substance and implementation of treatment; it is especially pointed out that 
indication may only be made by physicians who are familiar with the problems connected to 
the misuse of addictive substances and have some experience in the treatment of addiction 
patients (see ÖBIG 1999). It also describes in detail the requirements for a corresponding 
prescription. However, the regulations apply to all substitution substances, there is no spe-
cific regulation referring to buprenorphine. 
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Apart from the SMG and the Substitution Decree, which are effective on a nation-wide basis, 
some provinces have special regulations for the substitution treatment of persons under 20 
or with substances other than methadone (Werner 2003).  
The admission of buprenorphine for substitution treatment under the name of Subutex® as 
sublingual tablets (of 2 and 8 mg) became effective in 1999. In fact buprenorphine has been 
used since 1996 within the framework of clinical trials especially in pregnant drug addicts at 
the drug outpatient department of the General Hospital of Vienna (Schindler, Ortner und 
Fischer 2002). Despite the positive results of the studies at the outpatient department of the 
General Hospital of Vienna, the Austria Codex still lists pregnancy and breast-feeding as 
contraindications. Buprenorphine is not only suitable for maintenance therapy, but also for 
outpatient withdrawal therapy, whether short-term or in the course of gradual detoxification 
over many weeks (Schindler, Ortner und Fischer 2002). Other pharmaceutical specialties 
containing buprenorphine as an active ingredient are Temgesic® (ampoules and sublingual 
tablets), and Transtec® (transdermal patch). However, neither of the two is admitted for 
maintenance therapy. Temgesic® is used above all for outpatient detoxification treatment - 
together with Subutex® (Lipburger 2003). Buprenorphine is not suitable for oral use, as it is 
subject to a high first pass metabolism in the liver (Giacomuzzi, Riemer und Vigl 2002). This 
effect is side-stepped by means of sublingual use. According to Fischer (personal informa-
tion), Subuxon®, which also contains buprenorphine, will shortly be available in Austria, its 
admission by the EU is under way. 
In addition to the legal basis there are also some guidelines and recommendations on 
substitution therapy with buprenorphine. In Carinthia, the guidelines on opioid-based substi-
tution treatment (Prehslauer et al. 2001), give a description of the factors that should be 
taken into account when choosing the substitution substance (risk of misuse, level of psy-
chosocial functioning, life circumstances), rather than recommending a particular substance. 
The guidelines on oral maintenance therapy with synthetic opioids in opiate-addicted patients 
(Fischer und Kaspar 1999) contain general recommendations for substitution therapy includ-
ing psychosocial and psychotherapeutic care. They also discuss the differences between the 
substitution substances that are available, as well as specific target groups. In these guide-
lines buprenorphine therapy is recommended for highly motivated patients who are aware of 
their illness. In the recommendations on the use of buprenorphine for substitution treatment 
of opiate-addicted patients in Switzerland, Austria and Germany (Konsensustext 2000) the 
specific characteristics and effects of buprenorphine, fields of application, dosage informa-
tion, scientific studies, etc. are described. Here buprenorphine is recommended especially for 
the treatment of persons with an addiction of short duration and mild severity. It is also stated 
that in cases of multiple drug use partial detoxification is advisable before administration, as 
there is a risk of potentially harmful interactions caused by the parallel use of alcohol and of 
benzodiazepines. 
Practical experience and recommendations of experts are generally in line with the 
guidelines and recommendations mentioned above. All experts share the view that the 
choice of a substitution substance depends on the targets of substitution treatment and the 
individual situation of the drug-dependent person. Among other factors, recently consumed 
opioids, dosage level, duration of the dependence, previous experience of the addicted pa-
tients with other substitution substances and the appeal of the substances for them should 
Chapter 11: Buprenorphine 
 59
be taken into account. Some experts recommend, or use, buprenorphine for the short- to 
medium-term substitution especially of young drug users and addicted patients who aim at 
medium-term abstinence or those who have previously consumed a mix of cocaine and her-
oin (e.g. Stolz-Gombocz 2004; FSW 2004c; Schwarzenbrunner, personal information), oth-
ers view buprenorphine as the substance of first choice (e.g. Fischer, Hermann, personal in-
formation). However, it has repeatedly been pointed out that some clients, on account of their 
life circumstances, cannot cope with a clear perception of their situation. These clients need 
a substance which allows them to perceive matters from some distance. The experts also 
agree that for addicted patients with high psychiatric comorbidity (pre-psychotic or psychotic 
disease profiles, tendency to paranoid reactions) or multiple drug consumption patterns, be-
cause of the stimulating effect of buprenorphine and the risk of interactions, other substances 
should be chosen (e.g. De Cordoba, Presslich and Fischer 2004; Fischer, Hermann, per-
sonal information). Other possible reasons for the use of substitution substances other than 
buprenorphine include tumours, intolerance of buprenorphine or a simultaneous HIV therapy 
(Kern, personal information). 
Reported advantages of buprenorphine are its long duration of action, which entails the op-
tion to take it less frequently (once a day or even every second or third day), good tolerance, 
highly safe applicability owing to the ceiling effect, the fact that it can be discerned from opi-
ates in the urine, and lacking or greatly reduced withdrawal symptoms in newborn babies 
(e.g. Kraigher et al. 2001), its antidepressant and stimulating properties, low potential of de-
pendence and wide range of therapeutic applications, the relatively low risk of misuse and 
the reduced parallel use of other substances (Werner 2003; Madlung 2003; Stolz-Gombocz 
2004; Fischer and Kaspar 1999). Furthermore patients treated with buprenorphine are more 
accessible and less dysphoric in everyday situations, they show less disorders of the sexual 
functions, and craving is noticeably reduced (Giacomuzzi, Riemer und Vigl 2002). In general, 
less side effects were found than in methadone treatment, and it is much easier to discon-
tinue buprenorphine treatment or reduce the dosage. It has also been pointed out that in the 
case of substitution treatment with buprenorphine the amount of medication dispensed to the 
patients to take home can be handled much more liberally than in the case of methadone or 
slow release morphines (Schindler, Ortner and Fischer 2002). 
The disadvantages that have been named are serious interactions with benzodiazepines 
and respiratory depressants, the clear clinical picture, a restricted target group, the difficult 
phase of changing especially from methadone to buprenorphine due to withdrawal symp-
toms, in some cases persistent headaches, and its unpleasant taste (Werner 2003; Fischer 
und Kaspar 1999, Madlung 2003, Prehslauer et al. 2001). Stolz-Gombocz (2004) also states 
that compared to methadone, buprenorphine has a lower retention rate and at least in the 
first weeks, illicit use of opiates is not reduced as much as during methadone treatment. Ac-
cording to Hermann (personal information) especially women who have used high dosages 
show more withdrawal symptoms for a longer period when changing from methadone to bu-
prenorphine; however, these symptoms recede within the first three days and are much less 
dramatic than without treatment. 
According to experts, while the adaptation to a stabilising dose of or change to buprenor-
phine takes more time and effort than is the case for pure opioid-agonists, the process is 
rather unproblematic especially if the clients have been adequately informed. However, un-
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ease and pronounced clinical complaints may be experienced when changing from metha-
done to buprenorphine (Fischer und Kaspar 1999). After prolonged use of opiates in high 
doses it may occur that a satisfactory change from methadone to buprenorphine is not pos-
sible due to the ceiling effect. At the Innsbruck University Hospital, absolute intolerance of 
buprenorphine was registered only in approx. 5% of all cases, as a prepsychotic condition 
(Giacomuzzi, Riemer und Vigl 2002). As a rule, when changing from methadone to bupre-
norphine the methadone dosage should first be reduced (i.e. to approximately 30 mg), and 
the last consumption should be six hours (in the case of heroin) to 48 hours (methadone or 
slow release morphine) prior to the first use of buprenorphine (Werner 2003; Schindler, 
Ortner und Fischer 2002). According to Giacomuzzi, Riemer and Vigl (2002) even an interval 
of six to eight hours after heroin consumption may lead to withdrawal symptoms. Therefore 
many experts recommend to wait with the first administration of buprenorphine until the first 
clear withdrawal symptoms occur. Furthermore it is recommended that the adaptation to a 
stabilising dose should take place step by step. The recommended initial dose lies in the 
range of 1 to 2 mg (Kubec 2002), 2 to 4 mg (Konsensustext 2000) and 2 to 8 mg (Gia-
comuzzi, Riemer und Vigl 2002). Experts agree that the dose should be increased rapidly if 
the results are unsatisfactory. It is also possible to change from high doses of methadone to 
buprenorphine (Giacomuzzi und Riemer o. J., Giacomuzzi, Riemer und Vigl 2002). In the 
published cases a relatively high initial dose was used (16 mg buprenorphine), which was 
rapidly increased to 20 mg. Only after a phase of stability of some weeks, the amount was 
reduced to 12 mg of buprenorphine. At the Innsbruck University Hospital, the rate of reduc-
tion is approximately 2 mg of buprenorphine per week, however, the amount is adapted to 
the individual patient. As with other substances, withdrawal symptoms occurred, but they 
were no longer perceivable after three days. 
Furthermore it has been reported that the opioid effect of buprenorphine occurs after 20 min-
utes, the maximum is reached after 1.5 to 4 hours and the duration of action can last up to 72 
hours, depending on the dosage (Werner 2003; De Cordoba, Presslich und Fischer 2004; 
Stolz-Gombocz 2004). As an average daily dose, 8 mg (Kubec 2002), 8-16 mg (Fischer und 
Kaspar 1999; Giacomuzzi, Riemer und Vigl 2002), 6-12 mg (Madlung 2003) or 2-36 mg 
(Stolz-Gombocz 2004) are recommended, the maximum daily dose in Austria being 32 mg 
(Konsensustext 2000). 
The previous Reports on the Drug Situation in Austria (see e.g. ÖBIG 2003b) have shown 
that in the course of a growing diversification in substitution treatment (see also Chapter 
4.2) the number of persons treated with methadone is continually declining. On the other 
hand, the number of persons treated with slow release morphines (especially Substitol) or 
buprenorphine is on the rise. In 2003 in approximately one third of all first substitution treat-
ments registered in Austria the substance used was Substitol and approximately in one fifth 
of the cases, methadone or buprenorphine. In this development, regional differences can be 
noted: in 2003, in Burgenland, Carinthia and Lower Austria, for most of the registered first 
treatments methadone was used, while in Upper Austria, the Tyrol, Vorarlberg and Styria 
Substitol was chosen, in Salzburg the preferred substance was Codidol and in Vienna, bu-
prenorphine. As the numbers reported from the various provinces (FSW 2004b; Neubacher 
2004; Suchtkoordination OÖ 2003; Kern, Schabus-Eder, Prehslauer, personal information) 
not only refer to first substitution treatments but also include clients who have been in substi-
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tution treatment for a longer period, they reflect recent trends to a lesser extent. According to 
these figures, the situation is as follows: in 2003 in Vienna, Vorarlberg and Upper Austria the 
most used substitution substance was slow release morphines (51-65 %), followed by 
methadone (24-31 %) and then buprenorphine (11-15 %). In the Tyrol, Salzburg and Carin-
thia, however, methadone was used most often (32-46 %), followed by slow release mor-
phines (19-33 %) and buprenorphine (11-20 %). 
With regard to gender it was observed that in registered first treatments in 2003 buprenor-
phine was in third position among the substitution substances most often used by men and 
came second among women. In relation to age it turned out that in the age groups over 24 
and under 40, buprenorphine was the second most used substance in first treatments, but 
only in third position among the age groups in between. 
Categorising first treatments registered in 2003 by administering institution, it shows that 
drug care centres use buprenorphine most frequently, while for established physicians, it is 
the second-most used substitution substance, and in other institutions, it comes third or is 
used even less frequently. However, regarding established physicians regional differences 
must be taken into account. In Vorarlberg since 1987 substitution treatment has been carried 
out exclusively by physicians specialising in psychiatry and/or neurology (Jochum 2003), but 
there are initiatives to admit general practitioners as well. In Vienna, on the other hand, sub-
stitution treatment is mainly carried out by general practitioners and only few psychiatrists 
and/or neurologists (Kubec 2002). It has been pointed out that drug help centres and special-
ised institutions are better equipped for the substitution treatment of patients with multimor-
bidity or psychiatric patients and pregnant women. 
Most of the specific trainings in substitution treatment with buprenorphine were organised 
immediately after its admission. Since then there have been only isolated specific training 
events, e.g. in autumn 2003 at the Otto Wagner Hospital in Vienna (Hermann, personal in-
formation). In Vienna physicians who want to carry out substitution treatments and collect a 
special fee from the Health Insurance Fund must regularly assist further training events 
(Wiener Modell). In these quality circles, a number of issues are discussed according to cur-
rent needs, among them experience with various substitution substances. Moreover there 
are continual efforts to improve the quality of substitution treatment (see Chapter 5.3).  
An important focus of Austrian surveys is the use of buprenorphine by pregnant drug pa-
tients (see ÖBIG 1999, 2001a). In 1999 60 opiate-addicted persons were examined, 29 of 
them were substituted with buprenorphine and 31 with methadone (Fischer et al. 1999). The 
methadone group showed a better retention rate than the buprenorphine group, which could 
be due to the maximum dose of 8 mg of buprenorphine per day, to the side effects (unspe-
cific dysphoria), the condition of the patient (clearer state of mind, similar to an opioid-free 
state), but also to the fact that withdrawal symptoms caused by dropping out occur less fre-
quently than in the case of methadone.  
In a survey conducted in 2000 (Fischer et al. 2000) 15 opioid-addicted pregnant women were 
examined who were undergoing a change to maintenance therapy with buprenorphine. The 
maximum dose in this survey was 10 mg buprenorphine per day. It was found that the direct 
change from street heroin to buprenorphine was experienced as more agreeable than the 
change from another substitution substance to buprenorphine. In eight of the newborn ba-
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bies, no neonatal abstinence syndrome (NAS) was observed, four showed slight and three, 
moderate symptoms. This decisively lower share confirms the advantages of buprenorphine 
treatment of pregnant women over methadone treatment. No correlation was found between 
the average dose of buprenorphine and the occurrence, non-occurrence or intensity of NAS.  
Consequently some of the women who had taken part in the first survey were treated during 
a second pregnancy (Eder et al. 2001, Schindler et al. 2003). Different from the first survey, 
the women were already taking buprenorphine at the time of conception, as they had been 
treated with buprenorphine after their first pregnancy. These case studies confirm the posi-
tive effects of maintenance therapy with buprenorphine (no simultaneous consumption of il-
licit substances, no NAS). 
A survey by Ortner et al. (2004) examined the feasibility and effectiveness of substitution 
therapy with buprenorphine in a special treatment setting (3-weeks stabilisation phase in a 
special outpatient establishment and 12 weeks continuation of the therapy by a general prac-
titioner). It was shown that substitution treatment carried out by a general practitioner was as 
successful regarding the retention rate and additional consumption of drugs as treatment in a 
special outpatient establishment. The survey also confirms that if the initial dose and the 
maintenance dose are too low, the retention rate will be decreased. From the results of the 
survey it has been concluded that more opioid-addicted patients could receive adequate 
support if more general practitioners were involved in substitution treatment. It has been 
pointed out, however, that special trainings and guidelines especially for buprenorphine 
treatment would have to be made available to them. 
In a recent survey by Schindler et al. (2004) the effect on the driving ability of substitution 
therapy with buprenorphine versus methadone was examined by means of a standardised 
test. According to the results, substitution therapy clients showed no significant differences to 
a healthy control group in most items of the tests. 
A study by Giacomuzzi et al. (o. J./undated) compares substitution treatment with metha-
done, buprenorphine and morphine sulphate with regard to general and somatic side-effects. 
For each substance, 30 clients were examined after five to six months of continuous substitu-
tion. The study shows that buprenorphine and methadone are actually comparable, with par-
tially better results for buprenorphine (regarding stomach cramps, running eyes, loss of ap-
petite, heart palpitation, loss of drive, anxiety and depression). Morphine sulphate had the 
most negative results. The conclusion of the study is that the individual needs and life situa-
tion of the addiction patients must be taken into account when selecting a substitution sub-
stance. 
According to a diploma paper by Dinich (2001), both buprenorphine and methadone contrib-
ute to raising the self-esteem of clients in the course of a period of six months after beginning 
therapy. 
Another study by Giacomuzzi et al. (2003), in which 38 clients substituted with methadone 
and 29 clients substituted with buprenorphine were examined within the framework of the 
Lancashire Quality of Life Profile, confirms the comparability of buprenorphine and metha-
done as substitution substances. The average initial doses were 43.33 mg methadone and 
11.15 mg buprenorphine respectively, the average doses at the end of treatment were 24.54 
mg methadone and 9.93 mg buprenorphine. 14 out of 67 persons discontinued treatment 
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prematurely; no difference between the two groups was observed. In fact, after eight weeks 
the buprenorphine group had significantly higher overall satisfaction scores, but after 24 
weeks there was no significant difference. Regarding physical symptoms no significant dif-
ferences were observed. 
According to data from 100 patients of the drug department of Otto Wagner Hospital, there is 
no correlation between the amount of drugs consumed before substitution treatment, the 
complaints during change to the substitution substance and the dose of buprenorphine 
needed in maintenance therapy (Hermann, personal information). At present further data on 
substitution treatment are evaluated. Specifically, data on socio-biographical, psychological 
and psycho-pathological status shall be included. In cooperation with experts from Paris a 
comparison of the current practice of substitution treatment in Vienna and Paris is under-
taken. 
11.2 Misuse of buprenorphine 
In Austria there are hardly any data and no evaluations or surveys on the misuse of bupre-
norphine. Several Austrian experts hold the view that buprenorphine is not attractive or suit-
able for misuse, as it can trigger withdrawal symptoms on account of its properties as an-
tagonist-agonist (e.g. Beubler 2003; Prehslauer, personal information). So far there have 
been no reports of hazardous events or deaths in connection with misuse of buprenorphine 
in Austria (FSW 2004c; Hermann, personal information). Even 10- to 20-time overdoses 
seem to cause no problems, but in extreme cases, respiratory arrest may occur (Schwarzen-
brunner, personal information). In this context surveys conducted in France are quoted, 
which have shown that deaths are mostly due to the combined misuse of benzodiazepines 
and/or alcohol and buprenorphine (Konsensustext 2000).  
On the other hand, drug consumers have repeatedly reported intravenous use of buprenor-
phine (in some cases mixed with opiates) or snorting buprenorphine (in some cases mixed 
with Somnubene®) (Hermann, Fischer, Haltmayer, Schwarzenbrunner, personal information; 
FSW 2004c). The motives given for buprenorphine misuse are that users want to try the sub-
stance, that they want to get over withdrawal symptoms, or that even in very low doses bu-
prenorphine acts much faster when snorted or injected. (similar to speed) (Haltmayer, 
Schwarzenbrunner, personal information). From Carinthia it is reported that intravenous mis-
use of buprenorphine is only practised by very few addicted patients who are in very poor 
health (Prehslauer, personal information). In some provinces buprenorphine is available on 
the black market at comparatively low prices (FSW 2004c; Schwarzenbrunner, Prehslauer, 
personal information). In a survey by Giacomuzzi et al. (2001) comparing 30 clients in substi-
tution treatment with methadone and 31 persons without substitution treatment, less than ten 
percent of the latter group said they were using buprenorphine (Temgesic®). 
Because of this situation currently no harm reduction measures regarding buprenorphine 
are taken in Austria. Instead, information for drug users rather relates to substitution therapy 
with buprenorphine. A special issue of GAWI-News (entitled Das g’sunde Gansl) edited by 
the drug help service Ganslwirt provided information on buprenorphine, its specific effects 
and the withdrawal symptoms that might occur when changing to buprenorphine (VWS 
2004e). Overall harm reduction measures are described in Chapter 7. 
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In order to prevent substitution substances from entering the black market, criteria for safe 
dispensing have been developed for all substitution substances (see Chapter 5.3). The 
amounts of buprenorphine intended for substitution therapy available on the black market are 
unknown. Concluding from seizures the amount would be rather low. According to the Fed-
eral Ministry of the Interior, in 2003 there were 25 reports to the police involving Subutex® 
and 79 units were seized (Mader, personal information). By way of comparison, in 2003 Sub-
stitol® was the cause for reports to the police in 404 cases, and 1021.5 units were seized. 
This confirms the experts‘ opinion that misuse of buprenorphine occurs much less often than 
the misuse of slow release morphines and currently does not present a problem in Austria. 
The combined use of illicit substances during maintenance therapy with buprenorphine was 
examined in the course of several surveys (see Chapter 11.1). In some of them, no com-
bined use of illicit substances was found. But there are also studies by Giacomuzzi et al. 
(2003, 2004b) in which substitution treatment with buprenorphine and methadone are com-
pared in this respect. According to both studies, the buprenorphine group showed a signifi-
cantly lower combined use of opioids than the methadone group. Regarding parallel use of 
cocaine or benzodiazepines, a study comparing 38 methadone clients with 29 buprenorphine 
clients found no significant differences (Giacomuzzi et al. 2003), which confirms the results of 
Fischer et al. (1999). In another study (comparing 488 methadone and 205 buprenorphine 
clients) the buprenorphine group showed a significantly lower combined use of the substitu-
tion substance with benzodiazepines, cocaine, alcohol or codeines, which amounted to ap-
proximately one third of the combined use of methadone with these substances in the other 
group (Giacomuzzi et al. 2004b). As to age, in the buprenorphine group significantly lower 
combined use was observed in clients up to age 50, compared to the methadone group. In 
both groups simultaneous use of substitution substances and cocaine or morphines declined 
with age. While in the buprenorphine group, combined use of benzodiazepines increased 
with age, a parallel development regarding alcohol and codeines was registered in the 
methadone group. 
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12 Alternatives to prison targeting to 
drug using offenders 
This chapter deals with the alternatives to punishment1, of drug using offenders in Austria. In 
many European countries and also in the EMCDDA the more restricted concept of "alterna-
tives to prison" is applied. On the basis of the Austrian law system the broader concept of "al-
ternatives to punishment" corresponds better to the intentions of the lawmakers and the ac-
tual range of available measures. As the alternatives to punishment presented below refer to 
offences which are punished by prison sentences, they can be viewed as "alternatives to 
prison" in the broadest sense. However, it should be noted that in the vast majority of the 
cases where diversion is applied (see Chapter 12.2) because of the petty character of the of-
fences even in the case of conviction no unsuspended sentence, and thus no incarceration, 
follows. 
12.1 Political, organisational and structural information 
The principle of therapy instead of punishment and the availability of corresponding alterna-
tives to punishment of drug consuming offenders has been one of the pillars of Austrian drug 
policy for several decades (see also ÖBIG 2000). The Narcotic Drugs Act (SGG) of 1971 for 
the first time provided the possibility to let users of narcotic drugs who agreed to the neces-
sary medical treatment or monitoring go unpunished. In the context of the amendment of the 
SGG in 1985 the alternatives to punishment were extended to include deferment of charges 
for the duration of detoxification treatment and subsequent reduction of punishment. In the 
Narcotic Substances Act (SMG) of 1998 diversion regarding specific narcotic substances 
was further developed at several levels: it contains special regulations for cannabis products 
(see Table 12.1: section 35 (4) SMG), it provides a wider range of health-related measures 
(see Chapter 12.2) and the application of deferment of charges for certain offences commit-
ted to finance drugs is extended (see Table 12.1: section 39 (2) SMG) (Foregger et al. 1998).  
The most important alternatives to punishment for drug using offenders are regulated in the 
Narcotic Substances Act and refer only to this target group (see Table 12.1 for details). 
There are two relevant measures:  
The provisional deferment of charges (section 35 SMG) and the provisional suspension of 
sentence (section 37 SMG) can be applied in the case of petty crimes (possession and ac-
quisition of small amounts of drugs for personal use) and serve as an alternative to convic-
tion. These measures are applied regardless of an existing drug habit. Therefore they are 
only combined with a health-related measure if such a measure is deemed necessary by the 
competent health authority (see Table 12.1 and below). 
                                                
1 Alternative expressions used here are "diversion" and "therapy instead of punishment".  
   
Table 12.1: Overview of legal regulations with regard to alternatives to punishment applicable specifically to drug offences 
Section Short title Relevant passage Implementing 
authority 
Level of pro-
cedure 
35 SMG  
 
Provisional 
deferment of 
charge 
(1) Should a person be charged with purchase or possession in violation of existing regulations of a small amount of narcotic 
substance for his own use, the public prosecutor's office shall provisionally defer the charge for a probationary period of 
two years under the conditions set forth hereafter. 
(2) Should a person be charged with an offence otherwise punishable under Sections 27 and 30 or because of his depend-
ence on narcotic substances for an offence connected with the acquisition of a narcotic substance that is not within the 
competence of the Schöffengericht[local court consisting of one judge and two lay judges] or jury court, the public prosecu-
tor's office may provisionally defer the charge for a probationary period of two years ... if the culpability is not serious and 
the deferment does not appear less likely than a sentence to prevent the accused from committing ... offences. 
(3) Provisional deferment of a charge shall be contingent on ... 2. a report from the district administrative authority acting as 
health authority indicating whether the person charged requires a health-related measure under Section 11 or not and 
whether such a measure is expedient, feasible, reasonable and not manifestly futile under the given circumstances. 
(4) The public prosecutor's office may waive the requirement for a report from the district administrative authority if a person is 
charged exclusively for purchase or possession of substances or preparations made from cannabis plant in small quanti-
ties for his own use and if there is no reason to assume that the person requires a health-related measure. ... 
Public 
prosecutor's of-
fice 
Before 
initiating 
proceedings 
37 SMG Provisional 
suspension  
If an application for punishment has already been made with respect to the person charged, Sections 35 and 36 shall apply 
mutatis mutandis for the provisional suspension of the criminal proceedings by the court. The suspension of criminal proceed-
ings may also be made contingent on the accused agreeing to certain instructions (Section 51 Criminal Code). 
Court Criminal 
procedure 
39 SMG Stay of exe-
cution of sen-
tence 
(1) Under the general requirements and conditions ... a narcotic-dependent accused person may be granted, for a maximum 
period of two years, a stay of execution of sentence of a fine or of imprisonment of not more than two years in so far as he 
agrees to receive the necessary health-related measure referred to in Section 11. Under these conditions the court may 
also approve a stay of execution of sentence of imprisonment of up to three years. 
(2) In accordance with paragraph 1 the court may also approve the stay of execution of sentence for an offence punishable by 
no more than five years' imprisonment relating to the procurement by the accused of narcotic substances on account of 
dependence. 
Court Conviction 
13 SMG Special 
regulation for 
schools and 
military ser-
vice 
(1) If particular facts give grounds for suspecting that a school pupil is abusing narcotic drugs, the head of the school shall 
have him examined by the school doctor. ... Should the examination show that a health-related measure as referred to in 
Section 11 paragraph 2 is necessary and should this not be provided, or should the pupil...  refuse the examination by the 
school doctor, the head of the school shall inform the district administrative authority acting as health authority in lieu of fil-
ing a criminal charge. .... 
(2) If the medical examination of a person liable for military service or a medical examination by a military doctor of a conscript 
during his basic military service gives grounds for suspecting narcotic drug abuse,  ... (the competent authority) shall in-
form the district administrative authority acting as health authority in lieu of filing a criminal charge.  
School 
Competent 
military unit 
Before or 
instead of 
referral to the 
legal 
authorities 
Key: SMG = Narcotic Substances Act 
Summary: ÖBIG 
 
   
Table 12.2: Overview of general legal regulations with regard to alternatives to punishment applicable specifically to drug offences 
Section Short title Relevant passage Implementing 
authority 
Level of 
procedure 
90 StPO Diversion The public prosecutor shall .... desist from prosecuting an offence if it has been found on account of a sufficiently clear state of 
affairs that the withdrawal of a report under Section 90 is not applicable, but punishment in the form of  
1. paying a fine or 
2. doing community service or 
3. determining a probationary period, possibly in connection with probation assistance and the obligation of fulfilling certain 
tasks or 
4. a settlement out of court 
is not considered appropriate to prevent the suspect from committing offences or to counteract the committing of offences by 
others.  
Public prosecu-
tor's office 
Before 
initiating 
proceedings 
180 StPO Milder meas-
ure instead of 
custody be-
fore trial 
(4)  (1) ...  A person shall not be taken into or remain in custody before trial, if the purposes of custody ... can be achieved by 
... applying one or several milder measures. (5) Milder measures include: ...  4a.the order to undergo withdrawal treatment, 
other medical treatment, psychotherapy or a health-related measure (Section 11 SMG), if the accused agrees to do so. 
Court Judicial 
investigation 
before trial 
12 JGG Verdict of 
guilty without 
punishment 
If in the case of a juvenile offence a minor sentence would be applicable, the court shall defer from pronouncing a conviction, if 
it can be assumed that the verdict of guilty will suffice to prevent the offender from committing further punishable acts.  
 
Court Conviction 
13 JGG Verdict of 
guilty with 
reservation of 
punishment 
The pronouncement of a punishment on account of a juvenile offence shall be reserved for a probationary period between one 
and three years, if it can be assumed that the verdict of guilty and the pending pronouncement of punishment alone or in com-
bination with other measures will suffice to prevent the offender from committing further punishable acts.  
Court Conviction 
46 StGB Release from 
imprisonment 
upon proba-
tion 
(1) If an offender has served half of the ... term of imprisonment provided in the sentence..., the remaining period of imprison-
ment shall be cancelled under the condition of a probationary period, if it can be assumed that it will not be necessary to 
execute penal law in order to prevent the offender from committing further punishable acts.  
(2) If an offender has served two thirds of the ... term of imprisonment, ... the remaining period of imprisonment shall be can-
celled under the condition of a probationary period, unless there are special reasons to fear that the offender would com-
mit further punishable acts when released.  
Court Execution of 
sentence 
50 StGB If the punishment or preventive measure resulting in imprisonment is cancelled under the condition of a probationary period or 
if the offender is released from imprisonment or a preventive measure resulting in imprisonment under the condition of a pro-
bationary period, the court has to give instructions to him/her or pronounce an order of probationary assistance, insofar as this 
is necessary or expedient in order to prevent the offender from committing further punishable acts. 
51 StGB 
Pronounce-
ment of court 
instructions 
and order of 
probationary 
assistance 
 
(3)  The offender can also ... be given instructions to undergo withdrawal treatment, psychotherapeutic or medical treatment, if 
s/he agrees to do so. 
Court Judicial in-
vestigation 
before trial 
conviction 
execution of 
sentence 
: StGB = Criminal Code, StPO = Code of Criminal Procedure, JGG = Juvenile Court Act 
Summary: ÖBIG
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A stay of execution of sentence (39 SMG) is possible for more serious offences and func-
tions as an alternative to the execution of a sentence in the case of a unsuspended convic-
tion on account of a drug-related offence or an offence committed in connection with drug 
acquisition. This makes it an alternative to prison in the narrow sense. This procedure is re-
stricted to convicted persons who are dependent on drugs and agree to adopt a health-
related measure. If the offender has successfully completed the measure, the court shall 
suspend the sentence. 
As in other respects, also regarding the alternatives to punishment the Narcotic Substances 
Act makes no difference according to substance, with the exception of a special regulation 
facilitating the waiving of a report in cases where cannabis is involved (Section 35 (4) SMG). 
In Section 13 of the Narcotic Substances Act special regulations for specific institutions (es-
pecially schools) are contained (see Table 12.1), which provide for internal crisis manage-
ment without involving the law authorities, which represents another alternative to punish-
ment in the broadest sense.  
Apart from the Narcotic Substances Act, general laws on diversion are also applicable to 
drug using offenders (see Table 12.2). Compared to the drug-specific alternatives regulated 
by the Narcotic Substances Act, they are of minor importance and are thus not specifically 
referred to in the following.  
It should be added that the majority of alternatives to punishment are regulated by obligatory 
provisions (= offenders have a legal claim) and only a small part by optional provisions (= ju-
dicial authorities can react according to their discretion; see Tables 12.1 and 12.2). This 
means that the scope for action by the decision-making bodies is narrow. If the requirements 
and conditions defined by law are applicable, the prosecutors and courts are in most cases 
obliged to adopt alternative measures. 
The alternatives to punishment are regulated in federal laws and come under federal compe-
tence. The provinces have no scope for action, but they also endorse the principle of therapy 
instead of punishment and have drawn up their drug strategies and addiction plans accord-
ingly. The implementation of alternatives to punishment is not carried out within the frame-
work of a defined programme, but rather lies in the competence of all authorities involved. 
Therefore there is no central body coordinating and monitoring implementation. The Ministry 
of Health does, however, play a special role as the authority in charge of central monitoring 
in connection with the Narcotic Substances Act (especially reports, convictions, alternatives 
to punishment) under Section 24 of the Narcotic Substances Act. Under Section 25, the Min-
istry of Health within the framework of diversion gives information to the public prosecutors 
and the courts on any entries referring to the person in question in the database of narcotic 
substances. 
Other authorities directly involved in the implementation of alternatives to punishment as 
regulated by the Narcotic Substances Act are the prosecutors, the courts and the district 
health authorities (see also Table 12.1). The decision on applying alternatives to punishment 
are taken by the public prosecutors (before proceedings have been initiated) and the courts 
(after proceedings have been initiated, or after conviction). The basis for decision is a report 
issued by the district health authorities, which have the competence to determine whether a 
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health-related measure is necessary and if so, which measure should be applied (see also 
Chapter 12.2). 
The principle of therapy instead of punishment and the corresponding application of alterna-
tives to punishment for drug using offenders is widely supported by policy makers and the 
general public. Therapy instead of punishment is the drug-policy consensus of all parties rep-
resented in the Austrian parliament. Opinion polls confirm the strong acceptance of this prin-
ciple by the public, which has increased over the years. Compared over time, the attitudes 
towards drug policy investigated within the framework of drug surveys in Vienna show that 
the approval for "maintaining a general prohibition on drugs, but decriminalising drug addicts" 
has risen between 1995 (67%) and 2003 (76%), while the approval for "imprisonment on ac-
count of drug use" declined from 27% (1995) to 21% (2003) (IFES 2004; see Chapter 1.4). 
12.2 Interventions 
Data on the implementation of alternatives to punishment are available from the narcotic 
substances database (see Chapter 12.1) with regard to withdrawal of reports and waiving of 
proceedings 
Figure 12.1: Development of the implementation of statutory alternatives to punishment in Austria, from 
1994 to 2003 
Section 35 SMG = Provisional deferment of charge by the public prosecutor's office 
Section 35 (4) SMG = Waiving of reports in the case of small amounts of cannabis for personal use 
Section 37 SMG = Provisional suspension of proceedings by the court 
Note: The Narcotic Drugs Act was replaced by the Narcotic Substances Act on 1 January 1998. A specification of the kind of al-
ternative to punishment can be given for the period since 1998 only. Regarding Section 39 of the SMG (suspension of 
prison sentence based on the principle of therapy instead of punishment) no reliable data are currently available. 
Source: BMFG; calculations by ÖBIG 
The available data indicate a marked increase of diversion to alternatives to punishment over 
the decades. The number of cases rose from approximately 1 200 in 1981 (Litzka 1997), to 
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approximately 5 000 cases in the mid-1990s and ultimately reached its actual peak in 2003, 
with over 9 000 cases (see Figures 12.1 and Table A18 of Annex A). The increase corre-
sponds to the continually growing number of reports in the field of narcotic substances, es-
pecially over the past decade. This substantial rise was compensated by an increase in the 
implementation of alternatives to punishment, while the number of convictions has remained 
relatively stable over a long period of time (see Figure 12.2). Over the past few years the in-
crease in the diversion to alternatives to punishment in relation to the number of reports has 
somewhat gone down. At the same time - and partly in connection with this development - 
the number of convictions and especially the number of persons taken into imprisonment on 
account of drug-related offences has grown (see ÖBIG 2003b). 
Figure 12.2: Comparison of the development of drug-related reports, convictions and applications of 
the statutory alternatives to punishment in Austria from 1994 to 2003 
 
 
Sources: BMI Bundeskriminalamt (Federal Criminal Agency), Statistics Austria, BMGF; calculations by ÖBIG 
Regarding the stay of execution of sentence (Section 39 SMG), no reliable data are available 
from the narcotic substances database, on account of a great number of lacking reports. 
Data are available from the Federal Ministry of Justice (BMJ) for the past three years (2001: 
254, 2002: 337, 2003: 318 cases) .  
In general, the application of alternatives to punishment for drug using offenders is not con-
tingent on special conditions in Austria (see also above). Regarding the reports issued by the 
district health authorities, the Narcotic Substances Act expressly stipulates that it shall be 
examined whether the person in question needs a health-related measure, and whether such 
a measure is expedient, feasible, reasonable and not manifestly futile. If a health-related 
measure is deemed necessary, the same range of measures as defined in Section 11 of the 
SMG is available at all levels of procedure: (1) medical supervision of the person's health, (2) 
medical treatment including withdrawal and substitution treatment, (3) clinico-psychological 
counselling and care, (4) psychotherapy and (5) psychosocial counselling and care. In order 
to safeguard the adequacy of the measure taken, the court may explicitly make the suspen-
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sion of sentence contingent on inpatient treatment, on the basis of an expert opinion. Apart 
from this regulation there are no clauses regarding outpatient or inpatient treatment and care.  
Information on the results of examinations can be obtained from the data included in the nar-
cotic substances database. It should be noted that many reports are lacking. Still, the avail-
able data do permit some statements regarding the general situation and conclusions regard-
ing longer-term trends. An analysis of the years from 1999 to 2002 shows that a variety of 
approaches to the prescribed measures are taken in practice. The number of cases in which 
no health-related measures are prescribed is higher than the number of prescribed health-
related measures. Among the range of available measures, psychosocial care and treatment 
and medical supervision of the person's health are prescribed most often (see Table 12.3). 
Table 12.3: Reports by the district administration authority by content from 1999 to 2002 
Content of the report 1999 2000 2001 2002 
medical supervision 382 708 637 778 
medical treatment 419 433 431 531 
clinico-psychological care 65 136 128 79 
psychotherapy 80 70 72 59 
psychosocial care 435 663 923 1.041 
A health-related measure has 
been prescribed, namely 
total1 1 203 1 646 1 799 2.091 
no measure is deemed necessary 1 933 1 973 2 593 3.002 
measure would be inexpedient etc. or futile 19 25 44 68 
other reasons 1 044 1 371 1 904 381 
No health-related measure has 
been prescribed, because  
total1 3 025 3 394 4 549 3.449 
1) As several health-related measures can be prescribed in one report, the category "total" is not identical with the added 
number of individual measures. 
Source: ÖBIG 
A detailed analysis also shows marked differences with regard to the substances involved 
and the corresponding degree of severity of the drug problem. While in the case of cannabis 
often no health-related measures are prescribed, the approach is different regarding opiates. 
Psychosocial care and medical supervision are the measures most frequently prescribed to 
cannabis users, while opiate users are mostly required to undergo medical treatment (see 
Table 12.4). 
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Table 12.4: Content of reports by the district administration authority from 1999 to 2002 by narcotic 
substance 
1999 2000 2001 2002 Content of the report 
C1 O2 C1 O2 C1 O2 C1 O2 
medical supervision 208 73 390 98 365 100 463 142
medical treatment 9 219 17 373 13 390 9 429
clinico-psychological care 38 11 73 28 76 14 38 24
psychotherapy 32 19 29 25 25 24 6 28
psychosocial care 213 76 373 88 581 75 688 118
A health-related 
measure has been 
prescribed, namely 
total3 442 320 709 515 850 529 976 659
no measure is deemed necessary 920 92 1 191 179 1 709 214 1 855 220
measure would be inexpedient etc. 
or futile 11 3 5 7 26 1 43 8
other reasons 60 11 244 45 98 16 98 19
No health-related 
measure has been 
prescribed, because 
total3 1 003 113 1 447 243 1 836 232 1 995 247
1) Report refers cannabis only 
2) Report refers to opiates only or to opiates in combination with other drugs 
3) As several health-related measures can be prescribed in one report, the category "total" is not identical with the added 
number of individual measures. 
Source: ÖBIG 
For the implementation of health-related measures as alternatives to punishment, services of 
the entire drug help system (see also Chapter 5 and Map 5.1) may be used. In accordance 
with the principle of free choice of therapists, the implementing institution is selected by the 
drug using offenders. In principle the institutions make no difference between clients who are 
diverted to a health-related measure and other clients. In Austria there are no specific pro-
grammes or services with regard to measures as alternatives to punishment. The inpatient 
centre Schweizer Haus Hadersdorf in Vienna was founded with the principle of therapy in-
stead of punishment in mind, but it also attends to other clients. In general diversion meas-
ures are implemented by the regular staff of the respective institution according to the de-
fined health-related measures, i.e. social workers, physicians, psychotherapists, psycholo-
gists, and care staff of inpatient services. 
On account of lacking data it is not possible to give an overview of the share of clients who 
turn to drug help centres in the context of alternatives to punishment. However, data are 
available from some provinces and centres. In Upper Austria, approximately one third of the 
clients of drug help services have been referred due to court orders (Suchtkoordination OÖ 
2003). In Salzburg the share of clients receiving care upon court instruction rose from 27% in 
2000 to 46% in 2003 (Schabus-Eder, personal information). Also in Lower Austria counsel-
ling centres have registered a sharp rise in the number of clients in connection with the Nar-
cotic Substances Act.  
Among the clients of the association Grüner Kreis, who undergo therapy as a consequence 
of a court decision, there is a higher share of men (86% vs. 73%) and a lower share of young 
people (12% vs. 22%) than among those clients who undergo therapy of their own accord 
(Muhr 2003).  
As the prescribed health-related measures can be carried out in all drug help centres, the 
availability was usually considered sufficient in the past. But recently, problems have been 
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reported in some provinces. Because the great increase in the number of clients for whom a 
health-related measure is provided upon court order (the number of orders prescribing psy-
chosocial counselling and care having more than doubled between 1999 and 2002; see Ta-
ble 12.3), was not compensated by additional funding, some centres have capacity prob-
lems. In Upper Austria the corresponding institutions have had to restrict their services since 
June 2003; the application of health-related measures was discontinued in six districts. This 
endangers the implementation of alternatives to punishment, as in many cases prosecutors 
will not accept a delay and will subsequently instigate proceedings (see also below; Schwar-
zenbrunner, personal information). Also in Carinthia, due to financial problems no adequate 
access to health care can be guaranteed to drug using offenders (Prehslauer, personal in-
formation). 
Limited financial means pose the greatest problem with regard to applying alternatives to 
punishment. For the majority of prescribed health-related measures no specific budgets are 
allocated, so they are financed by the regular budget of drug help centres, which mainly 
comes from the provinces, the Federal Government and social insurance funds (see also 
Chapter 1). Section 41 of the Narcotic Substances Act provides subsidiary financing of 
health-related measures as alternatives to punishment by the Federal Government (Ministry 
of Justice) under certain conditions. However, this excludes psychosocial counselling and 
care, which is the most frequently prescribed measure (see Table 12.3). Moreover, for years 
there have been disputes between the Federal Government and the Provinces about the 
constitutional principle of subsidiarity, because some of the provincial laws in the field of so-
cial help stipulate subsidiary competence, which makes it unclear who is ultimately obliged to 
bear the costs. In the late 1990s the Federal Ministry of Justice spent approximately EUR 4 
million annually for costs related to Section 41 of the Narcotic Substances Act; in the first 
years of the present decade, this sum has been reduced to approximately EUR 3 million. As 
explained above, this is only a small part of the total expenditure on health-related measures 
as alternatives to punishment.  
The health-related measures prescribed as alternatives to punishment are monitored by the 
public prosecutors and the courts, who may request reports confirming the beginning and the 
progress of a measure. The only exception to this rule is medical supervision of health, which 
comes under the competence of the district health authorities. 
If a person persistently refuses to undergo a prescribed health-related measure, under Sec-
tion 38 of the Narcotic Substances Act proceedings may be subsequently instigated or re-
sumed, if this is considered necessary to prevent the person concerned from committing fur-
ther offences. However, this regulation is rarely applied. Over the past few years public 
prosecutors have reported no more than approximately 250 to 600 cases of subsequent in-
stigation of proceedings per year, while over the same period in approximately 4 600 to 
6 800 cases reports were permanently withdrawn after the probationary period had expired. 
This means that proceedings are subsequently instigated in no more than 10% of withdrawn 
reports. 
Under Section 39 of the SMG the stay of execution of sentence is revoked if the convicted 
person does not receive a health-related measure that has been prescribed, or if they are 
sentenced again on account of another offence under the SMG or an offence committed in 
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connection with their dependence on a narcotic substance and if imprisonment is considered 
necessary to prevent the convicted person from committing further offences. 
12.3 Quality assurance 
Austria has hardly taken any quality assurance measures (such as guidelines, standards, fur-
ther education programmes, trainings) with regard to alternatives to punishment. When the 
Narcotic Substances Act entered into force in 1998, a number of events presenting the new 
law were organised, on occasion of which the planned strategies of diversion were discussed 
in detail. The field of alternatives to punishment was included in all the curricula of drug-
specific further training programmes for relevant occupational groups developed on behalf of 
the Federal Ministry for Health and Women in 2003 (ÖBIG 2003a). This theme forms a cen-
tral part of the curriculum for public health officers, who play an essential role owing to their 
competence for reports on required health-related measures (see Chapter 12.1). In Carin-
thia, the curriculum has been implemented since September 2003 within the framework of 
further education measures for physicians in the public health sector. This was comple-
mented by a handbook containing standards for reports by the district health authorities (see 
also Chapter 1.2). 
Research specifically dedicated to alternatives to punishment is also scarce. In her law thesis 
Beishammer (1999) discusses the implementation of the principle of therapy instead of pun-
ishment. First of all she points out that the Austrian drug policy includes elements of a legal 
approach (prosecution of crimes), a social approach (therapy instead of punishment) and a 
liberal approach (withdrawal of reports to the police, etc.). Against this background the model 
of therapy instead of punishment should be viewed as a forced compromise between the jus-
tice authorities and the drug help institutions, which leads to conflicts especially when it 
comes to evaluating the methods, objectives and results of a therapy. The potential for con-
flict is especially apparent in the difference in importance attributed to abstinence as an im-
mediate aim of therapy. But this problem was partly solved by extending the scope of health-
related measures defined in the SMG (see Chapter 12.1), thus permitting the implementation 
of the principle of therapy instead of punishment on a larger scale. 
Dittrich et al. (2003) evaluated the results of an examination of 200 drug using offenders who 
applied for a stay of execution of sentence (Section 39 SMG; see Chapter 12.1) after the 
SMG entered into force in 1998. All the persons examined were dependent on a narcotic 
substance. Inpatient short-term treatments were recommended most frequently (1998: 
approx. 75%, 2001: approx. 50% of the cases), but their relevance declined in favour of out-
patient care in the course of the observation period. This development is attributed to the fal-
ling number of seriously addicted opiate patients, the rising significance of substitution treat-
ment and the generally growing diversity of available therapy services. According to the sur-
vey, the health-related measures defined by the SMG (see Chapter 12.2) permit adequate, 
specific therapy measures, whereas the principle of therapy instead of punishment in the 
1980s and 1990s almost exclusively resulted in long-term therapies. The authors recom-
mend that uniform criteria for the application of health-related measures be established with 
the aim of eliminating any regional differences within Austria.  
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At present, Austria takes part in creating a well-founded base of knowledge on extrinsically 
motivated therapy measures within the framework of the EU research programme QCT (QCT 
= quasi-compulsory treatment). In the course of this project, data comparing therapy pre-
scribed by court order and voluntary therapy are collected in a number of Austrian drug help 
institutions. Preliminary results will be available within the next few months. 
In the therapy community Grüner Kreis the rate of clients in therapy upon court order who 
discontinued treatment was lower than the drop-out rate of clients undergoing therapy of their 
own accord (30% vs. 50%; Grüner Kreis 2004). This is hardly surprising, as for the first 
group, discontinuing therapy may result in imprisonment. In the years before, the difference 
between the two groups was less marked, however (FSW 2004c). There is no information 
available on longer-term therapy effects.  
In a current study, the Addiction Research Institute in Vorarlberg compares clients in therapy 
upon court order with other clients. As yet, no results are available. 
  76 
13 Public Nuisance: definitions, trends in policies, 
legal issues and intervention strategies 
In Austria, public nuisance in connection with drugs is not an explicitly defined issue. How-
ever, questions in this respect are included in public opinion polls on attitudes to drugs and 
drug policy measures. The focus in this context is on public safety, the individual feeling of 
security, but also on acceptance of measures. Another field of debate is media coverage, 
where upon certain current events (such as the planned opening of a drug help service) un-
specific fears of the public are reflected, which contributes to ingraining existing prejudice. In 
some cases drug users are perceived as creating public nuisance, which has led to com-
plaints by local residents. Recently measures to increase social acceptability of drug users 
have been discussed. 
As a rule, in Austria, the issue is not drug-related crimes that are actually experienced or 
perceived, or the fear of crimes, but rather the individual feeling of security, which is irritated 
by marginalised social groups, among them drug users in the street scene (see Team Fokus 
2002, FSW 2004a). Such perceptions of disorder may occur when the habitual rules of be-
haviour in the (semi)public sphere are violated (see IKF 2000). It should also be noted that 
the main factor causing negative responses is visible drug trafficking. Drug use in public or 
actually observed drug-related crimes are hardly ever mentioned by passers-by or local resi-
dents (Team Fokus 2002). 
13.1 Measures taken 
On the one hand, the fact that public nuisance in connection with illegal drugs is not voiced 
as a burning issue is due to the strategic definition of drug dependency as an illness rather 
than a criminal act, which is also shared by the general public. As a consequence, this leads 
to a better understanding and higher acceptance of addiction-related measures (Springer 
2001, Team Fokus 2002). On the other hand, the Austrian drug policy with its focus on pre-
vention reduces many potential fields of conflict (see Springer 2001). More specifically, this 
refers to demand-oriented low threshold care for drug users and to the following measures: 
Within the framework of specific public relations work by drug help institutions, it is attempted 
to raise public understanding for addiction patients and to create a general awareness that 
addiction is not just a personal problem but has structural, social causes. Another aim is to 
overcome fears, negative expectations and prejudice against drug users by means of spe-
cific information and educational campaigns (Caritas Innsbruck 1999, www.doit.at) and to 
mediate between drug users and the general public (Suchtkoordination Steiermark 2003). 
The exchange of experience and joint discussion of problem areas within the framework of 
specific networks of drug help experts has also contributed to a situation where existing con-
flicts of interest are not carried into the public sphere but rather brought to fact- and solution-
oriented discussion by the competent institutions and decision-making bodies. Here the fo-
cus is on networking between the political level, police and drug help centres (see 
www.doit.at, Suchtkoordination Steiermark 2003, VWS 2003a, FSW 2004a). 
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When he entered office in spring 2003, the new Vienna Drug Coordinator defined social ac-
ceptability of the drug street scene as one of the focuses of his work (see Chapter 1.2), as a 
reaction to complaints about the drug street scene and drug trafficking in the public sphere. 
An important cornerstone of the corresponding measures is new approaches to social work 
in the public sphere. Since September 2003 monthly meetings of representatives of the po-
lice, Vienna’s public transport system and social work/streetwork have been organised to de-
velop a joint policy for coping with the drug scene and related problems. In this steering 
group, the specifically required measures at critical points of the public sphere and public 
means of transport are brought to a consensual vote (FSW 2004a). 
In order to respond to complaints and reports of pressing problems in the public environment, 
TEAM FOCUS was created by the City of Vienna in 1993. The aim of this team is to obtain a 
comprehensive, neutral overview of the background, causes and actors in the respective 
conflict situation or conflict area, by means of investigating into the social situation in the pub-
lic sphere. So far TEAM FOCUS has carried out three investigations in which problems re-
lated to the open drug scene were explicitly included in the agenda. On the basis of the re-
sults specific measures at the regional level were suggested (see Team Fokus 2001, 2002, 
2003).  
Demand-oriented low threshold measures play a vital role in preventing public nuisance. In 
almost all the provinces, syringe exchange programmes are run, with a return rate of ap-
proximately 95%, which has the effect that the number of syringes lying about have been 
drastically reduced (VWS 2004b, Do it yourself 2002; see Chapter 7.2). In Vienna, an addi-
tional syringe collection service which collects syringes in the public environment (MOSKITO) 
was organised by the Municipal Department for Parks and Gardens in 1992. In 2003, 8 008 
syringes were regularly disposed of by this service (FSW 2004b, FSW 2004c). At the begin-
ning of 2004 the project was transferred to the Municipal Department MA 48 (Waste Man-
agement), with the same tasks as before. 
Outreach work in the sense of drug streetwork also has the aim of increasing the social ac-
ceptability of the drug street scene. At Karlsplatz square in Vienna, in addition to expanding 
outreach help for drug users, a new intervention and conflict management team has been 
created, which primarily serves as a contact point for local residents and the general public 
and has a mediating function (FSW 2004a). 
Consumption rooms, where previously acquired drugs can be consumed under the condition 
that certain rules are observed, to a certain degree may help to relieve public space from 
drug consumption and the related problems, which increases the feeling of security in the 
general public (Springer 2003b). Drug use in public (e.g. toilets, parks, telephone booths) is 
thus reduced as well as the number of syringes left lying about especially due to the stressful 
situation of hurried drug consumption (see Neubauer 2003). It should be noted, however, 
that the successful implementation of consumption rooms relies on the consensus of all re-
sponsible actors involved (policy makers, experts, general public etc.). Plans for consumption 
rooms exist in Vienna and in Innsbruck. However, there are no signs that these plans will be 
implemented in the near future (Caritas Innsbruck 1999, Strobel und Zach 2002, VWS 
2003a). 
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Furthermore there are police measures intended to reduce drug trafficking in the streets sub-
stantially. In Vienna, the Drug Coordinator’s Office and the police regularly communicate 
about current problem situations, coordinating strategies and their implementation (VWS 
2004a). 
13.2 Results/ Evaluation 
In Austria studies and results of evaluation regarding public complaints or disturbances in 
connection with illicit drugs are mainly limited to public opinion polls carried out in some prov-
inces (Styria, Vorarlberg and Vienna) (IFES 2002, Institut für Suchtforschung 2001). In Vi-
enna, public opinion polls have been conducted in the context of drug monitoring every two 
years since 1995 (see Chapters 1.4 and 2.1). Other interesting findings result from the social 
investigations carried out by TEAM FOCUS in Vienna (see Chapter 13.1). Also in Vienna, 
two surveys on life quality and safety were conducted (IFES 2003a). 
In general the various polls refer to attitudes of the public to drugs and drug policy (see 
Chapter 1.4), frequency and places of contact, experience of nuisance and threat, and also 
to acceptance of a variety of measures. 
Regarding the feeling of security it has turned out in the polls that a general feeling of unease 
prevails, rather than clearly defined fears (IFES 1999b). This result concurs with the fact that 
complaints by local residents are usually caused not by crimes that have actually been ex-
perienced or witnessed, but rather by individual irritation (see Team Fokus 2002). From the 
results of the public polls in Vienna it can also be concluded that the feeling of threat in con-
nection with the open drug scene markedly declined between 1997 and 2001 (IFES 2001). 
Also in Vorarlberg, the majority of the population does not feel personally bothered by drug 
users. Only four percent indicate that they have experienced unpleasant situations involving 
drug users (Institut für Suchtforschung 2001). 
The presence of drug addicted persons or a drug scene in the immediate living environment 
does not affect the feeling of security of the public in Vienna, either. It is indicated as an issue 
that causes individually experienced nuisance with roughly the same frequency as pollution 
and decay, some obstacle in the street, or the presence of homeless people (see Team Fo-
kus 2002). As can be seen in Figure 13.1, close to half of the population in Vienna would not 
feel disturbed if a drug counselling centre were opened in their immediate vicinity. Only one 
fifth would feel very negative about it, and a small minority would not exclude the possibility 
to protest actively against such an establishment. It also becomes evident that most of the 
data hardly changed over the period of observation, between 1999 and 2003. Only the 
shares of people who do not have a problem with a drug help centre in their vicinity and of 
those who would actively protest against it, have risen slightly (IFES 2004). 
Physicians who treat drug addicted patients present no or no great problem to 80% of the 
population in Vienna (Feistritzer 2000).  
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Figure 13.1: Acceptance of a drug counselling centre in one’s living environment in Vienna, 
from 1999 to 2003 
 
Source: IFES 2004 
TEAM FOCUS investigated the situation around the mobile contact point at Südtirolerplatz in 
Vienna (see Chapter 13.1). The facility faced problems of political acceptance on the part of 
the district. Allegations were made that the mobile facility (which includes a syringe service) 
attracted more and more drug users. It was agreed to move the facility to another place tem-
porarily and to monitor scientifically any changes by means of interviews with the local resi-
dents and passers-by as well as resident business owners and employees of public means 
of transport. The results have shown that the allegations that the mobile service would attract 
an increasing number of drug users were unfounded. On the contrary it turned out that there 
were more protests of residents on account of syringes and needles left lying about in the 
streets after the facility had been moved (VWS 2003a, Team Fokus 2002). This result con-
firms (international) experience in connection with syringe exchange programmes and con-
sumption rooms (Caritas Innsbruck 1999). 
The attitude of the population to police interventions in relation to the feeling of security was 
also investigated. Almost half of the population of Vorarlberg expressed the view that police 
officers did not adequately protect the population from drugs and drug-related crimes (Institut 
für Suchtforschung 2001). In Vienna, opinions diverge with regard to police interventions as a 
drug policy measure. Approximately 40% are in favour of such interventions, while one third 
thinks this is the wrong approach. A focus on police interventions in this field is not regarded 
as expedient by the respondents (FSW/IFES 2002). In Styria two thirds of the respondents 
are in favour of more police interventions in the hope that this would cause an improvement 
of the drug situation (IFES 2002). 
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DATA BASES 
 
EDDRA = Exchange on Drug Demand Reduction Action 
Internet data base of the EMCDDA : http://eddra.emcdda.eu.int/eddra  
Austrian projects in the EDDRA data base: 
Alles im Griff? * – touring exhibition 
(Fachstelle für Suchtprävention, Lower Austria) 
Am Puls* - addiction assistance programme in the workplace 
(Magistrat der Stadt Linz) 
API Mödling – inpatient long-term therapy for drug addicts  
(Anton Proksch Institut, Lower Austria) 
Arbeitsprojekt WALD (occupational project) 
(H.I.O.B. – Anlauf- und Beratungsstelle für Drogenabhängige, Vorarlberg) 
Auftrieb – (drug) counselling centre for young people 
(Verein für Jugend und Kultur Wr. Neustadt, Lower Austria)  
Behandlung von Schwangeren an der Drogenambulanz des AKH Wien 
Sub-programme of Vienna’s model project on pregnancy and drugs, a comprehensive care 
project for addicted mothers and their children 
(AKH, Vienna) 
Berufsassistenz*; occupational assistance subproject of the Vienna Job Exchange in the 
context of the Equal development partnership 
(Wiener Berufsbörse, Vienna) 
Betreutes Wohnen 
(Verein Wiener Sozialprojekte, Wien) 
CARINA – long-term treatment facility for drug addicts 
(Stiftung Maria Ebene, Vorarlberg) 
ChEck iT! – scientific pilot project 
(Verein Wiener Sozialprojekte, Wien) 
CONTACT – hospital connection service for drug addicts 
(Fonds Soziales Wien) 
Drogenfreie Zone in der Justizanstalt Hirtenberg; drug-free zone 
(Justizanstalt Hirtenberg, Lower Austria) 
Drogenfreie Zone in der Justizanstalt Innsbruck; drug-free zone 
(Justizanstalt Innsbruck, Tirol)  
Drogeninstitut – drug outpatient department, (drug-free) treatment department* 
(Otto Wagner-Spital, Wien) 
 
 
* available in the data base by the beginning of 2005  
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drugaddicts@work - evaluation project on occupational reintegration in the labour market 
of drug-addicted clients  
(Fonds Soziales Wien) 
Drug Out – treatment department of the prison of Innsbruck 
(Justizanstalt Innsbruck, Tirol) 
Ehrenamtliche Bewährungshilfe für Insassen der Justizanstalt Favoriten (voluntary proba-
tion assistance) 
(Verein für Bewährungshilfe und soziale Arbeit - Bewährungshilfe Wien) 
Eigenständig werden* - education programme for prevention in schools  
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Eltern - Kind - Haus – counselling for drug-addicted parents and children in a therapeutic 
community  
(Verein Grüner Kreis) 
Erlenhof – therapy centre for addicted patients 
(Pro mente Oberösterreich) 
Europäische Netzwerkentwicklung in der Suchtprävention (building European networks of 
addiction prevention) 
(Institut Suchtprävention, Oberösterreich) 
Fantasy statt Ecstasy – Peer group education for addiction prevention in an upper secon-
dary school at Neumarkt (AKZENTE Salzburg - Suchtprävention, Salzburg) 
FITCARD - Gesundheitsförderung mit Lehrlingen; sub-programme of the programme 
“health promotion and addiction prevention in the workplace”  
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Fix und Fertig – socioeconomic enterprise  
(Verein Wiener Sozialprojekte) 
Fortbildungslehrgang zur Suchtvorbeugung im Kindergarten für Kindergartenpädagogen 
(further training in addiction prevention for kindergarten teachers) 
(VIVID - Fachstelle für Suchtprävention, Steiermark) 
Gelebte Suchtvorbeugung in der Gemeinde. Sub-programme of the pilot action “local 
capital for social purposes" of DG V of the EU programme Sozial Innovativ 2000 (EU re-
gional management East Styria) 
(Volkshilfe Steiermark, VIVID Fachstelle für Suchtprävention, Regionalbüro Oststeiermark) 
Generation E* - workshop for creative parent work 
(Institut für Suchtprävention, Fonds Soziales Wien) 
Gesundheit fördern - Sucht verhindern – action programme of the Ministry of Education  
(Bundesministerium für Unterricht und kulturelle Angelegenheiten) 
H.I.O.B. Assistance, information, orientation and counselling for drug addicts  
(H.I.O.B. - Anlauf- und Beratungsstelle für Drogenabhängige, Vorarlberg) 
in motion – multiplier project for prevention in schools  
(Institut Suchtprävention - eine Einrichtung von pro mente Oberösterreich) 
 
* available in the data base by the beginning of 2005 
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Jugendhaus – counselling for young people in a therapeutic community  
(Verein Grüner Kreis) 
Jugendberatungsstelle WAGGON – youth counselling centre 
(TENDER - Verein für Jugendarbeit, Niederösterreich) 
Kinder stark machen – Strengthening our Children – mass media campaign 
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Kinder stark machen mit Sport – Strengthening Children through Sports 
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Log In* - Leisure time activities to support social reintegration of (former) drug addicts 
(Anton Proksch Institut, Niederösterreich) 
Lukasfeld – short-term therapy department  
(Stiftung Maria Ebene hospital, Vorarlberg) 
Marienambulanz Graz* - medical first aid and basic care, low-threshold facility  
(Caritas der Diözese Graz Seckau) 
MDA basecamp – mobile drug work in recreational settings 
(Jugendzentrum Z6, Tyrol) 
Miteinander leben 2* – regional addiction prevention schools and recreational settings in 
rural areas  
(Institut für Suchtprävention, Wien) 
My job my way* - subproject for reintegration of long-term jobless drug addicts in the con-
text of the ida – Equal partnership 
(Abrakadabra, Caritas Tirol) 
Nachbetreuung von Kindern substanzabhängiger Mütter. After-care for children of 
addicted mothers; sub-programme of Vienna’s model project on pregnancy and drugs – 
comprehensive c are project for addicted mothers and their children 
(Neuropsychiatrische Abteilung für Kinder und Jugendliche am KH Rosenhügel, Wien) 
Needles or Pins – European Project for development of innovative social and occupational 
reintegration projects for persons with drug problems; sub-project of Vienna 
(Beratungsstelle DIALOG, Wien) 
Needles or Pins - European Project for development of innovative social and occupational 
reintegration projects for persons with drug problems; sub-project of Vorarlberg 
(Die Fähre, Vorarlberg) 
Needles or Pins* - Occupational reintegration of persons with addiction problems 
(Beratungsstelle DIALOG, Wien) 
Pilotprojekt Suchtvorbeugung in Trofaiach (prevention pilot project) 
(b.a.s. (betrifft alkohol und sucht) - steirischer Verein für Suchtkrankenhilfe) 
Rumtrieb – mobile youth social work in Lower Austria 
(Verein für Jugend und Kultur Wr. Neustadt, Niederösterreich) 
 
 
 
 
* available in the data base by the beginning of 2005 
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SAS - Schüler auf der Suche nach alternativen Lösungsmöglichkeiten (project for multipliers 
in schools, primary prevention by peer group approaches) 
(VIVID - Fachstelle für Suchtprävention, Steiermark) 
Step by Step – early detection and intervention in case of possible addiction problems 
(kontakt&co - Suchtpräventionsstelle, Tirol) 
Schweizer Haus Hadersdorf – medical, psychological and psychotherapeutic centre 
(Evangelisches Haus Hadersdorf - WOBES, Wien) 
Senobio – inpartient drug treatment 
(Senobio, Vorarlberg) 
Sozialmedizinische Drogenberatungsstelle Ganslwirt* (low threshold service) 
(Verein Wiener Sozialprojekte, Wien) 
Spielzeugfreier Kindergarten. Toy-free kindergarten; prevention by promoting life skills  
(ISP - Informationsstelle für Suchtprävention, Wien) 
Umbrella-Network-Projekt– analysis of HIV, AIDS and STD problems in European border 
regions and development of cooperative transboundary prevention methods, Austria and 
Switzerland 
 (Institut für Sozialdienste, Vorarlberg) 
URBAN - Wien Gürtel Plus. secondary prevention for young people in urban areas  
(Drogenberatungsstelle Change, Wien) 
Viktoria hat Geburtstag (prevention programme) 
(Fachstelle für Suchtprävention, Niederösterreich) 
Way Out* - early intervention service for young drug-using first offenders  
(Kooperation der Landesstelle Suchtprävention und Neustart, Kärnten) 
Wiener Berufsbörse – Vienna Job Exchange; association for occupational integration of 
persons addicted to drugs, pharmaceuticals or alcohol  
(Wiener Berufsbörse, Wien) 
Wien-Favoriten – treatment and care for drug-using offenders  
(Justizanstalt Wien-Favoriten, Wien) 
 
 
 
 
 
 
 
* available in the data base by the beginning of 2005 
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WEBSITES  
Please find below websites of relevant institutions and associations in the field of drugs and 
addiction in Austria.  
For a comprehensive list of European and international websites on drugs and addiction 
please consult  http://www.oebig.at under prevention/drugs/links 
 
Provincial Drug or Addiction Coordinations: 
Addiction Coordination of Burgenland 
http://www.burgenland.at  
Drug Coordination of Carinthia  
www.gesundheit-kaernten.at 
Addiction Coordination of Lower Austria  
http://www.noel.gv.at/service/gs/gs4/noesuchtkoordination.htm 
Drug and Addiction Coordination of Upper Austria  
http://www.ooe.gv.at/gesundheit/sucht 
Drug Coordination of Salzburg  
http://www.salzburg.gv.at/themen/gs/soziales_einstieg2/leistungen_und_angebote/abha
engigkeit.htm 
Addiction Coordination of Styria  
http://www.drogenberatung-stmk.at 
Addiction Coordination of the Tyrol  
http://www.jugendweb.at/drogen  
Addiction Coordination of Vorarlberg 
http://www.vorarlberg.at/vorarlberg/gesellschaft_soziales/gesellschaft/suchtkoordination
/start.htm 
Vienna Social Fund, Drug Coordination of Vienna  
http://www.drogenhilfe.at  
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Provincial Addiction Prevention Units: 
Carinthia: Landesstelle für Suchtprävention Kärnten 
www.gesundheit-kaernten.at 
Lower Austria: Fachstelle für Suchtvorbeugung NÖ  
http://www.suchtvorbeugung.at 
Upper Austria: Institut Suchtprävention OÖ 
http://www.praevention.at  
Salzburg: AKZENTE Salzburg 
http://www.akzente.net  
Styria: VIVID - Fachstelle für Suchtprävention, Steiermark 
http://www.vivid.at  
Tyrol: kontakt &co. Jugendrotkreuz, Tiroler Fachstelle für Suchtprävention 
http://www.kontaktco.at 
Vorarlberg: SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg 
http://www.supro.at  
Federal Ministries 
Federal Ministry for Health and Women  
http://www.bmgf.gv.at  
Federal Ministry of the Interior  
 http://www.bmi.gv.at   
Federal Ministry of Justice  
http://www.bmj.gv.at 
Federal Ministry of Education, Science and Culture  
http://www.bmbwk.gv.at  
Federal Ministry for Social Security, Generations and Consumer Protection  
http://www.bmsg.gv.at 
Other websites 
AIDS assistance  
http://www.aidshilfen.at 
Alles im Griff (touring exhibition on addiction prevention) 
http://www.alles-im-griff.at  
ARGE Suchtvorbeugung (Working Group for Addiction Prevention) 
http://www.suchtvorbeugung.net 
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Anton Proksch Institute 
http://www.api.or.at  
Carina – treatment centre 
http://www.mariaebene.at/carina/  
ChEckiT! – Vienna Social Projects Association 
http://checkyourdrugs.com   
CONTACT – hospital connection service 
http://www.drogenhilfe.at/rathilfe/skh/r-s-contact.htm 
dialog – counselling and care centre 
http://www.dialog-on.at  
Do it yourself – low threshold centre for drug users 
http://www.doit.at  
Drogenambulanz - AKH Wien (drug outpatient department of Vienna General Hospital) 
http://www.akh-wien.ac.at/drogenambulanz 
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) 
http://www.emcdda.eu.int 
Ex und Hopp (drug counselling centre) 
http://www.exundhopp.at  
Ganslwirt Vienna Social Projects Association 
http://www.vws.or.at/ganslwirt/index.html 
Grüner Kreis 
http://www.gruenerkreis.at 
Haus am Seespitz – (short-term treatment centre for drug patients) 
http://www.jugendweb.at/drogen/drogen_ein_det.asp?ID=12 
H.I.O.B. (drug counselling centre) 
http://www.caritas-vorarlberg.at  
Institut für Suchtforschung der Universität Innsbruck mit Sitz am Krankenhaus Maria Ebene 
(institute for addiction research of the University of Innsbruck at Maria Ebene Hospital) 
http://www.suchtforschung.at 
Komfüdro – communication centre for drug users  
http://213.229.59.43/_html/caritas/hilfe/komfuedro.cfm  
Krankenhaus Rosenhügel (hospital) 
http://www.health.magwien.gv.at/welt/kavw/nkr  
Ludwig Boltzmann Institute for Addiction Research 
http://www.api.or.at/lbi/index.htm 
Lukasfeld  (treatment centre) 
http://www.mariaebene.at 
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Marienambulanz (outpatient centre) 
 http://www.caritas-graz.at/home.php?cakt=einr&id=68 
 MDA basecamp (mobile drug prevention in the Tyrol)  
http://www.mdabasecamp.com  
Needles or Pins - dialog 
http://www.dialog-on.at/dialog/channels/standorte/base2_html  
Otto Wagner Hospital; drug institute - 
http://www.drogenhilfe.at/rathilfe/skh/r-s-ows.htm   
Österreichische Caritaszentrale - Integration durch Arbeit KEG (Caritas social integration 
enterprise) 
http://www.ida-equal.at 
Österreichischer Verein für Drogenfachleute (association of drug experts) 
www.oevdf.at 
Österreichisches Netzwerk Gesundheitsfördernde Schulen (Austrian network for health 
promotion in schools) 
http://www.schule.at/gesundheit  
pro mente Oberösterreich 
http://www.promenteooe.at 
Schultüte (FSW/ISP Wien)  – school cone project  
http://schultuete.at  
Stiftung Maria Ebene (hospital) 
http://www.mariaebene.at  
Substanz – association for accepting drug assistance 
http://www.substanz.at 
Verein für Bewährungshilfe und Soziale Arbeit (probation assistance and social work asso-
ciation) 
http://www.vbsa.at 
VIVA – drug counselling centre 
http://www.gesundheit-kaernten.at  
VWS - Vienna Social Projects Association 
http://www.vws.or.at 
Wiener Berufsbörse (Vienna Job Exchange) 
http://www.bhakwien13.at/Beruffoerd/default.htm 
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Table A1: Overview of selected general population surveys on drug experience among the Austrian 
population from 1998 to 2003 
Study 
(authors(s), year of 
publication) 
Area covered 
Year of  
data collection 
(period covered) 
Target group 
(sample) 
Drug types surveyed Percentage of 
respondents with 
drug experience 
Age group            % 
Linzer Suchmittelstudie / 
drug survey, Linz 
(Institut für Soziologie der  
Universität Linz o. J.) 
Linz 
1998 
(lifetime) 
General population 
aged 15 and older
(n = 394) 
Cannabis 
Cannabis 
Cannabis 
Cannabis 
Cannabis 
15 –19 
20 –29 
30 –39 
40 –49 
50 + 
28 
37 
19 
7 
5 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(Wiener Drogenkoordina-
tion und IFES 2000) 
Vienna 
1999 
(lifetime) 
General population
aged 15 and older
(n = 623) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
Other illegal drugs (e.g. LSD) 
16 + 
16 + 
16 + 
16 + 
16 + 
16 + 
11 
1 
1 
1–2 
1 
1–2 
Bevölkerungsbefragung 
OÖ / 
drug survey 
Upper Austria 
(market 2000) 
Upper Austria 
2000 
(lifetime) 
General population
aged 15 and older
(n = 1 011) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Morphine 
LSD 
Smart drugs 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
21 
4 
1 
4 
1 
3 
1 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(FSW und IFES 2002) 
Vienna 
2001 
(lifetime) 
General population
aged 15 and older
(n = 650) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
Other illegal drugs (e.g. LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
14 
1 
1 
1  
1 
2 
Suchtmittelstudie Steier-
mark / 
drug survey, Styria 
(IFES 2002) 
Styria 
2002 
(lifetime) 
General population
from 14 to 60 
(n = 1 000) 
Illegal drugs (total) 
Cannabis  
Other illegal drugs/total 
Other illegal drugs 
Other illegal drugs 
Other illegal drugs 
Other illegal drugs 
Other illegal drugs 
14 –60 
14 –60 
14 –60 
14 –19 
20 –29 
30 –39 
40 –49 
50 –60 
14 
13 
2 
15 
21 
17 
13 
6 
Bevölkerungsbefragung 
OÖ / 
drug  survey 
Upper Austria 
(market 2004) 
Upper Austria 
2003 
(lifetime) 
General population
aged 15 and older
(n = 1 018) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Heroin 
Morphine 
LSD 
Solvents 
Biogenic drugs 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
23 
3 
3 
3 
1 
2 
3 
5 
3 
Wiener Suchtmittelstudie 
(IFES 2004) / 
drug survey, Vienna 
Vienna 
2003 
(lifetime) 
General population
aged 15 and older
(n = 750) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
Biogenic drugs 
Other illegal drugs (e.g. LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
16 
2 
2 
3  
1 
3 
2 
Summarised by ÖBIG 
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Table A2: Overview of selected school and youth surveys on drug experience among young people in 
Austria from 1996 to 2003 
Study 
(author(s), year 
of publication)) 
Area covered 
Year of data 
collection 
(period covered) 
Target group 
(sample) 
Drug types surveyed Percentage of  
respondents with 
drug experience 
Age group             % 
Schulstudie Kärnten / 
school survey, Carinthia 
(Bohrn und Bohrn 1996) 
Carinthia 
1996 
(lifetime) 
Students in their 7th 
to 12th/13th school 
years 
(n = 1 234) 
Hashish 
Ecstasy 
LSD 
Cocaine 
Heroin 
13 –19 
13 –19 
13 –19 
13 –19 
13 –19 
7.7
3.2
1.0
0.3
0.3 
NÖ Jugendstudie / 
youth survey, Lower Austria 
(Brunmayr 1997) 
Lower Austria 
1996/97 
(lifetime) 
Students in their 9th 
to 12th/13th school 
years 
(n = 1 300) 
Hashish 
Ecstasy 
Hallucinogens 
Cocaine 
Heroin 
15–19 
15 –19 
15 –19 
15 –19 
15 –19 
20 
4 
>1 
>1 
>1 
Schulstudie NÖ / 
school survey, Lower Austria 
(Institut für Sozial- und 
Gesundheitspsychologie 1999)
Lower Austria 
1997 
(lifetime) 
Students in their 7th 
to 12th school years 
(n = 1 899) 
Cannabis 
Ecstasy 
LSD 
Cocaine 
Heroin 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
13.6
3.8
1.7
1.3
0.6 
Jugendstudie Tirol / 
youth survey, Tyrol 
(Schüßler u. a. 2000) 
Innsbruck 
1999 
(lifetime) 
Young people from 
14 to 19  
(n = 493) 
Hashish 
Other illegal drugs 
14 –19 
14 –19 
22 
3 
Schulstudie Burgenland / 
school survey, Burgenland 
(Schönfeldinger 2002) 
Burgenland 
2001 
(lifetime) 
Students in their 7th 
to 13th school years
(n = 1 899) 
Cannabis 
Ecstasy 
Cocaine 
Heroin 
Speed 
Hallucinogens 
Solvents 
Biogenic drugs 
12 –19 
12 –19 
12 –19 
12 –19 
12 –19 
12 –19 
12 –19 
12 –19 
20 
  4 
  2 
   1 
  3 
  3  
20 
  8  
HBSC-Studie / 
HBSC study 
(Dür und Mravlag 2002) 
Austria 
2001 
(lifetime) 
Students aged 15 
(n = 1 292) 
Cannabis 15 14 
Grazer Jugendstudie / 
youth survey, Graz 
(X-Sample 2002a) 
Graz  
2002 
(lifetime) 
Adolescents and 
young adults from 
12 to 25  
(n = 515) 
Cannabis 
Party drugs 
Cocaine 
Heroin 
Speed 
Hallucinogens 
Solvents 
Biogenic drugs 
12 –25 
12 –25 
12 –25 
12 –25 
12 –25 
12 –25 
12 –25 
12 –25 
 58.2 
 15.4 
  7.3 
  4.9 
  6.0 
  7.2  
  9.2 
 21.1  
Berufsschulstudie Salzburg / 
vocational school survey, Salz-
burg 
(Klopf und Weinlich, 
unpublished) 
Salzburg 
2003 
(lifetime) 
Vocational school 
students from 
 15 to 25  
(n = 609) 
Cannabis 
Ecstasy 
Cocaine 
LSD  
Hallucinogenic mushrooms  
Solvents 
15 –25 
15 –25 
15 –25 
15 –25 
15 –25 
15 –25 
 31 
  7 
  5 
  5 
  9 
15 
Bevölkerungsbefragung OÖ / 
general population survey 
Upper Austria 
(ISP 2004) 
Upper Austria 
2003 
(lifetime) 
Adolescents and 
young adults from 15 
to 24  
(n = 567) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
LSD 
Solvents 
Biogenic drugs 
15 –24 
15 –24 
15 –24 
15 –24 
15 –24 
15 –24 
15 –24 
34.2 
8.3 
8.8 
6.2 
5.6 
12.5 
10.1 
ESPAD Österreich / 
ESPAD Austria 
(Uhl et al. 2004) 
 
Austria 
2003 
(lifetime) 
Students from 
13 to 18  
(n = 5 619) 
Cannabis 
Ecstasy  
Cocaine 
Crack 
Heroin 
Amphetamines 
GHB 
LSD 
Solvents 
Magic mushrooms 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
13 –18 
22.5 
3.1 
2.2 
1.5 
1.2 
4.7 
0.8 
2.2 
15.3 
3.7  
Summarised by ÖBIG
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Table A3: Number of drug-related deaths in Austria by cause of death from 1994 to 2003 
Cause of death 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Intoxication by opiate(s) 63 49 69 39 27 25 18 17 17 40 
Poly-drug intoxication including opiate(s) 105 115 115 92 81 101 147 119 119 115 
Poly-drug intoxication by narcotic drug(s) 
excluding opiates 
4 4 6 5 1 2 2 3 3 8 
Psychoactive medicines 4 8 4 5 8 8 * * * * 
Intoxication of unknown type 1 2 1 0 0 0 0 0 0 0 
Directly drug-related deaths/total 177 178 195 141 117 136 167 139 139 163 
AIDS 41 28 23 9 20 11 13 12 4 13 
Other diseases 13 21 5 5 11 9 22 17 21 9 
Suicide (no intoxication) 13 9 2 8 8 12 16 9 15 3 
Accidents, homicides 6 5 5 9 4 3 8 6 0 1 
Unknown cause of death   0 0 0 0 2 3 1 1 0 0 
Indirectly drug-related deaths/total 73 63 35 31 45 38 60 45 40 26 
* = as of 2000 no longer taken into account  
Source: BMGF, calculations by ÖBIG 
Table A4: Number of directly drug-related deaths in Austria by province from 1994 to 2003 
Province 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 1994–2003 
Burgenland 0 3 2 2 2 0 0 0 0 2 11 
Carinthia 3 1 3 3 3 7 2 5 7 6 40 
Lower Austria 7 9 18 12 9 8 11 14 12 13 113 
Upper Austria 9 9 6 6 6 2 11 8 6 13 76 
Salzburg 4 6 6 11 11 7 6 7 7 5 70 
Styria 4 6 9 13 5 6 11 9 13 14 90 
Tyrol 18 12 12 8 12 14 11 16 13 13 129 
Vorarlberg 6 11 14 5 6 5 5 11 6 5 74 
Vienna 126 121 125 81 63 87 110 69 75 92 949 
Total 177 178 195 141 117 136 167 139 139 163 1 552 
Source: BMGF, calculations by ÖBIG 
Table A5: Number of indirectly drug-related deaths in Austria by province from 1994 to 2003 
Province 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 1994–2003 
Burgenland 4 0 0 1 0 0 0 0 1 0 6 
Carinthia 3 3 0 5 2 0 1 3 2 1 20 
Lower Austria 3 2 0 1 2 4 4 6 5 0 27 
Upper Austria 18 15 11 4 8 3 7 12 7 5 90 
Salzburg 1 1 0 1 2 2 1 0 0 0 8 
Styria 1 2 1 0 1 0 1 2 2 3 13 
Tyrol 8 11 6 7 6 7 7 0 2 2 56 
Vorarlberg 14 13 6 2 7 5 5 6 4 7 69 
Vienna 21 16 11 10 17 17 34 16 17 8 167 
Total 73 63 35 31 45 38 60 45 40 26 456 
Source: BMGF, calculations by ÖBIG 
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Table A6: Number of directly drug-related deaths in Austria by age group and total by gender from 
1994 to 2003 
Age group 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
 abs. % abs. % abs. % abs. % abs. % abs. % abs. % abs. % abs. % abs. % 
19 and younger 27 15.3 31 17.4 24 12.3 18 12.8 7 6.0 16 11.8 19 11.4 20 15.1 18 12.9 20 12.3
20 –24 48 27.1 35 19.7 45 23.1 32 22.7 35 29.9 23 16.9 33 19.8 21 14.4 20 14.4 37 22.7
25–29 36 20.3 37 20.8 34 17.4 25 17.7 20 17.1 23 16.9 31 18.6 19 13.7 24 17.3 28 17.2
30–34 34 19.2 42 23.6 47 24.1 30 21.3 20 17.1 27 19.9 27 16.2 27 19.4 23 16.5 24 14.7
35–39 24 13.6 20 11.2 31 15.9 23 16.3 16 13.7 28 20.6 27 16.8 25 18.0 24 17.3 29 17.8
40 and older 8 4.5 13 7.3 14 7.2 13 9.2 19 16.2 19 14.0 30 17.4 27 19.4 30 21.6 25 15.3
Total 177 100 178 100 195 100 141 100 117 100 136 100 167 100 139 100 139 100 163 100
Women 25 14.1 30 16.9 27 13.8 23 16.3 16 13.7 38 27.9 35 21.0 22 15.8 25 18.0 30 18.4
Men 152 85.9 148 83.1 168 86.2 118 83.7 101 86.3 98 72.1 132 79.0 117 84.2 114 82.0 133 81.6
abs. = absolute figures 
Source: BMGF, calculations by ÖBIG 
Table A7: Number of indirectly drug-related deaths in Austria by age group and total by gender from 
1994 to 2003 
Age group 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
 abs. % abs. % abs. % abs. % abs. % abs. % abs. % abs. % abs. % abs. % 
19 and younger 7 9.6 2 3.2 0 0.0 2 6.5 1 2.2 3 7.9 6 10.0 1 2.2 2 5.0 1 3.8
20–24 7 9.6 5 7.9 2 5.7 6 19.4 6 13.3 4 10.5 7 11.7 6 13.3 4 10.0 1 3.8
25–29 6 8.2 9 14.3 2 5.7 1 3.2 6 13.3 4 10.5 10 16.7 4 8.9 8 20.0 6 23.1
30–34 31 42.5 20 31.7 7 20.0 3 9.7 6 13.3 12 31.6 8 13.3 11 24.4 7 17.5 5 19.2
35–39 18 24.7 21 33.3 14 40.0 7 22.6 11 24.4 10 26.3 12 20.0 9 20.0 7 17.5 3 11.5
40 and older 4 5.5 6 9.5 10 28.6 12 38.7 15 33.3 5 13.2 17 28.3 14 31.1 12 30.0 10 38.5
Total 73 100 63 100 35 100 31 100 45 100 38 100 60 100 45 100 40 100 26 100
Women 15 20.5 15 23.8 9 25.7 6 19.4 8 17.8 10 26.3 25 41.7 15 33.3 9 22.5 8 30.8
Men 58 79.5 48 76.2 26 74.3 25 80.6 37 82.2 28 73.7 35 58.3 30 66.7 31 77.5 18 69.2
abs. = absolute figures 
Source: BMGF, calculations by ÖBIG 
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Table A8: Distribution of drug-related deaths in Austria by cause of death and age in 2003 
Age group 
Cause of death 
< 15 15–19 20–24 25–29 30–34 35–39 40–44 45–49 > 49 Total 
One opiate 0 4 6 5 5 5 3 1 1  30 
Several opiates 0 1 3 2 2 2 0 0 0  10 
+ alcohol 0 2 2 5 2 6 1 0 0  18 
+ psychoactive 
medicines 0 4 6 4 3 4 1 2 0  24 
Opiates 
+ alcohol & psychoactive 
medicines 0 2 3 1 1 2 4 0 0  13 
Narcotic drug(s) only 0 2 6 4 2 2 3 0 0  19 
ND + alcohol 0 0 3 1 1 2 3 0 0  10 
ND + psychoactive 
medicines 0 3 6 5 5 4 1 0 0  24 
Opiates 
and other 
narcotic 
drugs ND + alcohol & psycho-
active medicines 0 0 0 0 3 2 1 1 0    7 
Narcotic drug(s) only 0 2 1 0 0 0 2 0 0    5 
ND + alcohol 0 0 1 1 0 0 0 0 0    2 
ND + psychoactive 
medicines 0 0 0 0 0 0 1 0 0    1 
Narcotic 
drugs ex-
cluding 
opiates 
ND + alcohol & psycho-
active medicines 0   0   0   0   0   0   0   0  0 0 
In
to
xi
ca
tio
ns
 
Directly drug-related deaths/total 0   20 37   28   24   29   20 4 1 163 
    of these: men 0   15   30   25   21   21   18 2 1 133 
AIDS 0 0 0 3 1 3 4 2 0   13 
Other diseases 0 0 1 1 3 0 1 1 2     9 
Suicides (no intoxication) 0 1 0 1 1 0 0 0 0     3 
Accidents, homicides  0 0 0 1 0 0 0 0 0     1 
Unknown cause of death 0 0 0 0 0 0 0 0 0     0 
In
di
re
ct
ly
 d
ru
g-
 
re
la
te
d 
de
at
hs
 
Indirectly drug-related deaths/total 0 1 1 6 5 3 5 3 2   26 
    of these: men 0 1 1 4 3 1 3 3 2  18 
ND = narcotic drug(s) 
Source: BMGF, calculations by ÖBIG 
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Table A9: Distribution of drug-related deaths in Austria by cause of death and province in 2003 
Province 
Cause of death 
B C LA UA S ST T VB V A 
One opiate 0 0 4 1 0 4 0 0  21 30 
Several opiates 0 1 1 1 1 0 0 0 6 10 
+ alcohol 1 0 2 2 0 3 1 0 9 18 
+ psychoactive 
medicines 1 1 0 3 0 2 4 0  13 24 
Opiates 
+ alcohol & psycho-
active medicines 0 1 1 0 1 2 2 2 4 13 
Narcotic drug(s) only 0 1 3 0 0 1 0 0  14 19 
ND + alcohol 0 1 1 0 0 1 1 1 5 10 
ND + psychoactive 
medicines 0 0 1 5 3 0 2 2 11 24 
Opiates and 
other nar-
cotic drugs 
ND + alcohol & psy-
choactive medicines 0 1 0 1 0 0 1 0 4   7 
Narcotic drug(s) only 0 0 0 0 0 0 1 0 4   5 
ND + alcohol 0 0 0 0 0 1 0 0 1   2 
ND + psychoactive 
medicines 0 0 0 0 0 0 1 0 0   1 
Narcotic 
drugs excl. 
opiates 
ND + alcohol & psycho-
active medicines 0 0 0 0 0 0 0 0 0   0 
In
to
xi
ca
tio
ns
 
Directly drug-related deaths/total 2 6  13  13 5  14  13 5  92 163
AIDS 0 1 0 1 0 1 2 3 5 13 
Other diseases 0 0 0 4 0 1 0 1 3   9 
Suicide (no intoxication) 0 0 0 0 0 0 0 3 0   3 
Accidents, homicides  0 0 0 0 0 1 0 0 0   1 
Unknown cause of death 0 0 0 0 0 0 0 0 0   0 
In
di
re
ct
ly
 d
ru
g-
 
re
la
te
d 
de
at
hs
 
Indirectly drug-related deaths/total 0 1 0 5 0 3 2 7 8 26 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg, 
V = Vienna, A = Austria 
ND = Narcotic drug(s) 
Source: BMGF, calculations by ÖBIG 
Table A10: Development of AIDS cases in Austria by risk situation from 1994 to 2003 
Risk situation 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Homo-/bisexual contact 72 73 59 25 28 27 12 14 19 7 
Intravenous drug use 43 39 25 23 25 27 21 18 19 11 
Heterosexual contact 27 35 21 18 25 31 28 21 39 21 
Other cause/unknown 27 61 33 35 21 16 23 10 15 9 
Total 169 208 138 101 99 101 84 63 92 48 
Source: BMGF, calculations by ÖBIG 
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Table A11: Distribution of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act in Austria by first offenders and repeat offenders, development from 1994 
to 2003 
Reports 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Total number of reports 12 623 13 093 16 196 17 868 17 141 17 597 18 125 21 862 22 422 22 245 
First offenders 5 281 5 521 8 322 9 278 8 672 9 868 9 343 11 033 11 269 12 117 
Repeat offenders 7 117 7 313 7 511 8 325 8 228 7 463 8 296 10 052 10 380 9 288 
Difference between sum of individual figures and total figure = unknown offenders 
Since 1998: all reports, not only narcotic drugs but also psychotropic substances 
Note: On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
Table A12: Distribution of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act (narcotic substances only) in Austria from 1994 to 2003 
Province 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Burgenland 343 669 694 759 707 603 843 712 805 984 
Carinthia 524 534 1 280 961 1 076 1 208 1 088 1 758 1 676 1 659 
Lower Austria 1 772 1 655 1 550 2 686 2 519 2 389 2 624 2 975 3 319 3 017 
Upper Austria 1 133 1 405 1 941 2 256 2 334 1 946 1 887 2 677 3 054 2 782 
Salzburg 436 355 962 855 1 053 840 718 1 471 1 384 868 
Styria 739 851 1 093 1 125 973 1 367 1 305 1 601 1 910 1 570 
Tyrol 1 798 1 382 2 268 2 204 2 212 2 152 2 687 2 449 2 229 2 102 
Vorarlberg 888 1 082 1 040 933 1 144 1 848 1 183 1 447 1 265 1 146 
Vienna 4 990 5 160 5 368 6 089 4 606 4 858 5 233 6 212 6 210 7 652 
Total 12 623 13 093 16 196 17 868 16 624 17 211 17 568 21 302 21 852 21 780 
Difference between sum of individual province figures and total figure = reports not attributable to province 
Note: On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act, which also includes psychotropic 
substances. For the purpose of comparison only reports related to narcotic drugs have been considered for the period after 
1998. 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
Table A13: Distribution of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act in Austria by drug type from 1994 to 2003 
Drug type 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Cannabis 9 552 9 845 14 456 16 124 16 376 17 236 17 001 19 760 19 939 17 706 
Heroin und opiates 4 394 4 386 3 727 3 434 2 850 2 524 2 413 3 802 3 954 4 717 
Cocaine + crack 1 404 1 603 1 912 2 764 2 103 2 608 2 494 3 416 3 762 4 785 
LSD 234 315 640 893 736 532 477 506 327 214 
Ecstasy 116 496 1 375 1 942 1 411 1 517 2 337 2 940 2 998 2 473 
Amphetamines 103 81 342 1 068 - - 1 041 1 215 1 357 1 619 
Psychotropic substances - - - - 802 750 780 822 736 603 
Other drugs 306 302 430 850 - - - 1 288 1 524 1 311 
- = not evaluated separately or not specified 
Note: On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. Because of data broken down by 
type of drug one report to the police may have been listed under several headings, therefore the added figures  may differ from 
the total number of reports. 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
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Table A14: Distribution of reports to the police for violation of the Narcotic Substances Act 
in Austria by drug type and province in 2003 
Drug type B C LA UA S ST T VB V Total 
Cannabis 1 047 1 941 2 472 2 931 960 1 479 2 322 1 212 3 342 17 706 
Heroin und opiates 82 53 680 316 81 505 75 104 2 821 4 717 
Cocaine + crack 75 172 618 364 144 258 237 292 2 625 4 785 
LSD 13 9 69 35 5 40 10 15 18 214 
Ecstasy 53 325 524 536 215 205 263 149 203 2 473 
Amphetamines 78 67 424 494 106 189 23 54 184 1 619 
Psychotropic substances 2 26 47 10 11 5 29 5 468 603 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg, 
V = Vienna, A = Austria 
Note: Because of data broken down by type of drug one report to the police may have been listed under several headings, therefore 
the added figures may differ from the total number of reports.  
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
Table A15: Convictions under the Narcotic Drugs Act/Narcotic Substances Act and total number of 
convictions in Austria from 1994 to 2003 
Year Total number of convictions Convictions under Convictions under Convictions in Austria 
 under the SGG/SMG Section 12 SGG/
Section 28 SMG 
Section 16 SGG/
Section 27  SMG 
total number under the SGG/SMG 
(percentages) 
1994 3 275 1 230 2 010 69 458 4.7 
1995 3 261 1 124 2 102 69 779 4.7 
1996 3 454 1 027 2 382 66 980 5.2 
1997 3 797 1 036 2 717 65 040 5.8 
1998 3 327 1 041 2 207 63 864 5.2 
1999 3 359 1 022 2 230 61 954 5.4 
2000 3 240 933 2 245 41 624 7.8 
2001 3 862 1 141 2 671 38 763 10.0 
2002 4 394 1 108 3 243 41 078 10.7 
2003 4 532 1 161 3 318 41 749 10.9 
SGG = Narcotic Drugs Act 
SMG = Narcotic Substances Act 
On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. 
Section 12 SGG / Section 28 SMG = trafficking, possession, etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 16 SGG / Section 27 SMG = trafficking, possession, etc. of small quantities of narcotic drugs 
Note: These figures only refer to the leading offence, i.e. the offence with the highest range of punishment, so not all convictions un-
der the SGG, or the SMG, respectively, are covered.  
Source: Statistics Austria (Criminal Court Statistics) 
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Table A16: Final convictions under the Narcotic Drugs Act/Narcotic Substances Act in Austria 
by age, gender and basis of conviction in 2003  
Basis of conviction  14-19 years 20-24 years 25-29 years 30-34 years > 34 years Total 
SGG/SMG total men 1 151 1 467 567 355 526 4 067 
 women 120 163 80 31 71 465 
Section 12 SGG / Section 28 SMG men 171 360 174 130 214 1 049 
 women 21 37 19 9 26 112 
Section 16 SGG / Section 27 SMG men 980 1 104 388 220 281 2 973 
 women 99 125 59 21 41 345 
SGG = Narcotic Drugs Act 
SMG = Narcotic Substances Act 
On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. 
Section 12 SGG / Section 28 SMG = trafficking, possession, etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 16 SGG / Section 27 SMG = trafficking, possession, etc. of small quantities of narcotic drugs 
Note: These figures only refer to the leading offence i.e. the offence with the highest range of punishment, so not all convictions un-
der the SGG, or the SMG, respectively, are covered.  
Source: Statistics Austria (Criminal Court Statistics) 
Table A17: Final convictions under the Narcotic Drugs Act/Narcotic Substances Act, young people 
and adults, basis of conviction and type of punishment in 2003 
Prison sentence Basic of conviction  Fine 
Probation  No probation Partial probation 
Other 
punishment1 
Total 
SGG/SMG total young people 178 314 95 104 53 744 
 adults 1 223 1 108 881 513 63 3 788 
Section 12 SGG / Section 28 SMG  young people 5 26 33 28 0 92 
(felonies) adults 28 228 529 281 3 1 069 
Section 16 SGG / Section 27 SMG  young people 173 288 62 76 53 652 
(misdemeanours) adults 1 180 859 339 228 60 2 666 
Young people = persons younger than 19 at the time of the offence 
SGG = Narcotic Drugs Act 
SMG = Narcotic Substances Act 
On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. 
Section 12 SGG / Section 28 SMG = trafficking, possession, etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 16 SGG / Section 27 SMG = trafficking, possession, etc. of small quantities of narcotic drugs 
1 Other punishment: partial probation (Section 43 A (2) StGB), referrals to institutions (Sections 21 (1), 21 (2), 22 and 23 StGB), no 
additional punishment (Section 40 StGB) and, only in the case of young people, conviction with punishment re-
served (Section 13 JGG) and conviction without punishment (Section 12 JGG) 
Note: These figures only refer to the leading offence, i.e. the offence with the highest range of punishment, so not all convictions un-
der the SGG, or the SMG, respectively, are covered 
Source: Statistics Austria (Criminal Court Statistics) 
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Table A18: Development of alternatives to punishment applied in Austria from 1994 to 2003 
Withdrawal of report/ 
waiving of proceeding 
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Total 3 446 4 395 5 248 5 817 7 468 6 989 8 049 8 145 8 974 9 023 
Section 35 SMG (withdrawal of report) - - - - 6 557 5 979 6 924 7 346 7 817 7 902 
Of these: Section 35(4) SMG (can-
nabis) 
- - - - 1 380 1 330 1 410 1 570 1 876 1 499 
Section 37 SMG (waiving of 
proceedings) - - - - 911 1 010 1 125 799 1 157 1 121 
Section 35 SMG = temporary withdrawal of the report to the police by the public prosecutor  
Section 35(4) SMG = temporary withdrawal of the report to the police in the case of small quantities of cannabis for personal use 
Section 37 SMG = temporary waiving of proceedings by the court 
 
Note: On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. A specification of the kind of alter-
native to punishment can be given only for the period since 1998. Data on Section 39 of the SMG (postponement of prison 
sentence - therapy instead of punishment) is not available at present. 
Source: BMGF 
Table A19: Number of seizures of narcotic drugs/substances in Austria from 1994 to 2003 
Narcotic drug/substance 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Cannabis 3 510 3 757 4 838 4 957 4 683 5 079 4 833 5 249 5 294 5 422 
Heroin 1 225 1 298 1 110 861 654 452 478 895 836 1 263 
Cocaine 376 421 525 651 531 519 554 768 863 1 271 
Amphetamines 103 43 136 221 - - 141 161 202 294 
LSD 50 80 102 113 61 56 42 32 20 33 
Ecstasy 51 153 254 253 135 215 330 352 308 276 
Psychotropic substances - - - - 14 74 65 1 0 6 
Psychotropic medicines - - - - 521 517 501 566 515 432 
- = not evaluated separately or not specified 
Note: On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act, which also includes psychotropic 
substances. 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
Table A20: Seizures of narcotic drugs/substances in Austria by quantity from 1994 to 2003 
Narcotic drug/substance 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Cannabis (kg) 394 697 517 912 1 336 451 1 806 456 743.1 925.9
Heroin (kg) 80.2 47.0 81.3 102 118 78 230 288 59.5 42.8
Cocaine (kg) 52.6 55.3 72.7 87 99 63 20 108 36.9 58.3
Amphetamines (kg) 0.7 1.6 3.7 7.9 - - 1 3 9.4 54.2
LSD (no. of trips) 1 543 2 602 4 166 5 243 2 494 2 811 865 572 851 298
Ecstasy (no. of pills) 3 003 31 338 25 118 23 522 114 677 31 129 162 093 256 299 383 451 422 103
Psychotropic substances (kg) - - - - 0.128 4.004 1.294 0.002 0 0.2
Psychotropic medicines (units) - - - - 82 018 36 437 38 507 31 377 20 081 15 649
- = not evaluated separately or not specified 
Note: On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act, which also includes psychotropic 
substances. 
Source: BMI Bundeskriminalamt (Federal Criminal Agency) 
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Table A21: Ingredients of samples bought as ecstasy and analysed by the ChEck iT! Project at rave 
parties from 1997 to 2003  
Samples bought as ecstasy 
(percentages) 
Ingredients 
1997 
(n = 104) 
1998 
(n = 209) 
1999 
(n = 155) 
2000 
(n = 329) 
2001 
(n = 281) 
2002 
(n = 270) 
2003 
(n = 145) 
MDMA 33.65 32.54 84.52 82.37 75.80 67.78 83.45 
MDMA + MDE 2.88 0.00 0.00 3.04 2.14 14.07 7.59 
MDMA + MDA 0.96 0.96 0.00 0.91 1.42 6.67 0.00 
MDE and/or MDA 4.81 4.31 0.65 2.13 9.96 0.37 0.00 
MDMA + caffeine 0.00 0.96 1.29 1.22 0.00 0.74 0.69 
MDMA + amphetamines 0.96 0.96 0.65 0.61 0.36 0.00 0.69 
MDMA + various combinations* 25.96 2.87 4.52 2.13 0.36 0.00 3.45 
PMA/PMMA 0.00 0.00 0.00 1.52 0.36 0.00 0.69 
Amphetamines 1.92 9.09 4.52 1.52 0.36 1.85 1.38 
Methamphetamine 1.92 0.96 0.00 0.61 3.20 1.48 0.00 
Caffeine 0.96 3.35 0.00 0.91 0.00 1.48 0.00 
Quinine/quinidine 3.85 5.74 0.00 0.91 1.07 0.00 0.00 
Various combinations* 22.12 38.28 3.87 2.13 4.98 5.56 2.07 
* Various combinations: Combinations of more than two amphetamine derivatives and/or other substances and/or unknown 
substances 
Source: Vienna Social Projects Association (VWS) 
Table A22: Ingredients of samples bought as speed and analysed by the ChEck iT! project at rave 
parties from 1997 to 2003 
Samples bought as speed 
(percentages) 
Ingredients 
1997 
(n = 24) 
1998 
(n = 56) 
1999 
(n = 68) 
2000 
(n = 92) 
2001 
(n = 52) 
2002 
(n = 87) 
2003 
(n = 57) 
Amphetamines 4.17 84.21 55.88 58.70 57.69 45.98 35.09 
Amphetamines + caffeine 0.00 3.57 5.88 6.52 9.62 8.05 15.79 
Amphetamines + methamphetamine  0.00 0.00 1.47 0.00 0.00 0.00 0.00 
Amphetamines + various combinations* 33.33 8.93 10.29 8.70 5.77 17.24 29.82 
Methamphetamine 0.00 0.00 7.35 3.26 3.85 3.45 1.75 
Caffeine 0.00 5.36 0.00 3.26 7.69 8.05 0.00 
MDMA 0.00 1.79 4.41 3.26 0.00 1.15 0.00 
Ephedrine total 37.50 3.57 7.35 0.00 1.92 0.00 0.00 
Various combinations* 25.00 28.57 7.35 16.30 13.46 16.09 17.54 
* Various combinations: Combinations of more than two amphetamine derivatives and/or other substances and/or unknown sub-
stances 
Source: Vienna Social Projects Association (VWS) 
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Table A23: Number of persons currently registered for substitution treatment in Austria by first 
treatment/continued treatment and province in 2003 
Treatment B C LA UA S ST T VB V A* 
Continued treatment 36 107 573 382 352 404 215 399 3 043 5 522 
First treatment 16 42 152 73 40 211 30 40 287 891 
Total 52 149 725 455 392 615 245 439 3 330 6 413 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg, 
V = Vienna, A = Austria 
Note: Continued treatment refers to treatment started before the respective year, or to the repeated treatment of persons who have 
undergone substitution treatment before. First treatment refers to the treatment of persons who have never undergone substi-
tution treatment before. 
* The total number of substitution treatments in Austria is higher than the sum of substitution treatments by province since records of 
the provinces are incomplete in some cases. 
Source: BMGF, calculations by ÖBIG 
Table A24: Exchange and sale of syringes by province in 2003 
Province Number of syringe 
provision points 
Number of vending 
machines 
Number of syringes provided (exchanged 
or sold) 
Burgenland 0 0 0 
Carinthia 3 0 5201 
Lower Austria 0 0 0 
Upper Austria 1 0 39 968 
Salzburg 0 2 6 099 
Styria 1 1 129 3822  
Tyrol 2 3 163 328  
Vorarlberg 6 6 180 647 
Vienna 3 0 1 235 844 
Total 16 12 1 755 788  
1  Syringe exchange mainly in the context of personal contacts  
2 Syringes are only available in Graz 
Source: ÖBIG – Standard Table 10: Syringe Availability in 2004 
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Table A25: Austrian population statistics by age group and gender in 2002 (latest available data) 
Age group Men Women Total 
  0 to under  5 years 204 246 195 035 399 281 
  5 to under 10 years 235 478 224 566 460 044 
10 to under 15 years 246 600 233 977 480 577 
15 to under 20 years 245 592 234 261 479 853 
20 to under 25 years 246 658 239 535 486 193 
25 to under 30 years 257 835 258 985 516 820 
30 to under 35 years 323 550 320 972 644 522 
35 to under 40 years 358 174 347 628 705 802 
40 to under 45 years 327 294 318 653 645 947 
45 to under 50 years 271 737 273 433 545 170 
50 to under 55 years 251 599 255 225 506 824 
55 to under 60 years 219 464 229 578 449 042 
60 to under 65 years 233 642 251 461 485 103 
65 to under 70 years 151 060 176 177 327 237 
70 to under 75 years 141 282 183 236 324 518 
75 to under 80 years 100 102 186 038 286 140 
80 to under 85 years 53 476 123 537 177 013 
85 or older 33 218 99 802 133 020 
Total 3 901 007 4 152 099 8 053 106 
    
  0 to under 15 years 686 324 653 578 1 339 902 
15 to under 30 years 750 085 732 781 1 482 866 
30 to under 45 years 1 009 018 987 253 1 996 271 
45 to under 60 years 742 800 758 236 1 501 036 
60 to under 75 years 525 984 610 874 1 136 858 
75 or older 186 796 409 377 596 173 
Total 3 901 007 4 152 099 8 053 106 
 
Source: Statistics Austria, calculations by ÖBIG
Map A1: Overview of provinces, provincial capitals and districts
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2C-B 4-bromo-2,5-dimethoxyphenetylamine  
AC addiction coordinator 
AIDS acquired immune deficiency syndrome 
AMS Public Employment Service 
API Anton Proksch Institute 
AR addiction representative 
ARV anti-retroviral (treatment) 
BGBl Federal Collection of Statutes 
BMaA Federal Ministry for Foreign Affairs 
BMBWK Federal Ministry for Education, Science and Culture 
BMF Federal Ministry of Finance 
BMGF Federal Ministry for Health and Women 
BMSG Federal Ministry for Social Security, Generations and Consumer Protection 
BMI Federal Ministry of the Interior 
BMJ Federal Ministry of Justice 
BMLFUW Federal Ministry of Agriculture, Forestry, Environment and Water Management 
BMLV Federal Ministry of Defence 
BMVIT Federal Ministry for Transport, Innovation and Technology 
DFZ drug-free zone 
DMT dimethyltryptamine 
DOM dimethoxymethylamphetamine 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders - 4th edition 
EDDRA Exchange on Drug Demand Reduction Action 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
ESF European Social Fund  
ESPAD European School Survey Project on Alcohol and other Drugs 
EU European Union 
FSW Vienna Social Fund 
GHB gamma-hydroxydbutyric acid 
HBSC Health Behaviour in School-aged Children 
HBV hepatitis B virus 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
ICD-10 International Code of Disease – 10th edition 
ICD-9 International Code of Disease – 9th edition 
IFES Institute for Empirical Research 
ISP Addiction Prevention Institute 
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JGG  Juvenile Court Act 
LSD d-lysergic acid diethylamide 
MDA 3,4-methylenedioxyamphetamine 
MDE 3,4-methylenedioxy-N-ethylamphetamine 
MDMA methylenedioxymethamphetamine 
NAS neonatal abstinence syndrome 
ÖBIG Austrian Health Institute 
PAZ Police Detention Centre 
PMA paramethoxyamphetamine 
PMMA paramethoxymethamphetamine 
REITOX European Information Network on Drugs and Drug Addiction 
(Réseau Européen d’Information sur les Drogues et les Toxicomanies) 
SGG Narcotic Drugs Act 
SMG Narcotic Substances Act 
StgB Criminal Code 
StPo Code of Criminal Procedure 
TB tuberculosis 
VWS Vienna Social Projects Association 
WUK Workshop and Culture House, Vienna 
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List of Austrian Standard Tables and Structured Questionnaires of 2004  
The following list gives an overview of all Standard Tables und Structured Questionnaires drawn up 
for Austria in 2004 and submitted to the EMCDDA. If you are interested in obtaining any table or 
questionnaire please contact Ms. Monika Löbau  loebau@oebig.at). 
STANDARD TABLES 01: BASIC RESULTS AND METHODOLOGY OF POPULATION SURVEYS ON DRUG 
USE (IFES Vienna) 
STANDARD TABLES 01: BASIC RESULTS AND METHODOLOGY OF POPULATION SURVEYS ON DRUG 
USE (market Upper Austria) 
STANDARD TABLE 02: METHODOLOGY AND RESULTS OF SCHOOL SURVEYS ON DRUG USE 
STANDARD TABLE 03: CHARACTERISTICS OF PERSONS STARTING TREATMENT FOR DRUGS  
STANDARD TABLE 04: EVOLUTION OF TREATMENT DEMANDS 
STANDARD TABLE 05: ACUTE/DIRECT DRUG-RELATED DEATHS 
STANDARD TABLE 06: EVOLUTION OF ACUTE/DIRECT DRUG-RELATED DEATHS FIGURES 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Anton Proksch Institute: HBV, HCV, HIV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (drug-related deaths: HCV, HIV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (short-term therapy department of Lukasfeld: HBV, HCV, HIV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Marienambulanz outpatient department in Graz: HBV, HCV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Vienna Social Projects Association – Ganslwirt: HBV, HCV, HIV) 
STANDARD TABLE 10: SYRINGE EXCHANGE, DISTRIBUTION AND SALE  
STANDARD TABLE 11: ARRESTS/REPORTS FOR DRUG LAW OFFENCES 
STANDARD TABLE 13: QUANTITY AND NUMBER OF SEIZURES OF ILLICIT DRUGS 
STANDARD TABLE 14: PURITY AT STREET LEVEL OF ILLICIT DRUGS 
STANDARD TABLE 15: COMPOSITION OF TABLETS SOLD AS ILLICIT DRUGS 
STANDARD TABLE 16: PRICE IN EUROS AT STREET LEVEL OF ILLICIT DRUGS 
STANDARD TABLE 21: DRUG-RELATED TREATMENT AVAILABILITY 
STRUCTURED QUESTIONNAIRE 22: UNIVERSAL SCHOOL-BASED PREVENTION 
STRUCTURED QUESTIONNAIRE 23: HARM REDUCTION MEASURES TO PREVENT INFECTIOUS 
DISEASES IN INJECTING DRUG USERS 
 
